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Barrett’s	   oesophagus	   (BO)	   is	   a	   metaplastic	   premalignant	   disease	   which	   can	  
undergo	   a	   metaplasia-­‐dysplasia-­‐adenocarcinoma	   pathway.	   It	   represents	   an	  
example	  of	   field	  cancerization	  by	  which	  an	  area	  occupied	  by	  BO	  can	  undergo	  
molecular	   and	   genetic	   changes	   associated	  with	   carcinogenesis	  without	   being	  
phenotypically	   cancerous.	   Previous	   work	   suggested	   that	   non-­‐cancerous	   BO	  
contains	   a	   monoclonal	   population.	   More	   recent	   work	   demonstrated	   that	  
premalignant	  Barrett’s	  fields	  are	  polyclonal	  suggesting	  that	  clonal	  interactions	  
may	   be	   important	   in	   carcinogenesis.	   It	   is	   the	   aim	   of	   this	   thesis	   to	   further	  
investigate	  clonal	  interactions	  in	  BO	  by	  understanding	  the	  effects	  of	  therapy	  in	  
altering	   the	   relationships	   of	   clonal	   populations	   in	   BO,	   by	   assessing	   the	  
relationship	  of	  clonal	  populations	  in	  dysplasia	  as	  compared	  with	  the	  associated	  
cancer,	   and	   by	   attempting	   to	   elucidate	   a	   potential	   molecular	   mechanism	   of	  
clonal	  interactions.	  	  
	  
Results:	  
The	   overall	   results	   can	   be	   summarised	   as	   follows:	   1.Premalignant	   clonal	  
populations	   are	   well	   mixed	   allowing	   for	   clonal	   interactions.	   However,	   the	  
adenocarcinoma	   associated	   with	   high	   grade	   dysplasia	   is	   monoclonal	   and	  
derived	   from	   clonal	   populations	   found	   in	   the	   dysplasia,	   indicating	   possible	  
3	  
	  
clonal	   interactions	   during	   carcinogenesis.	   2.	   Patients	   with	   persistent	   disease	  
after	   endoscopy	   retain	   the	   same	   clonal	   populations.	   However,	   the	   clonal	  
populations	   of	   recurrent	   disease	   changes	   such	   that	   new	   clonal	   populations	  
arise	  or	  may	  benefit	  from	  the	  extinction	  of	  others.	  	  3.	  These	  clonal	  populations	  
may	   be	   derived	   from	   deep	   submucosal	   glands	   or	   may	   be	   found	   in	  
phenotypically	   normal	   squamous	   epithelium	   indicating	   a	   common	   stem	   cell	  
origin.	   4.	  A	  possible	  mechanism	  of	   clonal	   interaction	  may	  be	   the	   senescence	  
associated	  secretory	  phenotype:	  senescence	  is	  abundant	  in	  BO	  and	  can	  cause	  
proliferation	  in	  neighbouring	  cells	  in	  vitro.	  
Conclusion:	  
This	   thesis	  has	   investigated	   the	   implications	  of	   clonal	   interactions	   in	  BO.	  The	  
demonstration	   of	   temporal	   clonal	   heterogeneity	   as	   a	   result	   of	   endoscopic	  
therapy,	   as	   well	   as	   spatial	   clonal	   heterogeneity	   possibly	   resulting	   in	  
carcinogenesis,	   asks	   for	   a	  mechanistic	   explanation	  of	   clonal	   interactions.	   The	  
consequences	  of	  senescence	  may	  well	  provide	  one	  such	  mechanism.	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Chapter	  1 Introduction	  
	  
1.1 Macroscopic	  and	  microscopic	  histopathology	  of	  the	  normal	  oesophagus	  
1.1.1 Macroscopic	  Histology	  of	  the	  normal	  oesophagus	  
The	  normal	  human	  oesophagus	   is	   a	  muscular	   tubular	   structure	  designed	   to	  propel	  
food	   from	   the	   oropharynx	   to	   the	   stomach	   using	   peristalsis.	   It	   has	   no	   absorptive	  
functions	  and	  its	  only	  secretive	  function	  is	  that	  of	  mucin	  production	  to	  lubricate	  the	  
passage	   of	   food.	   In	   human	   adults	   it	   is	   around	   25cm	   long	   extending	   from	   the	  
cricopharyngeus	  muscle	   in	   the	   pharynx	   to	   the	   lower	   oesophageal	   sphincter	   at	   the	  
gastroesophageal	  junction	  (GOJ).	  	  
The	  GOJ	  is	  defined	  as	  the	  proximal	  limit	  of	  the	  gastric	  rugal	  folds.	  Endoscopically	  the	  z-­‐line	  is	  
the	   line	   that	  defines	   the	  end	  of	   the	  normal	   squamous	  mucosa	  and	  beginning	  of	   columnar	  
mucosa..	  The	  GOJ	  and	  the	  z-­‐line	  can	  lie	  at	  the	  same	  distance	  from	  the	  incisors	  or	  up	  2-­‐3cm	  




1.1.2 Microscopic	  Histology	  of	  the	  Normal	  Oesophagus	  
The	  main	  histological	  divisions	  above	   the	   striated	  muscle	   layers	   in	   the	  oesophagus	  
arethemucosa,	  submucosa,	  muscularis	  propria	  and	  the	  adventitia	  (Figure	  1-­‐1).	  In	  the	  
normal	   human	   adult,	   the	   mucosa	   consists	   of	   an	   epithelial	   layer	   containing	   non-­‐	  
keratinized	   stratified	   squamous	   epithelium	   with	   keratinocytes,	   endocrine	   cells,	  
Langerhans	   cells,	   Merkel	   cells	   and	   T	   cells	   with	   convoluted	   nuclei.	   The	   squamous	  
epithelium	   is	   stacked	   several	   layers	   deep.	   The	   cells	   in	   the	   basal	   layer	   of	   the	  
epithelium	   have	   a	   large	   nucleus	   to	   cytoplasmic	   ratio	   and	   as	   the	   luminal	   surface	  
approaches,	   the	   squamous	   cells	   progressively	   flatten.	   The	   basal	   layer	   is	   further	  
subdivided	  into	  the	  papillary	  layer,	  which	  refers	  to	  the	  basal	  layer	  that	  lies	  atop	  the	  
basal	  layers	  folds,	  and	  the	  interpapillary	  basal	  layer	  which	  lies	  between	  the	  papillae	  
(Figure	  1-­‐1).	  
Beneath	   the	   epithelial	   layer	   lies	   the	   lamina	   propria	   which	   is	   a	   fibrovascular	  
connective	  tissue	  compartment	  which	  projects	  up	   into	  the	  epithelium	  in	   finger	   like	  
folds.	  This	  lies	  above	  the	  muscularis	  mucosa	  which	  contains	  longitudinally	  arranged	  
smooth	  muscle	   bundles.	   Below	   this	   the	   submucosal	   lies	   contains	   a	   loosely	   bound	  
network	  of	  lymphatics,	  vessels,	  lymphoid	  follicles,	  Meissner’s	  plexus	  (sparse	  ganglia),	  
and	  submucosal	  glands.	  These	  glands	  are	  a	  continuation	  of	  the	  minor	  salivary	  glands	  
of	   the	   oropharynx	   and	   drain	   to	   the	   luminal	   surface	   via	   the	   submucosal	   squamous	  
lined	  ducts	  (Figure	  1-­‐1).	  	  




Figure	  1-­‐1:	  Histology	  of	  the	  normal	  oesophagus.	  
The	  normal	  oesophagus	  with	  the	   lumen	  above.	  The	  squamous	   lining	   is	   the	  most	   luminal	  cell	   layer	  
and	  on	  its	  basal	  aspect	  it	  is	  thrown	  into	  connective	  tissue	  papillae	  (CT	  papillae).	  Beneath	  this	  lies	  the	  
lamina	   propria	   which	   is	   bounded	   on	   its	   basal	   aspect	   by	   the	   muscularis	   mucosa.	   The	   squamous	  
epithelium,	   muscularis	   mucosae	   and	   lamina	   propria	   comprise	   the	   mucosa.	   The	   submucosa	   lies	  
beneath	   the	   mucosa.	   Circumferential	   and	   longitudinal	   muscle	   lies	   beneath	   the	   submucosa.	   Also	  
shown	  is	  a	  deep	  submucosal	  gland	  with	  a	  duct	  leading	  from	  it	  (starred)..	  These	  lie	  in	  the	  submucosa	  
and	  are	  associated	  with	  a	  squamous	  lined	  duct	  leading	  to	  the	  luminal	  surface.	  




1.2 Histology	  of	  Barrett’s	  oesophagus	  pathology.	  
1.2.1 Microscopic	  Pathology:	  
Barrett’s	   oesophagus	   is	   defined	  as	   the	   replacement	  of	   the	  normal	   squamous	   lined	  
oesophagus	   with	   a	   mucinous	   columnar	   lined	   oesophagus	   (CLO)	   typically,	   but	   not	  
exclusively	   interspersed	  with	   goblet	   cells,	   enterocytes,	   Paneth	   cell,	   endocrine	   cells	  
(Odze	   2008;	   Odze	   2005)andMUC5AC	   positive	   foveolar	   cells	   (producing	  Mucin-­‐5AC	  
protein),	  normally	  restricted	  to	  the	  epithelium	  of	  the	  stomach.The	  crypts	  themselves	  
may	   show	   architectural	   changes	   such	   as	   budding,	   irregularity,	   branching,	   and	  
atrophy	   (Odze	   2006).	   It	   is	   thought	   that	   ongoing	   gastro-­‐oesophageal	   reflux	   disease	  
plays	  an	  important	  part	  and	  is	  a	  common	  symptom	  in	  the	  development	  of	  Barrett’s	  
oesophagus	  	  (Haggit	  1994).	  
The	   lamina	   propria	   between	   Barrett’s	   crypts	   often	   contains	   areas	   of	   mild	  
inflammation	  but	  acute	   inflammation	  can	  also	  be	  present	   in	  the	  context	  of	  surface	  
ulceration	   and	   erosions.	   The	   glandular	   compartment	   in	   Barrett’s	   oesophagus	   (BO)	  
varies	  according	  to	  location	  with	  the	  distal	  oesophagus	  containing	  more	  gastric-­‐type	  
oxyntic	   glands	   than	   proximal	   portions	   (Chandrasoma	   et	   al.	   2001).	   This	   is	   also	   the	  
case	  with	  deep	  submucosal	  glands	  and	  associated	  squamous	  lined	  ducts.	  	  
The	   importance	  of	  mucinous	  goblet	   cells	   (Figure	  1-­‐2)	   in	   the	  diagnosis	  of	  BO	  varies	  
between	  the	  United	  Kingdom	  and	  the	  United	  States:	  American	  guidelines	  state	  that	  
the	  presence	  of	  goblet	  cells	  is	  necessary	  for	  the	  diagnosis	  of	  BO	  (Spechler	  et	  al.2011).	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This	  is	  based	  on	  the	  proposition	  that	  goblet	  cell	  CLO	  confers	  a	  risk	  of	  progression	  to	  
adenocarcinoma	   whereas	   non-­‐goblet	   cell	   BO	   confers	   a	   lower	   risk.	   However,	   it	   is	  
increasingly	  evident	  that	  this	  is	  not	  the	  caseas	  up	  to	  70%	  of	  metaplastic	  non-­‐goblet	  
epithelium	   may	   show	   immunopositivity	   for	   markers	   of	   intestinal	   differentiation	  
anyway,	  such	  as	  DAS-­‐1,	  villin	  and	  CDX2(Gatenby	  et	  al.	  2008;	  Kelty	  2007).	  Non-­‐goblet	  
epithelium	  may	  demonstrate	  DNA	  or	  chromosomal	  abnormalities	  indicating	  a	  risk	  for	  
neoplastic	   progression	   (Chaves	  et	  al.2007;	   Liu	  et	  al.	   2009;	  Hahnet	  al.	   2009).	  Other	  
long	  term	  studies	  have	  also	  suggested	  that	  adenocarcinoma	  develops	  with	  equal	  risk	  
in	   goblet	   and	   non-­‐goblet	   cell	   metaplasia	   (Gatenby	   et	   al.	   2008;	   Kelty	   et	   al.	   2007).	  
Furthermore	  foveolar	  dysplasia	  can	  develop	  independently	  of	  the	  presence	  of	  goblet	  
cells	   (Chandrasoma	  et	  al.	  2001)	  As	  such	  the	  definition	  of	  BO	   in	  this	  report	   includes	  
both	  goblet	  and	  non-­‐goblet	  cell	  metaplasia	  (Gatenby	  et	  al.	  2008;	  Kelty	  2007;	  Takubo	  
et	  al.2009)	  which	  is	  consistent	  with	  the	  current	  UK	  guidelines	  on	  the	  diagnosis	  of	  BO	  
(Fitzgerald	  et	  al.	  2013).	  
1.2.2 Macroscopic	  Pathology	  of	  Barrett’s	  Oesophagus:	  
Endoscopically,	  BO	   is	  recognisable	  as	  a	  salmon	  pink	  mucosa	  distinct	   from	  the	  paler	  
mucosa	  of	   the	  normal	   squamous	   surface.	  Macroscopic	   recognition	   is	   important	   so	  
that	   surveillance	   biopsies	   can	   be	   taken.	   Scoring	   systems	   have	   been	   developed	   to	  









Figure	  1-­‐2:	  Non-­‐dysplastic	  Barrett's	  crypts	  
A	   Haematoxylin	   and	   eosin	   stain	   of	   a	   non-­‐dysplastic	   Barrett’s	   characterised	   by	   columnar	   type	  
epithelium.	   Goblet	   cells	   are	   also	   present	   (long	   arrow)	   but	   are	   not	   a	   necessary	   feature	   for	   the	  
diagnosis	  of	  Barrett’s	  in	  the	  UK.	  An	  inflammatory	  infiltrate	  in	  the	  lamina	  propria	  is	  often	  associated	  
with	  this	  (short	  arrow)	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The	   most	   commonly	   used	   is	   the	   Prague	   C	   and	   M	   score	   which	   requires	   a	  
measurement	   of	   the	  most	   proximal	   extent	   of	   the	   Barrett’s	   segment	   as	  well	   as	   its	  
most	   proximal	   circumferential	  margin	   (to	  distinguish	  between	   tongues	  of	   Barrett’s	  
mucosa)	  above	  the	  GOJ	  (Sharma	  et	  al.	  2006).	  
The	  GOJ	  is	  usually	  located	  at	  the	  same	  place	  as	  the	  squamo-­‐columnar	  junction	  (also	  
called	  the	  Z-­‐line).	  Some	  individuals	  have	  a	  proximally	  displaced	  or	  irregular	  Z-­‐line	  so	  
that	   the	   columnar	   epithelium	  between	   the	   proximal	   gastric	   folds	   and	   the	   Z-­‐line	   is	  
called	  ultrashort	   (<1cm)	  BO.	  Attempts	  have	  been	  made	  at	   sub	   classifying	  Barrett’s	  
lengths	   into	  short	   (<3cm)	  and	   long	  segment	  Barrett’s	   (>3cm)	  but	   this	   is	  of	  dubious	  
significance.	   Furthermore,	   Barrett’s	   epithelium	   is	   typically	   dotted	   with	   areas	   of	  
relatively	   normal	   squamous	   epithelium	   the	   source	   of	   which	   appears	   to	   locate	   to	  
deep	  submucosal	  glands	  (discussed	  later	  in	  section	  1.4.4).	  
1.3 Metaplasia	  dysplasia	  adenocarcinoma	  pathway	  in	  Barrett’s	  oesophagus	  
1.3.1 UK	  clinical	  surveillance	  programme	  for	  Barrett’s	  oesophagus	  
Because	   Barrett’s	   oesophagus	   can	   develop	   into	   adenocarcinoma	   in	   a	   step-­‐wise	  
fashion,	   from	   metaplasia	   to	   low	   grade	   dysplasia	   (LGD)	   through	   to	   high	   grade	  
dysplasia	   (HGD)	   and	   eventually	   cancer,	   it	   is	   recommended	   that	   patients	   undergo	  
routine	  endoscopic	   screening	   tests.	   In	   the	  UK	   this	   is	  performed	  every	   two	  years	   in	  
those	   with	   metaplasia	   without	   dysplasia	   (also	   known	   as	   non-­‐dysplastic	   Barrett’s	  
oesophagus	  or	  NDBO)	  and	  more	   frequently	   if	   low	  or	  high	  grade	  dysplasia	   is	   found	  
(Playford	   2006).	   The	   endoscopist	   should	   perform	   4	   quadrantic	   biopsies	   every	   2cm	  
from	  within	  the	  affected	  segment.	  This	  is	  primarily	  to	  increase	  the	  detection	  rate	  of	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dysplasia	   (Reid	   et	   al.	   2000;	   Reidet	   al.	   1988a)which	   is	   not	   always	   macroscopically	  
visible	  (Montgomery	  et	  al.2002;	  Buttar	  et	  al.2001).	  
1.3.2 Histopathology	  of	  low	  and	  high	  grade	  dysplasia.	  
Dysplasia	   refers	   to	   neoplastic	   epithelium	   confined	   to	   within	   the	   basement	  
membrane	   and	   is	   sub	   classified	   into	   low	   or	   high	   grade	   dysplasia	   based	   on	   the	  
severity	  of	   its	  cytological	   features.	  These	   features	   include	  crowded,	  elongated	  cells	  
with	   hyperchromatic	   nuclei	   and	   an	   increased	   nucleus:	   cytoplasm	   ratio.	   HGD	   may	  
have	   the	   additional	   features	   of	   marked	   loss	   of	   cell	   polarity,	   atypical	   mitoses	   and	  
pleomorphism	  as	  well	  as	  architectural	  distortion	  such	  as	  increased	  crypt	  complexity	  
and	  crypt	  branching	  and	  villiform	  change.	  Once	  the	  dysplastic	  cells	  have	  penetrated	  
through	   the	   basement	   membrane	   this	   is	   known	   as	   invasive	   intramucosal	  
adenocarcinoma,	   and	   once	   the	   muscularis	   mucosa	   has	   been	   breached	   then	   the	  
lesion	   is	   termed	  an	   invasive	  submucosal	  adenocarcinoma	   (Montgomery	  2001;	  Reid	  
1988b).	  
1.3.3 Risk	  at	  each	  stage	  of	  developing	  cancer.	  
The	  overall	   risk	  of	  developing	   cancer	  having	  been	  diagnosed	  with	  NDBO	   is	   around	  
0.33%	  per	  year	  (Desai	  et	  al.	  2012).	  It	  also	  appears	  that	  some	  of	  the	  risk	  is	  dependent	  
on	   the	   stability	   of	   the	   Barrett’s	   NDBO	   so	   that	   the	   longer	   a	   patient’s	   surveillance	  
biopsies	  have	  revealed	  NDBO	  only,	   the	   lower	   the	  chance	   that	   the	  patient	  will	  ever	  
develop	  worse	  pathologies	  (Gaddam	  et	  al.	  2013).	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The	   risk	   of	   progression	   from	   low	   and	   high	   grade	   dysplasia	   to	   more	   severe	  
pathologies	   is	   difficult	   to	   predict.	   In	   one	   study,	   30%	   of	   those	   diagnosed	   with	   low	  
grade	  dysplasia	  (LGD)	  on	  biopsy	  developed	  a	  more	  severe	  pathology	  at	  a	  later	  date	  
(Montgomery	   2001).	   There	   is	   also	   evidence,	   however,	   that	   LGD	   can	   regress	   or	  
remain	   static	   for	   several	   years	   (Reid	   et	   al.	   1992;	   Katz	   et	   al.	   1998;	   O’Connor	  et	   al.	  
1999).	   Certainly	   in	   the	   short	   term,	   LGD	   seems	   to	   remain	   stable	   and	   does	   not	  
progress	  to	  cancer	  (Miros	  et	  al.	  1991),	  although	  the	  relative	  instability	  of	  LGD	  versus	  
NDBO	   is	   clear	   when	   comparing	   the	   cumulative	   risk	   for	   HGD	   or	   adenocarcinoma	  
development:	  85.0%	   in	  109.1	  months	  vs	  4.6%	   in	  107.4	  months	   for	  NDBO	   (Curvers,	  
ten	  Kate,	  Krishnadath,	  Visser,	  Elzer,	  Baak,	  Bohmer,	  Mallant-­‐Hent,	  van	  Oijen,	  Naber,	  
Scholten,	  Busch,	  Blaauwgeers,	  Meijer	  &	  J.	  J.	  G.	  H.	  M.	  Bergman	  2010).	  
Some	  of	  the	  confusion	  aurrounding	  the	  progression	  rates	  for	  patients	  with	  low	  grade	  
dysplasia	  is	  derived	  from	  the	  difficulty	  of	  the	  histopathological	  diagnosis.	  Because	  of	  
the	  subtelties	  of	  some	  of	  the	  cellular	  characteristics	  of	  LGD	  these	  can	  be	  seen	  in	  non	  
dysplastic	   and	   inflamed	   tissue.	   Consequently	   an	   approach	   whereby	   consensus	  
between	   histopathologists	   is	   reuired	   for	   a	   LGD	   diagnosis	   has	   proven	   more	  
informative.	   Using	   this	   approach	   Curvers	   et	   al.	   (Curvers,	   ten	   Kate,	   Krishnadath,	  
Visser,	   Elzer,	   Baak,	   Bohmer,	   Mallant-­‐Hent,	   van	   Oijen,	   Naber,	   Scholten,	   Busch,	  
Blaauwgeers,	  Meijer	  &	  J.	  J.	  Bergman	  2010)	  demonstrated	  that	  a	  significant	  number	  
of	   biopsies	   originally	   graded	   as	   LGD	   could	   be	   downgraded	   to	   NDBE	   and	   that	   the	  
overall	  progression	  rate	  was	  0.44%	  per	  year.	  Of	  those	  that	  had	  consensus	  agreement	  
for	  LGD,	  the	  progression	  rate	  was	  13.4%	  per	  year.	  Confirmed	  LGD	  may	  therefore	  be	  




HGD	  also	  has	  a	  variable	  course	  as	  regression	  as	  well	  as	  rapid	  progression	  can	  occur	  
(Weston	  et	  al.	  2000;	  Rastogi	  et	  al.	  2008;	  Thomas	  et	  al.	  2005)	  although	  once	  HGD	  has	  
developed	  overall	  it	  can	  take	  several	  years	  to	  progress	  to	  adenocarcinoma(Falk	  et	  al.	  
1999;	  Schnell,	  S.	  J.	  Sontag,	  et	  al.	  2001;	  Rastogi	  et	  al.	  2008)	  although	  exact	  estimates	  
are	   difficult	   to	   determine	   as	   HGD	   and	   adenocarcinoma	   can	   co-­‐exist:	   2-­‐33%	   of	  
oesophagectomy	  specimens	  for	  HGD	  will	  also	  contain	  adenocarcinoma	  (Schnell	  et	  al.	  
2001;	  Falk	  et	  al.	  1999;	  Rastogi	  et	  al.	  2008).	  
Early	   adenocarcinoma	   is	   still	   amenable	   to	   endoscopic	   therapy	   depending	   on	   the	  
degree	  of	  submucosal	  invasion.	  Oesophageal	  cancer	  is	  staged	  along	  the	  tumour	  node	  
metastasis	  (TNM)	  staging	  protocol	  which	  denotes	  the	  tumour	  size	  (T),	  the	  presence	  
of	  nodes	  (N)	  and	  the	  presence	  of	  metastases	  (M).	  Further	  subclassification	  involves	  
the	   degree	   of	   submucosal	   invasion	   classified	   as	   SM1,	   SM2	   or	   SM3	   depending	   on	  
which	   third	  of	   the	   submucosa	   the	   cancer	  has	   invaded	   (SM1	  being	   the	   shallowest).	  
Because	  the	  risk	  of	  lymph	  node	  metastases	  is	  low	  for	  SM1	  tumours,	  whereas	  the	  risk	  
increases	  dramatically	  with	  SM2	  tumours	  (Ancona	  et	  al.	  2008;	  Rice	  et	  al.	  1998),	  some	  
centres	   advocate	   T1SM1	   oesophageal	   cancers	   as	   being	   suitable	   for	   endoscopic	  
therapy,	  with	  higher	  stages	  suitable	  for	  surgical	  resection	  or	  palliation	  only.	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1.4 The	  origins	  of	  Barrett’s	  metaplasia	  
1.4.1 The	  gastric	  epithelium	  as	  a	  source	  of	  Barrett’s	  oesophagus.	  
Initial	   theories	   on	   the	   development	   of	   Barrett’s	   oesophagus	   (BO)	   concentrated	   on	  
the	  possibility	  of	  an	  upward	  cell	  migration	  of	  the	  cells	  from	  the	  transitional	  zone	  of	  
the	  GOJ.	  These	  cells	  would	  colonise	  the	  gastric	  cardia	  and	  because	  of	  the	  exposure	  
to	  refluxate	  and	  inflammation,	  would	  become	  columnar	  epithelial	  islands	  which	  then	  
colonise	  the	  distal	  oesophagus	  (Hamilton	  &	  Yardley	  1977).This	  theory	  has	  fallen	  out	  
of	  favour	  following	  the	  demonstration	  that	  in	  canine	  models,	  in	  which	  mucosal	  strips	  
are	  taken	  above	  a	  squamous	  barrier	  (which	  itself	  lies	  between	  the	  gastric	  transitional	  
zone	  and	  the	  distal	  oesophagus)	  ,	  columnar	  epithelium	  can	  still	  develop	  despite	  this	  
intact	  barrier	  to	  migration	  (	  Li	  et	  al.	  1994).	  However,	  this	  occurred	  in	  only	  2	  dogs	  of	  
the	   19	   studied,	   and	   failed	   to	   take	   account	   of	   the	   possibility	   of	   buried	   Barrett’s	  
providing	   continuity	   with	   the	   intact	   gastro-­‐oesophageal	   junction	   (see	   section	  
1.8.2.3.3).	  
A	  compelling	  argument	  for	  the	  gastric	  origins	  of	  BO	  is	  derived	  from	  an	  understanding	  
of	   the	  cells	   types	  present.	  BO	  contains	  a	  mix	  of	  goblet	  cells	   interspersed	  with	  non-­‐
goblet	  columnar	  cells	  which	  resemble	  gastric	   foveolar	  cells.	  By	  definition,	   this	   is	  an	  
incomplete	   type	   metaplasia,	   seen	   in	   gastric	   intestinal	   metaplasia	   (Correa	   et	   al.	  
2010)and	   is	   characterised	  as	  co-­‐expression	  of	   the	  mucin	  core	  MUC5AC,	  MUC1	  and	  
MUC6	  which	  is	  characteristic	  of	  the	  gastric	  epithelium,	  as	  well	  as	  MUC2	  and	  MUC3,	  
characteristic	  of	   intestinal	  differentiation	   (Glickman	  et	  al.	   2006).	  This	   suggests	   that	  
the	   specialised	   epithelium	   of	   Barrett’s	   can	   show	   evidence	   of	   gastric	   lineage	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differentiation	   as	   well	   as	   intestinal	   differentiation	   (Reis	   et	   al.	   1999),	   although	  
complete	  intestinalisation	  (also	  known	  as	  Type	  I	  intestinal	  metaplasia)	  can	  also	  occur	  
(White	   et	   al.	   2008).	   The	   similarities	   between	   gastric	   glands	   Barrett’s	   crypts	   has	  
support	   from	  unpublished	  observations	   in	   our	   laboratory	   by	   demonstration	   of	   the	  
similar	  gene	  expression	  distributions	  between	  the	  two	  tissues.	  For	  example,	  the	  core	  
mucin	  protein	  MUC5AC	  and	  the	  trefoil	  factor	  TFF1	  are	  expressed	  superficially	  in	  the	  
pyloric	   stomach	   gland,	   and	   MUC6	   and	   TFF2	   are	   found	   at	   the	   gland	   base.	   This	  
distribution	  of	  gene	  expression	  is	  also	  seen	  in	  the	  Barrett’s	  crypt	  and	  is	  preserved	  in	  
Barrett’s	  dysplasia.The	  Wnt	  targetLGR5,	  a	  bona	  fide	  stem	  cell	  marker	   in	  the	  human	  
colon	   pathway	   (Barker	   &	   Clevers	   2010)	   is	   also	   found	   in	   the	   middle	   part	   of	   the	  
Barrett’s	   crypts	   on	   fluorescent	   in	   situ	   hybridisation,	   indicating	   that	   the	   location	   of	  
the	   stem	   cell	   niche	   is	   similar	   to	   that	   of	   the	   gastric	   pyloric	   gland.	   Finally,	   on	  
iododeoxyuridine	   labelling	   of	   cells	   in	   vivo	   in	   human	   subjects	   prior	   to	   resection,	  
labelled	   cells	   can	   be	   seen	   to	   demonstrate	   a	   bidirectional	   flux	   whereby	   the	   only	  
labelled	   cells	   at	   the	   end	   of	   the	   experiment	  were	   seen	   in	   the	   base	   and	   top	   of	   the	  
oesophageal	   crypt,	   whereas	   labelled	   cells	   were	   initially	   seen	   in	   the	  middle	   of	   the	  
crypt(Pan	  et	   al.	   2013).	   This	  mirrors	   the	  bidirectional	   flux	   of	   a	   normal	   gastric	   gland	  
with	  the	  gastric	  stem	  cell	  located	  in	  the	  gland	  neck.	  
1.4.2 Remnant	  embryonic	  cell	  source	  from	  the	  gastro	  oesophageal	  junction	  as	  a	  
potential	  source	  of	  Barrett’s	  oesophagus	  
Putative	  evidence	  for	  gastro-­‐oesophageal	  cell	   junctionmigration	  comes	  from	  recent	  
mouse	   work.	   Having	   proposed	   that	   p63	   null	   mice	   develop	   a	   columnar	   lines	   fore-­‐
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stomach,	  Wanget	  al.	  isolated	  the	  most	  robustly	  expressed	  protein	  (Car4+,	  Kr7+)	  and	  
traced	  cells	   in	  the	  mouse	  embryo	  carrying	  this	  protein.	   In	  p63	  wild	  type	  mice,	  they	  
demonstrated	   that	   Car4+,	   Kr7+	   were	   rendered	   less	   proliferative	   by	   being	  
undermined	   and	   sloughed	   off	   when	   in	   contact	   with	   p63	   positive	   squamous	  
epithelium.	   Some	   of	   the	   Car4+,	   Kr7+	   cells	   remained	   precisely	   at	   the	   squamo-­‐
columnar	   junction	   (SCJ).	   In	   the	   p63	   null	   mouse,	   Car4+,	   Kr7+	   cells	   proliferated	  
throughout	  the	  epithelium.	  In	  order	  to	  test	  whether	  Car4+,	  Kr7+	  were	  the	  source	  of	  
the	  adult	  Barrett’s	  epithelium,	  the	  oesophageal	  epithelium	  was	  damaged	  by	  the	  use	  
of	  diphtheria	  toxin	  and	  subsequently	  Kr7+	  cells	  proliferated	  through	  the	  epithelium.	  
Such	  mouse	  work	  has	  caveats	  however,	  namely	  that	  the	  squamo-­‐columnar	  junction	  
is	  in	  the	  proximal	  stomach	  in	  the	  mouse,	  a	  very	  different	  anatomical	  location	  to	  that	  
of	   the	   human.	   Furthermore	   the	   metaplasia	   in	   p63	   null	   mice	   may	   be	   different	   to	  
human	  Barrett’s:	  CDX2,	  a	  homeobox	  gene	  commonly	  expressed	  in	  BO,	  was	  not	  seen	  
in	   the	   mouse	  model	   (Wang	   et	   al.	   2011)	   and	   the	   histological	   phenotype	   was	   of	   a	  
columnar	  cell	  monolayer-­‐	  very	  different	   to	   the	  glandular	   structures	   seen	   in	  human	  
Barrett’s	   oesophagus.	   Another	   important	   argument	   against	   a	   SCJ	   specific	   origin	   of	  
Barrett’s	   is	   the	   fact	   50%	   of	   patients	  who	   have	   undergone	   oesophagectomy	  which	  
typically	   involves	   removal	   of	   the	   squamo-­‐columnar	   junction,	   can	   still	   develop	   BO	  
within	  2	  years	  after	  the	  operation	  (Wolfsen	  et	  al.	  2004).	  
1.4.3 Transdifferentiation	  as	  a	  source	  of	  Barrett’s	  oesophagus	  
Transdifferentiation	  offers	  a	  further	  explanation	  and	  refers	  to	  the	  formation	  of	  one	  
fully	  differentiationed	  state	   from	  another(Slack	  2007)(Slack	  2007)(Slack	  2007)(Slack	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2007).	   This	   occurs	   during	   murine	   embryonic	   development	   in	   which	   the	   normal	  
columnar	  lined	  oesophagus	  is	  converted	  to	  a	  squamous	  epithelium.	  Furthermore	  the	  
cells	  undergoing	  this	  transformation	  can	  express	  markers	  of	  squamous	  and	  columnar	  
cells(Yu	  et	  al.	  2005).	  The	  reverse	  process	  may	  be	  seen	  in	  the	  human	  adult	  in	  the	  form	  
of	  a	  multi-­‐layered	  epithelium	  in	  which	  there	  exists	  a	  basal	  squamous	  portion	  and	  a	  
superficial	   columnar	   portion(Glickman	   et	   al.	   2001).	   However	   the	   theory	   does	   not	  
account	   for	   the	   fact	   that	   ablation	  of	   columnar	  mucosa	   can	   result	   in	   squamous	   re-­‐
epithelialisation	   (Shields	   et	   al.	   2001;	   Barham	   et	   al.	   1997).	   Furthermore,	   Barrett’s	  
crypt	  are	  clonal,	  a	  fact	  that	  could	  only	  be	  predicted	  from	  a	  true	  metaplasia	  resulting	  
from	  the	   transcriptional	   reprogramming	  of	   tissue	  specific	   stem	  cells.	  This	  has	  been	  
demonstrated	   by	   detecting	   clonal	   mutations	   in	   the	   mitochondrial	   DNA-­‐encoded	  
gene	   cytochrome	   c	   oxidase	   (CCO)	   in	   Barrett’s	   crypt	   and	   demonstrating	   that	   clonal	  
patches	   are	   formed	   via	   crypt	   fission	   (Nicholson	   et	   al.	   2011).	   This	   has	   also	   been	  
demonstrated	  in	  the	  stomach	  using	  the	  same	  technology	  (McDonald	  et	  al.	  2008).	  
1.4.4 Squamous	  epithelium	  as	  a	  source	  of	  Barrett’s	  oesophagus	  
An	  alternative	  view	  is	  that	  following	  exposure	  to	  environmental	  stressors	  such	  as	  bile	  
and	   acid	   reflux	   squamous	   stem	   cells	   are	   induced	   to	   form	   columnar	   rather	   than	  
squamous	  cell	  epithelium.	  The	  location	  of	  such	  a	  stem	  cell	  is	  still	  under	  investigation.	  
A	  squamous	  origin,	  whereby	   the	  stem	  cell	  population	   lies	  within	   the	  basal	   layer	  of	  
the	   squamous	   epithelium	   derives	   some	   support	   from	   studies	   of	   the	   squamous	  




Human	   studies	   assessing	   proliferation	   in	   oesophageal	  mucosa	   have	   demonstrated	  
that	   proliferation	   is	   less	   frequent	   in	   the	   epithelial	   basal	   layer	   at	   the	   top	   of	   the	  
papillae	  and	  therefore	  a	  potential	  stem	  cell	  location	  (Jankowski	  et	  al.	  1992).	  Chang	  et	  
al	   also	   found	   evidence	   for	   transdifferentiation	   by	   culture	   of	   squamous	   biopsies	   in	  
retinoic	  acid	   (RA).	  The	  retinoic	  acid	  receptor,	   in	   the	  squamous	  epithelium	   is	  bound	  
by	   bile	   acid,	   a	   constituent	   of	   reflux(Radominska-­‐Pandya	   &	   Chen	   2002).	   RA	   was	  
shown	  to	  be	  upregulated	  in	  Barrett’s	  oesophagus	  and	  culture	  of	  squamous	  biopsies	  
in	  RA	  caused	  the	  sloughing	  off	  of	  squamous	  tissue	  and	  the	  merging	  of	  submucosal	  
glands	   with	   the	   luminal	   surface	   whilst	   undergoing	   some	   limited	   columnar	  
differentiation	  (Chang	  et	  al.	  2007).	  However	  the	  differentiation	  seen	  did	  not	  emulate	  
the	   glandular	   structures	   characteristic	   of	   native	   Barrett’s	   oesophagus	   nor	   did	   they	  
include	  the	  presence	  of	  goblet	  cells	  so	  that	  the	  transdifferentiation	  seen	  may	  have	  in	  
fact	  been	  a	  result	  of	  the	  destruction	  of	  the	  squamous	  epithelium	  and	  lamina	  propria	  
with	  the	  subsequent	  exposure	  of	  submucosal	  glands.	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More	  robust	  evidence	  may	  derive	  from	  demonstrating	  common	  genomic	  mutations	  
shared	   between	   squamous	   and	   columnar	   lined	   epithelium.	   This	   has	   been	  
demonstrated	  with	  the	  finding	  of	  a	  shared	  mitochondrial	  mutation	  (Nicholson	  et	  al.	  
2011)	  between	  the	  two	  tissue	  types	  adjacent	  to	  each	  other.	  However	  the	  possibility	  
remains	  that	  both	  the	  squamous	  and	  Barrett’s	  epithelium	  are	  both	  derived	  from	  the	  
same	  precursor	  stem	  cell	  which	  is	  not	  necessarily	  located	  in	  the	  squamous	  epithelial	  
layer,	  such	  as	  the	  deep	  oesophageal	  submucosal	  gland	  or	  duct	  (see	  section1.4.5).	  
1.4.5 Deep	   submucosal	   glands	   and	   ducts	   as	   a	   possible	   source	   of	   Barrett’s	  
oesophagus	  
Another	   potential	   source	   of	   Barrett’s	   stem	   cells	   is	   the	   duct	   and	   gland	   of	   the	  
oesophageal	   submucosal	   glands	   which	   are	   lined	   proximally	   by	   columnar	   cells	   and	  
distally	  by	  squamous	  cells	  (Leedhamet	  al.	  2008).This	  is	  supported	  by	  the	  finding	  of	  a	  
silent	  CDKN2A	  mutation	   found	   in	   common	  with	   a	   submucosal	   gland	   duct	   and	   the	  
neighbouring	   Barrett’s	   epithelium	   which	   implies	   a	   cell	   of	   common	   origin.	  
Furthermore,	   using	   human	   tissue	   it	   has	   been	   shown	   that	   squamous	   islands	   are	  
universally	  associated	  with	  oesophageal	  gland	  duct	  epithelium	  (Coad	  et	  al.	  2005).	  An	  
interesting	  question	  remains	  as	  to	  whether	  Barrett’s	  oesophagus	  contains	  one	  stem	  
cell	   population	   capable	   of	   producing	   both	   Barrett’s	   and	   squamous	   epithelium	   or	  
whether	  these	  are	  two	  separate	  populations.	  The	  demonstration	  of	  a	  mitochondrial	  
mutation	  shared	  between	  squamous	  epithelium	  and	  the	  adjacent	  Barrett’s	  suggests	  
that	   there	   is	   only	   one	   stem	   cell	   population	   (Nicholson	   et	   al.	   2011)	   whereas	   the	  
presence	  of	  neo-­‐squamous	  islands	  with	  mutations	  which	  are	  mostly	  not	  shared	  with	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the	   surrounding	   Barrett’s	   suggests	   otherwise	   (Paulson	   et	   al.	   2006)	   although	   this	  
paper	  did	  show	  one	  shared	  mutation	  thus	  continuing	  the	  debate	  as	  to	  this	  source	  of	  
Barrett’s	  mucosa.	  
1.5 Genetic	  and	  epigenetic	  aberrations	  involved	  Barrett’s	  carcinogenesis	  
Once	  metaplasia	   has	   developed	  only	   a	  minority	   of	   patients	  will	   develop	   dysplastic	  
changes	   and	   adenocarcinoma	   (Desai	   et	   al.	   2012).	   The	   progression	   to	  
adenocarcinoma	   is	   marked	   by	   several	   molecular	   and	   genetic	   changes.	   Although	  
putatively	   correlations	   have	   been	   attempted	   between	   the	   order	   of	   the	  molecular	  
and	  genetic	  changes	  and	  the	  histopathological	  phenotype,	  such	  correlations	  remain	  
contentious.	   Although	   molecular	   changes	   exist	   that	   are	   not	   discussed	   here,	   the	  
molecular	   changes	   relevant	   to	   this	   report	   are	   discussed	  below.	  Molecular	   changes	  
relevant	  to	  other	  areas	  described	  in	  this	  report	  are	  described	  in	  the	  relevant	  areas.	  
1.5.1 Tumour	  Suppressor	  Genes	  
Several	  tumour	  suppressor	  genes	  have	  been	  linked	  to	  the	  development	  of	  Barrett’s	  
adenocarcinoma	   (Michael	   et	   al.	   1997;	   Dolan	   et	   al.	   1998),	   although	   the	   most	  
prominent	  and	  well	  validated	  remain	  TP53	  and	  CDKN2A.	  
1.5.1.1 CDKN2A	  
p16	   is	  an	   important	  cell	  cycle	  regulatory	  protein	   involved	   in	  control	  of	   the	  passage	  
from	   G1	   to	   S	   phase	   in	   response	   to	   cellular	   stress	   (see	   section	   1.7	   for	   detailed	  
pathways).	  The	   locus	   for	   the	  gene	  responsible	   for	  p16,	  CDKN2A,	   is	   located	  at	  9p21	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and	  encodes	  for	  CDKN2A	  as	  well	  as	  Alternate	  Reading	  Frame	  (ARF)	  each	  of	  which	  has	  
a	  distinct	  promoter	  but	  which	   results	   in	   alternatively	   spliced	   transcripts	   that	   share	  
exons	  2	  and	  3.	  Because	  the	  open	  reading	  frame	  for	  exon	  2	  is	  different	  between	  the	  
two	   transcripts,	   two	   different	   proteins	   are	   translated	   (Weber	   et	   al.	   2000;	   Serrano	  
1997).	  p16	   inhibits	  cyclin	  D	  kinase	  4/6	  mediatedhyperphosphorylationof	  Rb	  to	  bind	  
with	   transcription	   factor	  E2F1	   leading	   to	  G1	  cell	   cycle	  arrest	   (Serrano	  1997).	   If	   the	  
CDKN2A	   locus	   is	   lost,	   then	   Rb	   becomes	   phosphorylated	   with	   the	   subsequent	  
disengagement	   from	   E2F	  which	   is	   then	   available	   to	   initiate	   transcription	   for	   entry	  
into	  the	  S	  phase	  (Rayess	  et	  al.	  2012).	  
Several	  mechanisms	  exist	   for	  p16	   loss.	  The	  p16	  promoter	  can	  become	  methylated,	  
the	   gene	   can	   become	   mutated	   or	   can	   be	   affected	   by	   loss	   of	   heterozygosity.	   The	  
protein	  expression	  will	  be	  lost	  when	  both	  alleles	  are	  affected.	  Promoter	  methylation,	  
in	  which	  CpG	   islands	   in	   the	  promoter	  become	  methylated,preventing	   transcription	  
factor	   binding,	   has	   been	   seen	   to	   occur	   in	   metaplasia	   and	   retained	   through	   the	  
metaplasia:dysplasia:carcinoma	  (MDC)	  pathway	  (Hardie	  et	  al.	  2005)	  in	  3-­‐30%	  of	  non-­‐
dysplastic	  BO	  cases	  (Klump	  et	  al.	  1998;	  Wong	  et	  al.	  1997).	  Mutations	  occur	  in	  around	  
15%	   of	   patients	   with	   BO	   with	   the	   majority	   being	   transitions	   at	   CpG	   sites	   and	  
insertions/deletion;	   60%	   of	   these	   occur	   at	   one	   of	   three	   sites:	   c.172	   (R58X),	   c.238	  
(R80X)	  and	  c.247	  (H83Y)	  (Paulson	  et	  al.	  2008a).	  
Loss	  of	  heterozygosity	  may	  also	  occur	  in	  metaplasia	  (Galipeau	  et	  al.	  1999).	  This	  can	  
be	   a	   copy	   neutral	   event	   in	   which	   two	   non-­‐functional	   alleles	   are	   inherited	   from	   a	  
parental	  cell,	  or	  a	  copy	  loss	  event	  in	  which	  one	  allele	  is	  lost.	  This	  is	  reported	  to	  occur	  
in	  up	  to	  60%-­‐90%	  of	  patients	  with	  non-­‐dysplastic	  BO	  and	  thus	   is	  thought	  to	  be	  the	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predominant	   mechanism	   for	   p16	   inactivation	   (Paulson	   et	   al.	   2008a;	   Barrett	   et	   al.	  
1996).	   The	   mechanism	   of	   allelic	   damage	   is	   less	   important	   than	   the	   lack	   of	   p16	  
expression.	  Thus	  the	  order	  and	  combination	  of	  genetic	   insults	  to	  CDKN2A	  does	  not	  
appear	  to	  be	   important.	  For	  example	  the	  oesophageal	  cancer	  risk	  when	  comparing	  
patients	  with	  p16	  mutation	  alone	  versus	  methylation	  or	  loss	  of	  heterozygosity	  (LOH)	  
alone	  is	  the	  same	  (Paulson	  et	  al.	  2008a).	  
1.5.1.2 TP53	  
TP53	   is	  a	  tumour	  suppressor	  gene	  which	  is	  considered	  to	  be	  most	  mutated	  gene	  in	  
human	  cancers	  (Hollstein	  et	  al.	  1991).	  It	  is	  located	  on	  chromosome	  17p	  and	  encodes	  
the	   protein	   p53.	   The	   main	   functions	   of	   p53	   are	   to	   activate	   the	   DNA	   repair	  
mechanisms	   if	  damage	  has	  occurred,	  activate	  p21	  mediated	  cell	  cycle	  arrest	  at	   the	  
G1/S	   cell	   cycle	   checkpoint,	   and	   to	   initiate	  apoptosis	   if	   the	  DNA	  damage	   cannot	  be	  
repaired	  (Zhang	  et	  al.	  2011).	  
The	  P53	  protein	   contains	  5	  major	  domains.	  The	  N-­‐terminal	   transcription-­‐activation	  
domain	  (TAD)	  that	  activates	  transcription	  factors;	  a	  proline-­‐rich	  domain	  that	  allows	  
interactions	   with	   other	   proteins;	   a	   DNA	   binding	   domain	   (exons	   5-­‐8)	   ;	   a	  
tetramerization	  domain	  crucial	   for	  p53	  activity	   in	   vivo	   and	  a	   regulatory	  C	   terminus	  
domain.	  P53	  is	  constantly	  produced	  by	  every	  cell	  yet	  in	  the	  absence	  of	  DNA	  damage,	  
murine	   double	   minute	   2	   protein	   (mdm2)	   monoubiquitinates	   p53	   and	   thus	   it	   is	  
degraded	   (Michael	   &	   Oren	   2003).	   P53	   accumulation	   occurs	   when	   conformational	  
changes	  initiated	  by	  DNA	  damage	  or	  stress,	  prevent	  the	  mdm2-­‐P53	  interaction	  and	  
thus	  prolong	  its	  half-­‐life	  from	  minutes	  to	  hours.	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TP53	   mutations	   are	   relatively	   uncommon	   in	   non-­‐dysplastic	   Barrett’s	   mucosa	  
(Novotna	  et	  al.	  2006),	  although	  possibly	  more	  common	  if	  the	  non-­‐dysplastic	  area	  is	  
associated	   with	   a	   cancer	   elsewhere	   in	   the	   oesophagus	   (Schneider	   et	   al.	   1996)	  
whereas	   in	  adenocarcinoma	  they	  can	  be	  found	   in	  up	  to	  half	  of	  cases	   (Catalogue	  of	  
somatic	   mutations	  
(http://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TP53#histo).	   This	   indicates	  
that	   TP53	   mutations	   may	   occur	   later	   in	   Barrett’s	   progression;	   LOH	   of	   TP53	   can	  
occupy	   large	   areas	   of	   the	   Barrett’s	   oesophageal	   mucosa	   via	   clonal	   expansion	  
(Galipeau	  et	  al.	  1999).	  
1.5.1.3 Epigenetic	  changes	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Methylation	  of	  gene	  promoters	  is	  also	  thought	  to	  be	  important	  in	  the	  progression	  to	  
Barrett’s	   adenocarcinoma.	   Initial	   studies	   concentrated	  on	   tumour	   suppressor	   gene	  
hypermethylation	   as	   discussed	   with	   CDKN2A	   (see	   section	   1.5.1.1).	   Frequent	  
hypermethylation	   in	   adenocarcinoma	   samples	   has	   also	   been	   demonstrated	   for	   a	  
number	   of	   other	   genes	   on	   targeted	   analysis	   such	   asAdenomatous	   polyposis	   coli	  
(APC),	  Estrogen	  receptor	  1	  (ESR1)	  and	  cadherin	  1	  (CDH1)(Kawakami	  et	  al.	  2000)(Eads	  
et	  al.	  2000)	  and	  others	  although	  the	  exact	  role	  of	  methylation	  in	  the	  progression	  to	  
adenocarcinoma	   has	   not	   been	   fully	   elucidated.	   To	   confuse	  matters,	   genome	  wide	  
methylation	   studies	   have	   suggested	   global	   hypomethylation	   may	   also	   be	   an	  
important	  mechanism	  during	  carcinogenesis	  and	  that	  progressors	  were	  more	   likely	  
to	  demonstrate	  global	  hypomethylation	  during	  progression	  to	  adenocarcinoma(Wu	  
et	  al.	  2013;	  Agarwal	  et	  al.	  2012).	  Thus	  selective	  hypermethylation	  of	  targeted	  genes	  
on	   a	   background	   of	   global	   hypomethylation	   may	   be	   a	   characteristic	   of	   Barrett’s	  
progression.	  
1.5.1.4 Other	  genes	  and	  aneuploidy	  
Systematic	   unbiased	   sampling	   of	   genomic	   mutations	   in	   oesophageal	  
adenocarcinoma	  have	  very	   recently	  come	  to	  publication.	  This	  has	  become	  possible	  
since	   the	   advent	   of	   newer	   high	   throughput	   technologies	   such	   as	   next	   generation	  
sequencing.	   Such	   studies	   have	   not	   only	   confirmed	   that	   TP53	   and	   CDKN2A	   are	  
frequently	  mutated	  in	  adenocarcinomas	  but	  also	  that	  chromatin	  remodelling	  genes	  
such	   ARID1A	   and	   SMARCA4	   (members	   of	   the	   Switch/	   sucrose	   nonfermentable-­‐
complex)	   are	   mutated	   in	   at	   least	   a	   quarter	   of	   oesophageal	   adenocarcinomas	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(Streppel	  et	  al.	  2013;	  Dulak	  et	  al.	  2013).	  This	  provides	  further	  evidence	  for	  the	  role	  of	  
epigenetic	  modifications	  in	  the	  progression	  to	  Barrett’s	  adenocarcinoma.	  
Several	   other	   novel	   mutations	   have	   also	   been	   discovered	   using	   these	   newer	  
technologies	  including	  ELMO1	  and	  DOCK2,	  constituents	  of	  the	  RAC1	  GTPase	  pathway	  
(Dulak	   et	   al.	   2013)	   which	   has	   been	   implicated	   in	   cancer	   invasion,	   decreased	  
apoptosis	   and	   increased	   cell	   survival	   (Wertheimer	   et	   al.	   2012).	   SMAD4,	   a	   gene	  
involved	  in	  TGFβ	  signalling	  pathway	  has	  also	  been	  confirmed	  as	  being	  mutated	  in	  a	  
significant	  number	  of	  adenocarcinoma	  samples	  (Dulak	  et	  al.	  2013),	  although	  it	  is	  also	  
likely	   to	   lose	   further	  expression	   through	  promoter	  methylation	   (Onwuegbusi	  et	  al.	  
2006).	  
Weaver	  et	  al.	  have	  also	  recently	  published	  a	  comprehensive	  whole	  genome	  analysis	  
with	   amplicon	   resequencing	   of	   112	   oesophageal	   adenocarcinomas	   (Weaver	   et	   al.	  
2014).	  They	  demonstrated	  that	  the	  majority	  of	  mutations	  present	   in	  non-­‐dysplastic	  
mucosa	  were	  also	  present	  in	  the	  non-­‐dysplastic	  Barrett’s,	  and	  that	  TP53	  and	  SMAD4	  
mutations	   occurred	   in	   a	   stage	   specific	  manner.	   In	   particular	   they	   highlighted	   that	  
non-­‐dysplastic	   Barrett’s	   mucosa	   was	   highly	   mutated	   perhaps	   underlining	   the	   idea	  
that	   idea	   that	   individual	  mutations	   are	   unlikely	   to	   be	   as	   important	   as	   the	   context	  
they	  exist	  in.	  
Aneuploidy	  refers	  to	  the	  presence	  of	  cells	  with	  a	  chromosome	  number	  other	  than	  2N	  
(diploid)	   or	   4N	   (tetraploidy).	   Aneuploidy	   does	   not	   correlate	   single	   gene	  mutations	  
but	   rather	  with	   overall	   genomic	   instability.	   Aneuploidy	   exists	   in	   over	   90%ˆof	   HGD	  
and	   adenocarcinoma	   and	   the	   presence	   of	   an	   aneuploidy	   population	   is	   correlated	  
with	   Barrett’s	   progression	   to	   adenocarcinoma	   (Reid.	   et	   al.	   2000).	   It	   is	   thought	   to	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occur	   late	   in	   this	  progression	   (Barrett	  et	  al.	   1999).	  Although	   it	  has	  been	  suggested	  
that	   this	   could	   be	   used	   particularly	   in	   low	   grade	   dysplasia	   as	   a	   predictor	   of	  
progression	  to	  adenocarcinoma	  (Teodori	  et	  al.	  1998)	  some	  authors	  have	  suggested	  
that	  correlation	  with	  histology	  is	  not	  robust	  (Reid	  et	  al.	  2000).	  
1.6 Field	  cancerization	  and	  Barrett’s	  metaplasia	  
1.6.1 Introduction:	  
The	  concept	  of	  a	  metaplasia:carcinoma	  sequence	  (MCS)	  pathway	  is	  consistent	  with	  
the	   idea	   that	   somatic	  mutations,	  as	  well	  as	  other	  genetic	  aberrations	   found	  within	  
cancers,	   can	   be	   found	   in	  morphologically	   normal	   tissue	   before	   a	   cancer	   develops.	  
This	   concept	   was	   first	   proposed	   in	   the	   context	   of	   the	   head	   and	   neck	   squamous	  
cancers	  (HNSCC)	  (Slaughter	  et	  al.	  1953).	   Initial	  observations	  had	  demonstrated	  that	  
HNSCC	  tumours	  frequently	  arise	  multifocally	  and	  that	  there	  was	  a	  significant	  risk	  of	  
the	  development	  of	  metachronous	   tumour	  development.	   Slaughter	  and	  colleagues	  
proposed	  the	  explanation	  for	  this	  was	  “preconditioning	  of	  an	  area	  of	  epithelium	  to	  
cancer	  growth	  by	  a	  carcinogenic	  agent”	  (Slaughter	  et	  al.	  1953).	  Subsequent	  work	  has	  
demonstrated	  that	  the	  area	  or	  field	  of	  epithelium	  apparently	  predisposed	  to	  cancer	  
development	  can	  often	  share	  a	  common	  genetic	  aberration,	  such	  as	  a	  somatic	  point	  
mutation,	  suggesting	  that	  the	  field	  is	  clonal	  in	  origin(Braakhuis	  et	  al.	  2005).	  Thus	  field	  
cancerization	   studies	   now	   focus	   on	   understanding	   how	   the	   mutant	   clones	   that	  
ultimately	  lead	  to	  a	  “field-­‐defect”	  are	  established	  and	  spread.	  	  
There	   is	   increasing	   evidence	   that	   field	   cancerisation	   occurs	   in	   a	   variety	   of	   tissues.	  
Sampling	   of	   the	   tracheobronchial	   tree	   of	   one	   individual	   with	   a	   long	   history	   of	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smoking	  without	  lung	  cancer,	  revealed	  the	  same	  mutation	  in	  TP53	  in	  seven	  out	  of	  10	  
sites	  studied	  (Franklin	  et	  al.	  1997).	  That	  such	  field	  cancerization	  may	  lead	  to	  cancer	  
has	  been	  detected	  using	  LOH	  at	  chromosome	  12p	  in	  normal	  bronchial	  epithelium	  of	  
long-­‐term	   smokers	   which	   was	   also	   observed	   in	   non-­‐small	   cell	   lung	   cancers	   in	   the	  
same	  patients	   (Grepmeier	  et	  al.	  2005).	   In	   the	  pancreas,	  analysis	  of	  microdissected,	  
morphologically	  normal,	  peritumoral	  tissue	  (intraductal	  papillary-­‐mucinous	  tumours)	  
has	  demonstrated	   identical	  mutations	  as	  were	  present	   in	   the	  tumour	   (Kitago	  et	  al.	  
2004).	  Similar	  findings	  have	  been	  found	  in	  the	  bladder	  (Simon	  et	  al.	  2001),	  prostate	  
(Hanson	  et	  al.	  2006),	  breast	  (Deng	  et	  al.	  1996)	  and	  colon	  (Galandiuk	  et	  al.	  2012).	  
1.6.2 How	  Does	  An	  Epithelial	  Field	  Become	  Cancerized?	  
The	   process	   that	   leads	   to	   a	   cancerized	   epithelial	   field	   is	   mechanistically	   poorly	  
understood.	  Assessment	  of	   such	  a	  mechanism	  has	   relied	  on	  studies	  demonstrating	  
the	   growth	   patterns	   of	   clonal	   populations	   of	   cells,	   that	   is,	   cells	   which	   share	   a	  
common	  ancestry.	  Such	  clonality	  studies	  rely	  on	  the	  demonstration,	  for	  example	  of	  a	  
shared	   somatic	   mutation,	   common	  methylation	   patterns	   or	   shared	   LOH	   patterns:	  
data	  that	  have	  often	  been	  used	  in	  understanding	  cellular	  dynamics	  in	  the	  colon.	  The	  
colonic	  epithelium	  is	  pitted	  with	   invaginations	  called	  crypts;	  the	  putative	  stem	  cell-­‐	  
the	  parent	  cell	  of	  the	  epithelium	  within	  each	  crypt-­‐	  is	  located	  at	  the	  base	  of	  the	  crypt	  
(Snippert	   et	   al.	   2010;	   Barker	   &	   Hans	   Clevers	   2010).	   The	   mechanism	   by	   which	   a	  
mutated	   stem	   cell	   may	   occupy	   a	   colonic	   crypt	   occurs	   by	   a	   process	   of	   niche	  
succession,	  whereby	  one	   stem	  cell	   comes	   to	  dominate	   the	  niche	   in	   the	   crypt	  base	  
which	  is	  the	  site	  of	  the	  putative	  stem	  cell,	  and	  monoclonal	  conversion,	  whereby	  the	  
crypt	  epithelium	  is	  composed	  of	  the	  progeny	  of	  the	  dominant	  stem	  cell.	  This	  results	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in	   a	   fully	   clonal	   crypt	   (Barker	   et	   al.	   2007;	   Ponder	  et	   al.	   1985).	   The	  mechanism	   by	  
which	  this	  mutated	  crypt	  then	  propagates	  the	  mutation	  is	   likely	  to	  occur	  through	  a	  
process	  of	  crypt	  fission	  (Greaves	  et	  al.	  2006).	  
During	   post-­‐natal	   development	   of	   the	   gastrointestinal	   tract	   there	   is	   a	   need	   to	  
populate	   the	   gut	  with	   crypts.	   This	   occurs	   by	   crypts	   initially	   bifurcating	   at	   the	  base	  
and	  then	  separating	  longitudinally	  to	  produce	  two	  daughter	  crypts.	  During	  post-­‐natal	  
development	  this	  process,	  known	  as	  crypt	  fission,	  occurs	  very	  frequently	  (Maskens	  &	  
Dujardin-­‐Lotis	  1981).	  The	  process	  is	  not	  however	  limited	  to	  development	  and	  is	  up-­‐
regulated	   during	   healing	   of	   ulcerative	   colitis	   lesions	   (Cheng	  et	   al.	   1986)	   as	  well	   as	  
during	   regeneration	  after	  exposure	   to	   ionizing	   radiation	   (Cairnie	  &	  Millen	  1975)	  or	  
chemotherapy	   (Wright	   &	   Al-­‐Nafussi	   1982)and	   after	   inflammation	   (Cheng	   et	   al.	  
1986)..It	  is	  also	  likely	  to	  be	  a	  mechanism	  to	  explain	  field	  cancerization;	  analysis	  of	  a	  
dysplastic	  crypt	  caught	  in	  fission	  demonstrated	  that	  both	  arms	  contained	  TP53	  allele	  
gains	  with	   a	   single	   chromosome	  17	   centromere,	   and	   that	   these	   features	  were	  not	  
present	  in	  the	  surrounding	  crypts	  (Chen	  et	  al.	  2005).	  
Crypt	   fission	   is	   thus	  considered	   to	  be	   the	  canonical	  method	  of	   clone	  spread	   in	   the	  
colon.	  It	  can	  also	  be	  seen	  in	  the	  stomach	  (McDonald	  et	  al.	  2008)	  and	  small	  intestine	  
(Gutiérrez-­‐González	   et	   al.	   2009)	   .	   The	   progression	   to	   gastric	   adenocarcinoma	   is	  
marked	   initially	   by	   the	   development	   of	   gastritis	   with	   the	   subsequent	   epithelial	  
conversion	   to	   intestinal	   metaplasia	   (Correa	   &	   Shiao	   1994).	   The	   field	   containing	  
intestinal	   metaplasia	   can	   develop	   dysplastic	   changes	   which	   can	   lead	   to	   invasive	  
disease.	   Using	   laser	   capture	   microdissection	   and	   assessment	   of	   the	   presence	   of	  
somatic	   mutations	   on	   a	   gland	   by	   gland	   basis,	   it	   has	   been	   shown	   that	   a	   large	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dysplastic	   field	   can	   arise	   from	   one	   gland	   containing	   intestinal	   metaplasia,	  
demonstrating	   the	   existence	   of	   field	   cancerization	   in	   the	   stomach.	   Furthermore	  
using	   non-­‐functional	   mitochondrial	   mutations,	   it	   can	   be	   shown	   that	   patches	   of	  
gastric	   glands	   share	   a	   common	   mitochondrial	   mutation,	   whereas	   immediately	  
surrounding	   the	   patch	   glands	   are	   wild	   type	   (Gutiérrez-­‐González	   et	   al.	   2011).	   The	  
replication	  of	  a	  gland	   such	   that	   it	   is	  monoclonal	   and	   identical	   to	   its	  neighbour	   can	  
only	  practically	  be	  explained	  by	  a	  fission	  process.	  
By	  extrapolation	   therefore,	   can	  crypt	   fission	  be	  used	   to	  explain	   the	   spread	  of	   field	  
cancerization	  in	  the	  columnar	  oesophagus?	  The	  mechanism	  of	  spread	  of	  the	  field	  has	  
proved	  more	  difficult	   to	  elucidate	   than	  elsewhere	   in	   the	  gastrointestinal	   tract	  as	   it	  
can	   look	   histologically	  more	   disorganised	   and	   increasingly	   so	   when	   field	   becomes	  
dysplastic.	   The	   demonstration	   that	   patches	   of	   crypts	   are	   clonal	   for	  mutations	   is	   a	  
useful	   surrogate	   for	   the	   process	   of	   crypt	   fission	   having	   taken	   place.	   As	   in	   the	  
stomach,	   a	   common	   mitochondrial	   mutation	   has	   been	   demonstrated	   in	   localised	  
patches	   of	   oesophageal	   crypts	   and	   it	   seems	   likely	   that	   crypt	   fission	   plays	   an	  
important	   role	   in	   field	   cancerization	   in	   the	   oesophagus	   (Nicholson	   et	   al.	   2011)	  
although	  confirmation	  is	  needed.	  
The	  mechanism	  that	  regulates	  fission	  is	  not	  understood.	  It	  has	  been	  suggested	  from	  
mathematical	   models,	   that	   the	   increase	   in	   stem	   cell	   numbers	   could	   cause	   the	  
epithelial	  sheet	  to	  buckle	  and	  therefore	  initiate	  fission	  (Edwards	  &	  Chapman	  2007).	  
Furthermore,	   because	   crypt	   fission	   is	   increased	   in	   the	   adenomas	   of	   patients	   with	  
familial	   adenomatous	   polyposis-­‐	   an	   inherited	   colorectal	   condition	   predisposing	  
patients	   to	   the	   development	   of	   numerous	   colonic	   polyps	   -­‐	   the	   gene	   APC	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(adenomatous	   polyposis	   coli)	   which	   is	   mutated	   in	   this	   condition,	   has	   also	   been	  
implicated	  in	  regulating	  fission	  (Wasan	  et	  al..	  1998).Whether	  this	  is	  a	  direct	  effect	  on	  
the	  control	  of	  the	  fission	  rate,	  or	  as	  a	  result	  of	  alterations	  to	  the	  stem	  cell	  population	  
remains	  unclear.	  
Regardless,	  it	  seems	  likely	  that	  fission	  could	  account	  for	  the	  ability	  of	  clones	  to	  travel	  
large	   distances	   through	   the	   gastrointestinal	   (GI)	   tract.	   Large	   fields	   of	   monoclonal	  
cancerization	   have	   been	   demonstrated	   in	   the	   oesophagus,	   stomach	   and	  
gastrointestinal	  tract:	  the	  same	  p16-­‐mutation	  has	  been	  demonstrated	  throughout	  a	  
16cm	   segment	   of	   Barrett’s	   oesophagus	   (Galipeau	   et	   al.	   1999).	   Recently	   a	   Crohn’s	  
patient	  has	  been	  described	  with	  a	  common	  mutation	  demonstrated	   in	   the	  rectum,	  
ascending	  colon	  and	  terminal	  ileum	  (Galandiuk	  et	  al.	  2012).	  Dysplastic	  areas	  covering	  
a	   large	   proportion	   of	   the	   stomach	   surface	   have	   been	   shown	   to	   have	   the	   same	  
somatic	   mutation(Gutiérrez-­‐González	   et	   al.	   2011).Given	   the	   presence	   of	  
inflammation	   in	   Barrett’s	   and	   Crohn’s,	   it	   is	   therefore	   possible	   that	   the	   increased	  
crypt	   fission	   rate	   that	   is	   known	   to	   occur	   in	   inflammation,	   is	   responsible	   for	   the	  
distances	   travelled	   by	   the	   clones.Field	   cancerization	   in	   Barrett’s	   oesophagus	   had	  
been	   suggested	   to	   be	   due	   to	   the	   growth	   of	   a	   single	   clone	   throughout	   the	   entire	  
Barrett’s	   segment	   (Wong	   et	   al.	   2001)based	   on	   clonal	   analysis	   of	   whole	   biopsies.	  
Although	  it	  is	  likely	  that	  patches	  of	  BO	  are	  monoclonal	  and	  that	  these	  patches	  are	  a	  
result	   of	   ongoing	   crypt	   fission,	   laser	   microdissection	   and	   genetic	   analysis	   of	  
individual	   Barrett’s	   crypts	   has	   demonstrated	   that	   the	   field	   of	   cells	   predisposed	   to	  
cancer	  may	  contain	  several	  genetically	  distinct	  clones;	  prior	  studies	  showing	  








Figure	  1-­‐3:Clonal	  expansion	  in	  Barrett’s	  
Crypts	  are	  seen	  in	  cross	  section	  on	  the	  diagram.	  1)Crypt	  fission	  is	  the	  canonical	  mechanism	  by	  which	  
field	   cancerization	   occurs	   in	   the	   gastrointestinal	   tract.	   The	   crypt	   division	   starts	   at	   the	   base	   and	  
progresses	  longitudinally.	  2)	  The	  consequences	  of	  field	  cancerisation	  may	  be	  that	  spatially	  separate	  
clonal	  populations	   interact	   via	  a)	  Cellular	   competition	  b)	  Cellular	   co-­‐operation	  or	   via	   interaction	  
with	  the	  stroma.	  




monoclonality	   of	   lesions	   were	   possibly	   confounded	   by	   the	   sequencing	   of	   whole	  
biopsies,	   rather	   than	   individual	   crypts,	   which	  may	  mask	  mutations	   present	   at	   low	  
frequency	   (Leedhamet	   al.	   2008).	   Genetic	   diversity	   within	   a	   Barrett’s	   segment	   is	  
predictive	  for	  the	  risk	  of	  progression	  to	  adenocarcinoma	  (Maley	  et	  al.	  2006).	  These	  
observations	   raise	   the	   possibility	   of	   clonal	   interaction	   as	   a	   driving	   force	   for	  
carcinogenesis.	   Such	   clonal	   interaction	   could	   take	  many	   forms,	   such	   as	   clonal	   co-­‐
operation,	  clonal	  competition	  and	  interaction	  of	  clonal	  populations	  with	  the	  stroma.	  
1.6.2.1 Clonal	  interactions	  
1.6.2.1.1 Clonal	  competition	  
An	  interesting	  possibility	  involves	  clonal	  competition.	  The	  concept	  of	  competition	  in	  
biological	   systems	   has	   been	  well	   studied	   in	   the	   field	   of	   ecology.	   It	   is	  most	   simply	  
defined	   as	   the	   interaction	   of	   two	   species	   (interspecific)	   or	   two	   members	   of	   one	  
species	   (intraspecific)	  which	   leads	   to	   the	   removal	   or	   depletion	   of	   another	   species'	  
resource.	  A	  resource	  is	  defined	  as	  an	  element	  that	  is	  consumed	  by	  an	  organism,	  can	  
be	   depleted,	   is	   used	   for	   maintenance,	   growth,	   or	   reproduction	   and	   reduces	  
population	  growth	  when	  its	  availability	  is	  limited	  (Keddy	  2001).	  
The	  elements	  of	  such	  a	  definition	  are	  therefore:	  
a) The	  competitors	  should	  (usually)	  neighbour	  each	  other.	  
b) A	  limiting	  resource	  that	  is	  competed	  over.	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c) The	   competitors	   should	  have	  a	  detectable	  effect	  on	  each	  other	   so	   that	   the	  
removal	  of	  one	  competitor	   results	   in	   removal	  of	   that	  competitive	  effect	   for	  
the	  remaining	  element.	  
The	   status	   of	   ‘competitor’	   is	   context	   dependent	   so	   that	   a	   species	   does	   not	  
demonstrate	   competitive	   behaviour	   when	   not	   in	   proximity	   with	   a	   competing	  
species.Competitive	   modes	   of	   cellular	   interaction	   have	   been	   described	  
predominantly	  in	  Drosophila	  melanogaster.	  Having	  created	  a	  Drosophila	  strain	  which	  
was	  chimeric	  for	  cells	  with	  genes	  expressing	  a	  ribosomal	  protein	  known	  as	  Minutes	  
(M),	   immunohistochemistry	   and	   in	   situ	   immunofluorescence	   has	   been	   used	   to	  
demonstrate	  that	  wild-­‐type	  (Wt)	  cells	  could	  repopulate	  the	  chimeric	  wing	  epithelium	  
and	  that	  the	  cells	  at	  the	  border	  between	  M/Wt	  and	  Wt/Wt	  demonstrated	  apoptosis	  
(Morata	   &	   Ripoll	   1975).	   Further	   work	   using	   the	   same	   chimeric-­‐fly	   model	   has	  
established	  further	  characteristics	  of	  cellular	  competition	  in	  Drosophila.	  Competition	  
appears	   to	   occur	   between	   cells	   of	   different	   clonal	   origin	   and	   this	   competition	   is	  
proximity	   dependent.	   The	   induction	   of	   apoptosis	   is	   considered	   the	   primary	  
mechanism	   of	   competition;	   cells	   not	   located	   at	   a	   clone	   border	   are	   unlikely	   to	  
apoptose.	   Further,	   the	   death	   of	   a	   cell	   in	   one	   clone	   cell	   stimulates	   proliferation	   of	  
cells	  in	  the	  competing	  clone.	  Finally,	  competition	  does	  not	  alter	  wing	  homeostasis;	  in	  
the	   case	   of	   the	   imaginal	   disc,	   the	   disc	   remains	   normal	   in	   structure	   and	   function	  
irrespective	  of	  the	  competitive	  processes	  within	  it	  (Simpson	  &	  Morata	  1981).	  	  
The	   central	   role	   for	   apoptosis	   as	   the	   driver	   of	   the	   rival	   clone’s	   growth	   has	   been	  
further	  demonstrated	  by	  the	  use	  of	  baculovirus	  p35	  protein	  to	  block	  the	  apoptotic	  
machinery	   which	   has	   the	   result	   of	   reducing	   the	   ability	   of	   winner	   cells	   to	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proliferate(Moreno	  et	  al.2002).	  Interestingly,	  transgenic	  tumour	  cells	  induced	  in	  flies	  
have	  also	  been	  shown	  to	  be	  the	  “loser”	  in	  cell	  competition	  experiments.	  Apical-­‐basal	  
polarity	   genes	   discs	   large	   (dlg),	   scribble	   (scrib)	   or	   lethal-­‐giant	   larvae	   (lgl)	   help	   to	  
orientate	  cells	  within	  the	  Drosophila	  imaginal	  discs	  (the	  wing	  precursor).	  Constitutive	  
mutations	   of	   any	   of	   these	   genes	   cause	   fatal	   neoplastic	   growth	   in	   the	   developing	  
embryo.	  However	   constitutional	  mosaics	  with	  homozygous	  mutations	  do	  not	   form	  
tumours	   and	   homozygous	   mutated	   areas	   are	   engulfed	   by	   wild	   type	   epithelium	  
(Rhiner	  et	  al.	  2010).	  
Based	   on	   the	  Drosophila	   experiments	   it	   has	   been	   proposed	   that	   competition	  may	  
play	  a	  part	   in	   field	  cancerization(Rhiner	  &	  Moreno	  2009).	  Field	  changes	  have	  been	  
demonstrated	   in	   mammalian	   systems.	   Chimeric	   rat	   livers	   can	   be	   created	   by	  
transplantation	   of	   foetal	   liver	   progenitor	   cells	   into	   hosts.	   Oertel	   et	   al.	   have	  
transfected	  progenitor	  hepatocytes	  and	  hepatoblasts	  with	  a	   lentivirus	   containing	  a	  
reporter	   gene-­‐	   green	   fluorescent	   protein	   (GFP)	   (Oertel	   et	   al.	   2003).	   When	  
regenerative	  stimulation	  occurs	  by	  performing	  a	  partial	  hepatectomy	  in	  the	  recipient	  
rat,	  and	  subsequent	  stimulation	  of	   the	  reported	  gene,	   the	  younger	  donor	  cells	  can	  
be	   seen	   to	   respond	   vigorously	   and	   eliminate	   the	   host	   cells	   by	   apoptosis	   until	   an	  
entirely	  donor	  derived	  liver	  is	  generated	  (Oertel	  et	  al.	  2003).	  	  
However,	   the	  apparently	   central	   role	  of	   apoptosis	   in	  Drosophila	  models	  of	   cellular	  
competition	   described	   above	   has	   not	   been	   reflected	   in	   luminal	   gastrointestinal	  
neoplasia.	   Therein,	   even	   in	   high-­‐grade	   dysplasia,	   markers	   for	   apoptosis	   are	   not	  
common	  (Katada	  et	  al.	  1997;	  Wetscher	  et	  al.	  1998),	  although	  it	  should	  be	  noted	  that	  
most	   studies	   have	   not	   been	   designed	   to	   examine	   putative-­‐competition	   at	   clone	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borders	  per	  se.	  Thelack	  of	  apoptosis	  in	  luminal	  dysplasia	  does	  not	  necessarily	  mean	  
that	  competition	  is	  not	  occurring	  in	  these	  tissues;	  apoptosis	  may	  also	  not	  be	  the	  only	  
expense	   that	  a	   ‘loser’	   cell	  population	  pays.	  Other	  potential	   cell	  behaviours	   such	  as	  
cell	  cycle	  arrest	  and	  senescence,	  or	  even	  the	  induction	  of	  a	  slower	  proliferation	  rate,	  
could	  conceivably	  be	  induced	  by	  ‘winner’	  cells	  in	  the	  neighbouring	  loser	  populations-­‐	  
this	  has	  yet	  to	  be	  assessed.	  
1.6.2.1.2 Clonal	  co-­‐operation	  
Clonal	   co-­‐operation	   in	  which	   two	   clonal	   populations	   are	  mutually	   protumorigenic,	  
has	   also	   been	   documented.	   Using	  mitotic	   recombination	  Drosophila	  melanogaster	  
can	  be	  engineered	  so	  some	  of	  the	  epithelial	  cells	  in	  the	  eye	  antennal	  imaginal	  discs	  
lack	   the	   Ras	   oncogenic	   protein	   (RasV12),	   and	   others	   lack	   scribbled	   (scrib-­‐).	   The	  
combination	   of	   cells	   produces	   tumours	   far	   larger	   than	   lack	   of	   either	   gene	   alone,	  
through	  upregulation	  of	  JAK/STAT-­‐activating	  cytokines	  (Wu	  et	  al.	  2010).	  This	  has	  also	  
been	   demonstrated	   using	   human	   cell	   lines	   recapitulating	   the	   brain	   tumour	  
glioblastoma.	   The	   tumour	   often	   contains	   a	   mutated	   epidermal	   growth	   factor	  
receptor	   (EGFR)	  which	   is	  present	  with	   far	   less	  abundance	   than	   the	  wild	   type	  EGFR	  
but	   nevertheless	   maintains	   the	   tumour	   growth	   and	   heterogeneity	   through	   the	  
paracrine	  effect	  of	   IL-­‐6	  and	   leukaemia	   inhibitory	   factor	  on	  the	  EGFR	  wild	  type	  cells	  
(Inda	  et	  al.	  2010).	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1.6.2.1.3 Clonal	  demographics	  
A	  further	  important	  omission	  in	  the	  description	  of	  clonal	   interactions	  is	  an	  intimate	  
description	   of	   the	   demographics	   of	   clonal	   populations.	   Clonal	   populations	   must	  
neighbour	  each	  other	  but	  this	  does	  not	  necessarily	  imply	  a	  straight	  border	  between	  
the	  populations.	  Certainly	  clonal	  populations	  in	  drosophila	  models	  adhere	  to	  definite	  
borders	  when	   apposed	   resulting	   in	   apoptosis	   of	   cells	   along	   the	   border	   of	   the	   less	  
robust	   population	   (Morata	   &	   Ripoll	   1975).	   Such	   straight	   borders	   have	   also	   been	  
demonstrated	   in	   the	   colons	   of	   human	   females	   heterozygous	   for	   X-­‐linked	  
polymorphisms	  such	  as	  can	  be	  found	  in	  the	  gene	  glucose-­‐6	  pyruvate	  dehydrogenase.	  
Because	   of	   random	   X-­‐linked	   inactivation	   during	   embryogenesis,	   these	   females	   are	  
functionally	  mosaic	   at	   the	  mRNA	   level	   so	   that	   clonal	   populations	   can	  be	   visualised	  
with	   immunohistochemical	   stains	   (Novelli	   et	   al.	   2003).	   Although	   not	   specifically	  
assessed	  in	  Barrett’s,	  the	  clonal	  populations	  do	  not	  seem	  to	  share	  such	  a	  neat	  border	  
with	   the	   populations	   being	   rather	   more	   intermixed	   (Leedham	   et	   al.	   2008)	   Such	  
demographic	  descriptions	  are	   important	  not	  only	   in	  terms	  of	  describing	  how	  clonal	  
populations	  may	  interact	  but	  also	  as	  a	  description	  of	  the	  effect	  of	  clonal	  interactions.	  
It	   has	   been	   proposed	   that	   clonal	   populations	   with	   a	   similar	   fitness	   can	   slow	   each	  
other’s	  evolution,	  as	  characterised	  by	  the	  acquisition	  of	  new	  mutations,	  when	  these	  
populations	  collide	  (E.	  Martens	  &	  Hallatschek	  2011).	  	  
1.6.2.1.4 Genetic	  heterogeneity	  
Genetic	   heterogeneity	   is	   a	   prerequisite	   for	   clonal	   interactions	   to	   occur.	   Such	  
heterogeneity	  refers	  to	  the	  presence	  of	  several	  clonal	  populations	  in	  a	  tumour	  where	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clonality	  can	  be	  defined	  as	  a	  genetically	   identical	   subpopulation	  of	  cells	  descended	  
from	   a	   most	   recent	   common	   ancestor	   cell	   so	   that	   thesubpopulation	   inherits	   the	  
genetic	  aberrations	  of	   its	  parent	  (Kostadinov	  et	  al.	  2013).	  The	  presence	  at	  different	  
stages	   of	   carcinogenesis,	   as	   well	   as	   the	   spatial	   and	   temporal	   manifestations	   of	  
heterogeneity	   within	   a	   tumour,	   are	   beginning	   to	   be	   clarified.	   As	   such	   most	   GI	  
premalignant	   lesions	   are	   thought	   to	   be	   monoclonal	   although	   exceptions	   do	   exist	  
such	   as	   familial	   adenomatous	   polyposis	   (H.	   Clevers	   2011)as	   well	   as	   Barrett’s	  
oesophagus	  (Leedhamet	  al.	  2008).	  
The	  spatial	  characteristics	  of	  heterogeneity	  are	  also	  important	  to	  define	  in	  order	  to	  
determine	   the	   nature	   of	   clonal	   interactions.	   Clonal	   populations	   can	   exist	   in	  
geographically	   disparate	   areas	   (Gerlinger	   et	   al.	   2012)	   as	   well	   as	   being	   well	   mixed	  
(Inda	   et	   al.	   2010).	   Crypt	   by	   crypt	   analysis	   of	   oesophagectomy	   specimens	   from	  
patients	  with	  Barrett’s	  related	  adenocarcinomas	  indicates	  that	  some	  intermixing	  may	  
exist	   in	   Barrett’s	   related	   dysplasia	   so	   that	   any	   clonal	   interaction	   may	   be	   with	   a	  
nearest	  neighbour	  rather	  than	  a	  population	  effect	  (Leedhamet	  al.	  2008).	  
Heterogeneity	   is	   further	   complicated	   by	   a	   lack	   of	   temporal	   stasis	   particularly	   after	  
therapy	   is	   applied	   to	   a	   tumour.	   Such	   temporal	   heterogeneity	  whereby	   clones	  may	  
become	  more	   or	   less	   dominant	   over	   time	   has	   been	   demonstrated	   haematological	  
malignancies	   after	   chemotherapy	   (Landau	   et	   al.	   2013)	   when	   a	   previously	  
subdominant	  clone	  becomes	  dominant	  after	  chemotherapy	  has	  reduced	  the	  burden	  
of	   the	  originally	  dominant	  clone.	  Changes	   in	  clonal	  dominance	  over	   time	  have	  also	  
been	  seen	  after	  non-­‐steroidal	  anti-­‐inflammatory	  medication	  in	  Barrett’s	  oesophagus	  
(Kostadinov	   et	   al.	   2013).	   Given	   this	   temporal	   heterogeneity	   it	   would	   also	   be	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intriguing	  to	  determine	  how	  clonal	  populations	  vary	  with	  clinical	   response	  to	  other	  
therapies	  for	  Barrett’s	  such	  as	  endoscopic	  ablation.	  
1.6.3 Selective	  advantages	  of	  clonal	  populations	  
Although	  I	  have	  discussed	  several	  possible	  mechanisms	  for	  the	  growth	  of	  a	  mutant	  
clone,	   the	   consistent	   proliferation	   of	   any	   particular	   clone	   requires	   it	   to	   have	   a	  
selective	  advantage	  compared	  to	  other	  clonal	  populations.	  Several	  different	  cellular	  
phenotypes	   may	   confer	   such	   a	   selective	   advantage.	   Mutations	   of	   CDKN2A	   can	  
prevent	   production	   of	   functional	   p16	   protein	   and	   therefore	   encourage	   cells	   to	  
escape	  or	  prevent	  senescence	  (Hardie	  et	  al.	  2005).	  CDNK2A	  LOH,	  whereby	  one	  allele	  
of	   the	   gene	   is	   damaged,	   has	   been	   recognised	   as	   an	   event	   that	   can	   occur	   at	   the	  
metaplasia	   stage	   in	   progression	   to	   oesophageal	   cancer	   in	   the	   context	   of	   Barrett’s	  
oesophagus,	  as	  has	  methylation	  of	   its	  promoter	  region	  and	  point	  mutations(Wong,	  
Paulson,	  L	  J	  Prevo,	  et	  al.	  2001)The	  selective	  advantage	  conferred	  by	  the	  mutation	  in	  
this	   case	   could	   therefore	   be	   an	   escape	   from	   oncogene-­‐induced	   or	   replicative	  
senescence.Although	  generally	  occurring	  later	  in	  the	  metaplasia-­‐dysplasia-­‐carcinoma	  
progression,	   the	   gene	  TP53	   that	   produces	   the	   tumour	   suppressor	   protein	   p53	   can	  
also	  be	  mutated.	  When	  functioning	  normally,	  one	  of	  the	  roles	  of	  the	  p53	  is	  to	  control	  
apoptosis	   in	   response	   to	   cellular	   damage	   from	   a	   number	   of	   sources.	   Thus	   the	  
selective	  advantage	  may	  be	  as	  a	  result	  of	  apoptosis	  resistance.	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1.6.4 The	  clinical	  importance	  of	  field	  cancerization	  
Field	   cancerization	   can	   be	   demonstrated	   in	   many	   different	   tissues.	   The	  
gastrointestinal	  tract	  is	  of	  particular	  interest	  because	  of	  the	  burden	  of	  disease	  in	  this	  
organ	   in	   Western	   populations	   (Siegel	   et	   al.	   2012).	   Gastroenterologists	   have	   long	  
been	   aware	   of	   the	   cancerized	   field	   within	   the	   oesophagus,	   stomach	   and	   colon.	  
Barrett’s	  oesophagus	  in	  particular	  has	  a	  small	  risk	  of	  progression	  to	  adenocarcinoma	  
but	   enough	   to	  warrant	  many	   countries	   to	   engage	   in	   endoscopic	   surveillance	   on	   a	  
routine	   basis.	   These	   surveillance	   programmes	   have	   also	   been	   extended	   to	  
colonoscopic	   surveillance	  particularly	   for	  high	   risk	   conditions	   such	  as	   inflammatory	  
bowel	   disease	   (Cairns	   et	   al.	   2010).	   Such	   programmes	   are	   often	   unpleasant	   for	  
patients,	   not	   without	   inherent	   risk	   and	   are	   expensive.	   The	   discoveries	   that	   field	  
cancerization	   will	   provide	   may	   lead	   to	   biomarkers	   that	   will	   be	   able	   to	   stratify	  
patients	   by	   cancer	   development	   risk,	   rather	   than	   simply	   being	   biomarkers	   for	   the	  
presence	   of	   the	   disease.	   By	   demonstrating	   that	   certain	   molecular	   changes	   within	  
precancerous	   fields	   increase	   the	   risk	   of	  malignancy,	   patients	  with	   those	   particular	  
changes	  could	  be	  streamlined	  into	  a	  regular	  surveillance	  programme.	  Similarly,	  those	  
without	   the	   high-­‐risk	   molecular	   changes	   may	   not	   need	   to	   be	   surveyed.	   Although	  
such	  molecular	  biomarkers	  have	  not	  come	  to	  full	  fruition	  in	  gastroenterology	  there	  
are	   several	   avenues	   that	   are	   promising.	   As	   an	   example,	   LOH	   of	   TP53	   identifies	  
patients	  with	  Barrett's	  oesophagus	  who	  are	  likely	  to	  progress	  from	  non-­‐dysplastic	  or	  
low	   grade	   dysplasia	   to	   high	   grade	   dysplasia	   (Reid	   et	   al.	   2001).	   Patients	   with	  
aneuploidy	   and	   tetraploidy,	   which	   usually	   occurs	   after	   TP53	   inactivation	   and	   is	  
detectable	   by	   flow	   sorting	   of	   biopsies	   from	   Barrett’s	   oesophagus,	   are	   also	   more	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likely	   to	   progress	   to	   adenocarcinoma	   (Rabinovitch	   et	   al.	   2001).Thus	   molecular	  
abnormalities	  within	  a	  cancerized	  field	  could	  conceivably	  be	  used	  to	  stratify	  patients	  
according	  to	  risk.	  
A	   further	   important	   implication	   of	   field	   cancerization	   is	   considering	   how	  much	   to	  
resect	  when	  surgically	  removing	  a	  tumour.	  Currently	  assessment	  of	  surgical	  margins	  
relies	  on	  demonstrating	  the	  absence	  of	  cancer	  infiltration	  at	  resection	  margins.	  As	  an	  
example,	   a	   clear	  margin	   at	   oesophagectomy	   for	   Barrett’s	   related	   adenocarcinoma	  
relates	   to	   an	   improved	   prognosis	   (Dexter	   et	   al	   2001).	   Complementing	   this	   with	  
molecular	   studies	   to	  demonstrate	   that	   resection	  margins	  do	  not	   share	   the	  genetic	  
abnormalities	  of	  the	  field	  from	  which	  the	  resected	  cancer	  arose	  may	  provide	  further	  
prognostic	   information.	   For	   example,	   53%	   of	   patients	   with	   a	   KRAS	   codon	   12	  
mutation	   within	   normal	   resection	   margins	   following	   resection	   of	   pancreatic	  
adenocarincoma	  were	  subsequently	  found	  to	  have	  an	  unfavourable	  prognosis	  when	  
compared	  to	  normal	  molecular	  margins	  (Kim	  et	  al.	  2006).	  Furthermore	  extension	  of	  
routine	   resection	   margins	   for	   cancers	   that	   may	   exist	   in	   large	   areas	   of	   field	  
cancerization,	  may	   improve	   cure	   rates.	   Field	   cancerization	  of	  Barrett’s	   oesophagus	  
may	  extend	  a	  considerable	  distance	  (Galipeau	  et	  al.	  1999).	  Similar	  reports	  have	  been	  
noted	   in	   a	   Crohn’s	   colitis	   patient	   in	   whom	   the	   mutation	   responsible	   for	   a	   locally	  
resected	   rectal	   tumour	  was	   found	   in	   the	   ascending	   colon	   and	   terminal	   ileum	   and	  
gave	  rise	  to	  further	  adenocarcinomas	  (Galandiuk	  et	  al.	  2012).	  It	  is	  conceivable	  then,	  
that	  localised	  resection	  could	  prove	  inadequate	  to	  prevent	  tumour	  recurrence.	  
Quite	  apart	  from	  Barrett’s	  oesophagus,	  studies	  in	  field	  cancerization	  may	  also	  lead	  to	  
an	  understanding	  of	  non-­‐pathogenic	  tissue	  repopulation,	  and	  therefore	  may	  answer	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some	   fundamental	   questions	   regarding	   tissue	   development	   and	   cell	   population	  
homeostasis.	   Tracing	   the	   distribution	   of	   a	   clonal	   cell	   population	   by	   the	   use	   of	  
somatic	  or	  mitochondrial	  mutations	  has	  already	  been	  used	   to	  determine	  how	  cells	  
can	  clonally	  repopulate	  a	  colonic	  crypt.	  The	  principles	  of	  field	  cancerization	  can	  also	  
be	   applied	   to	   transplant	  medicine	   to	   determine	   how	   repopulation	   of	   a	   tissue	   can	  
occur	  with	   the	   implantation	   of	   a	   healthy	   cell	   population.	   Thus	   cell	   transplantation	  
rather	   than	  whole	  organ	   transplantation	  would	  benefit	   from	  understanding	  how	  a	  
clonal	  population	  comes	  to	  dominate	  a	  field	  although	  in	  this	  context	  it	  would	  be	  to	  
create	   a	   healthier	   organ	   rather	   than	   one	   at	   risk	   of	   developing	   cancer.	   This	  
development	   and	  maintenance	   of	   healthy	   tissue	   populations	   from	   implanted	   cells	  
has	  started	  to	  be	   investigated	   in	  gastroenterology	   (Oertel	  et	  al.	  2003;	  Uccelli	  et	  al.	  
2008).	  
1.7 Senescence	  in	  Barrett’s	  oesophagus	  
1.7.1 Overview	  of	  cellular	  senescence	  
Borrowing	   from	   ecological	   definitions	   (see	   section	   1.6.4),	   interacting	   clonal	  
populations	  should	  have	  a	  detectable	  effect	  on	  one	  another.	  Mechanisms	  of	  clonal	  
interactions	   have	   not	   been	   described	   in	   human	   cells	   either	   in	   vivo	   or	   in	   vitro	  
although	  cells	  from	  the	  same	  population	  can	  have	  a	  range	  of	  effects	  on	  each	  other’s	  
behaviour.	  	  
One	   such	   interaction	   may	   be	   cellular	   senescence.	   This	   refers	   to	   irreversible	   cell	  
growth	   arrest	   which	   can	   occur	   with	   the	   appropriate	   oncogenic	   stress	   (Rodier	  
&Campisi	  2011).	   It	  was	  originally	  described	   in	  the	  context	  of	  a	  process	  that	   limited	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the	   number	   of	   times	   a	   cell	   can	   divide	   known	   as	   Hayflick’s	   limit	   (Hayflick	   1965).	  
Although	  we	   now	   know	   this	   to	   be	   only	   one	   aspect	   of	   cellular	   senescence,	   escape	  
from	  senescence	   is	  now	  deemed	  to	  be	  one	  of	   the	  hallmarks	  of	  cancer	   (Hanahan	  &	  
Weinberg	  2011).	  It	  is	  becoming	  increasingly	  apparent	  that	  senescent	  cells	  can	  affect	  
neighbouring	  cells	  either	  of	   the	   same	  or	  different	   type	  although	   the	  nature	  of	   this	  
influence	  is	  still	  a	  matter	  of	  debate.	  Senescence	  is	  a	  cellular	  response	  to	  a	  range	  of	  
different	   insults	   and	   is	   abundant	   in	   Barrett’s	   oesophagus	   (Going	   et	   al.	   2002)	   .	   It	  
therefore	  represents	  a	  potential	  model	  to	  demonstrate	  a	  mechanism	  of	  intercellular	  
interactions.	  
1.7.2 The	  induction	  of	  senescence.	  
Understanding	  the	  causes	  of	  senescence	  also	  allows	  us	  to	  sub-­‐classify	  it.	  The	  original	  
description	  is	  known	  as	  replicative	  senescence	  and	  is	  a	  telomere	  dependent	  process	  
(Hayflick	  1965).	  DNA	  damage,	  especially	  that	  which	  causes	  double	  strand	  breaks,	  can	  
also	   cause	   a	   cell	   to	   undergo	   senescence(Parrinello	  et	   al.	   2003).	   Senescence	   in	   this	  
context	  is	  strongly	  p53	  dependent	  accompanied	  by	  p21	  expression	  (DiLeonardo	  et	  al.	  
1994),	   and	   can	   also	   induce	   p16	   as	   a	   second	   pathway	   to	   maintain	   growth	   arrest	  
(Krishnamurthy	  et	  al.	  2004;	  Jacobs	  &	  de	  Lange	  2004).	  DNA	  damage	  can	  be	  caused	  by	  
a	  variety	  of	  different	   insults	  such	  as	   ionizing	  radiation	  (Mirzayanset	  al.	  2005;	  Tsaiet	  
al.	  2009).	  and	  chemotherapeutic	  insults	  (Herbiget	  al.	  2004).	  
Oncogenes	   can	  also	  be	  potent	   inducers	  of	   senescence.	   The	  oncogenic	   form	  of	  Ras	  
and	   members	   of	   its	   pathway	   are	   well	   known	   to	   induce	   senescence	   in	   fibroblasts	  
(Dimri	  et	  al.	  2000;	  Lin	  et	  al.1998;	  Michaloglou	  et	  al.2005).Senescence	  in	  this	  context	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may	   act	   to	   counteract	   excessive	   mitogenic	   stimulation.	   The	   pathways	   involved	   in	  
oncogene	   induced	   senescence	  may	   be	   similar	   to	   telomere	   induced	   senescence	   in	  
that	   oncogene	   induced	   senescence	   (OIS)	   can	   induce	   a	   DNA	   damage	   response	   and	  
can	   also	   induce	   p16	   and	   senescence	   associated	   heterochromatin	   foci	   (SAHF)	  
formation	  (Narita	  et	  al.	  2003;	  Ohtani	  2001).	  Although	  oncogene	  induced	  senescence	  
does	   not	   occur	   in	   all	   cells	   (Benanti	   &	   Galloway	   2004),	   it	   is	   still	   relevant	   to	   the	  
development	   of	   cancer	   in	   mammalian	   systems.	   Activated	   oncogenes	   producing	  
strong	   mitogenic	   signalling	   in	   mice	   produce	   lesions	   consisting	   of	   senescent	   cells,	  
andbenign	  naevi	   in	   human	   skin	   contain	   cells	   that	   express	  oncogenic	  BRAF	  and	  are	  
senescent	  (Colladoet	  al.	  2005;	  Michaloglou	  et	  al.	  2005).	  
Finally,	   senescence	   can	   be	   induced	   by	   a	   range	   of	   other	   stimuli	   loosely	   collected	  
under	  the	  title	  of	  stress.	  For	  example,	  chronic	   interferon	  stimulation	   induces	  a	  p53	  
dependent	  DDR	  and	  subsequent	  senescence	  response	  (Campisi&	  d’	  Adda	  di	  Fagagna	  
2007).	   Cell	   culture	   stress	   (culture	   shock)	   such	   as	   inadequate	   or	   hyperphysiological	  
growth	   conditions	   can	   also	   induce	   a	   p16	   dependent,	   telomere	   independent	  
senescence	  response,	  as	  can	  oxidative	  stress	  (Ramirezet	  al.	  2001),	  which	  may	  or	  may	  
not	  be	  p16	  dependent	  (Itahana	  et	  al.2003).	  
1.7.3 Senescence	  pathways	  
Regardless	   of	   the	   many	   and	   disparate	   causes	   of	   cellular	   senescence,	   its	   initiation	  
seems	   to	   depend	   on	   major	   tumour	   suppressor	   pathways	   controlled	   by	   p16/Rb	  
(phosphorylated	  retinoblastoma	  protein),	  as	  well	  as	  by	  p53	  (see	  Figure	  1-­‐4).	  p16	  is	  a	  
cyclin	   dependent	   kinase	   inhibitor	   and	   is	   able	   to	   bind	   both	   CDK4	   and	   6	   (Rocco	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&Sidransky	   2001)	   (see	   section	   1.5.1.1).	   p53	   is	   also	   a	   central	   senescence	   initiating	  
pathway	   involving	   p21	   is	   also	   a	   cyclin	   dependent	   kinase	   inhibitor,	   which	   prevents	  
cell-­‐cycle	   progression	   by	   inhibiting	   the	   activity	   of	   cyclin	   E-­‐associated	   CDK2.	   Its	  
transcription	   from	   CDKN1A	   is	   under	   the	   direct	   control	   of	   p53.	   The	   relative	  
contributions	  of	  the	  p16-­‐Rb	  and	  p53	  pathway	  to	  senescence	  are	  unclear.	  Phenotypic	  
changes	  exist,	  however,	  that	  are	  common	  to	  both:	  
a)	   Irreversible	  growth	  arrest.	  Occasionally,	  p53	  suppression	  can	  reverse	  senescence	  
in	  p16	  inactivated	  cells	  although	  this	  has	  never	  been	  seen	   in	  vivo	  (Beausejour	  et	  al.	  
2003).	  
b)	  An	  increase	  in	  cell	  size	  (Hayflick	  1965).	  
c)	  They	  express	  senescence	  associated	  β-­‐galactosidase	  which	  identifies	  lysosomal	  β-­‐
D-­‐galactosidase,	   an	   enzyme	  which	   is	   expressed	   as	   part	   of	   the	   increased	   lysosomal	  
compartment	  that	  characterises	  senescent	  cells	  (Dimri	  et	  al.	  1995).	  
d)	  Unless	  unable	   to,	  most	  senescent	  cells	  express	  p16	  which	   itself	  can	  activate	   the	  
formation	   	   of	   senescence	   associated	   heterochromatin	   foci,	   nuclear	   DNA	   domains	  
enriched	  for	  histone	  modifications	  (Narita	  et	  al.	  2003).	  
e)In	   the	   context	   of	   persistent	   DNA	   damage	   response	   signalling,	   senescent	   cells	  
secrete	   a	   range	   of	   proteases,	   cytokines	   and	   other	   factors	   which	   is	   termed	   the	  
senescent	  associated	  secretory	  phenotype	  This	  has	  powerful	  autocrine	  and	  paracrine	  
effects	   which	   can	   be	   pro	   and	   anti-­‐tumorigenic	   (Acosta	   et	   al.	   2008;	   Kuilman	   et	   al.	  






Figure	  1-­‐4:	  Overview	  of	  major	  senescence	  pathways.	  
The	   two	  most	   important	   are	   the	   p53-­‐p21	   pathway	   and	   the	   p16-­‐Rb	   pathway.	   Both	   pathways	   are	  
activated	  in	  response	  to	  a	  range	  of	  cellular	  insults	  which	  result	  in	  upregulation	  of	  the	  DNA	  damage	  
response	  pathway.	  The	  p53-­‐p21	  pathway	  is	  activated	  in	  response	  to	  the	  presence	  of	  human	  protein	  
kinases	  ATM	  (ataxia-­‐telangiectasia,	  mutated)/ATR	  (ATM	  and	  Rad3-­‐related).	  SA-­‐β	  Gal=	  Senescence	  
associated	  β	  galactosidase;	   SAHF=	   senescence	  associated	  heterochromatin	   foci;	   SASP=	   senescence	  
associated	  secretory	  profile.	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1.7.4 The	  pathology	  of	  senescence-­‐	  the	  senescence	  associated	  secretory	  profile	  
Senescence	  has	  been	  well	  studied	  in	  the	  context	  of	  cancer.	  Mutations	  in	  CDKN2A,	  Rb	  
or	  TP53	  pathways	  exist	   in	  most	  cancers,	  and	  markers	  of	  senescence	  are	  reduced	  in	  
cancers,	  whereas	   their	   premalignant	   counterparts	   such	   as	  malignant	   human	   naevi	  
and	   colorectal	   adenomas	   show	   abundant	   senescence	   (Bartkova	   et	   al.	   2005;	  
Michaloglou	  et	  al.	  2005).	  
However	   senescence	   may	   be	   more	   complex	   than	   simply	   a	   mechanism	   to	   cause	  
growth	  arrest	  in	  damaged	  cells.	  Cells	  that	  have	  undergone	  a	  growth	  arrest	  continue	  
to	  be	  metabolically	  active.	  Large	  scale	  mRNA	  arrays	  have	  demonstrated	  that	  there	  is	  
a	   plethora	   or	   expressed	   factors;	   this	   is	   now	   termed	   the	   senescence	   associated	  
secretory	  profile	   (SASP)	   and	  has	  been	  demonstrated	  as	  a	   relatively	  well	   conserved	  
expression	   profile	   in	   a	   number	   of	   human	   cell	   types	   including	   liver	   stellate	  
cells(Schnabl	  et	  al.	  2003)endothelial	  cells	  (Shelton	  et	  al.	  1999),	  and	  epithelial	  cells	  of	  
the	  retinal	  pigment,	  mammary	  gland,	  colon,	  lung,	  pancreas,	  and	  prostate	  (Collado	  et	  
al.	   2005;	   Coppe	   et	   al.	   2008;	   Shelton	   et	   al.	   1999;	   Schwarze	   et	   al.	   2002).	   The	   SASP	  
consists	  of	  a	  several	  families	  of	  proteins	  which	  can	  be	  broadly	  divided	  into	  two	  major	  
categories:	  soluble	  signalling	   factors	   (interleukins,	  chemokines	  and	  growth	  factors),	  
secreted	   proteases,	   and	   secreted	   insoluble	   proteins/extracellular	   matrix	   (ECM)	  
components	  such	  as	  matrix	  metalloprotein	  members	   (MMP)	  (	  Liu	  &	  Hornsby	  2007;	  
Millis	  et	  al.	  1992)	  and	  serine	  proteases	  (Comi	  et	  al.	  1995).	  Of	  the	  former	  category,	  IL-­‐
6	   and	   IL-­‐8	   are	   the	   most	   prominent.	   The	   expression	   of	   these	   cytokines	   has	   been	  
associated	  with	   DNA	   damage	   and	   oncogenic	   stress–induced	   senescence	   of	  mouse	  
and	   human	   keratinocytes,	   melanocytes,	   monocytes,	   fibroblasts,	   and	   epithelial	  
64	  
	  
cells(Coppe	   et	   al.	   2008;	   Kuilman	   et	   al.	   2008;	   Lu	   et	   al.	   2006).	   They	   are	   also	   under	  
direct	  regulation	  by	  the	  DDR	  and	  are	  upregulated	  in	  response	  to	  ATM	  (Rodier	  et	  al.	  
2009).	  IL-­‐1	  is	  similarly	  upregulated	  in	  senescent	  cells	  (Bode-­‐Boger	  et	  al.	  2005;	  P	  et	  al.	  
2003;	  McLachlan	  et	  al.	  1995).	  IL-­‐8	  secretion	  is	  accompanied	  by	  an	  upregulation	  of	  IL-­‐
8	   receptor	   expression	   possibly	   as	   a	   mechanism	   of	   self-­‐regulation	   of	   senescence	  
(Acosta	  et	  al.	  2008).	  Within	  this	  category,	  other	  secreted	  factors	  such	  as	  the	  insulin	  
growth	   factor	   family	  and	  colony	  stimulating	   factors(Wang	  et	  al.	  1996;	  Coppe	  et	  al.	  
2008)are	  also	  secreted.	  
The	  effect	  of	  SASP	  is	  manifold.	  One	  of	  the	  most	  prominent	  effects	  is	  the	  proliferation	  
of	  epithelial	  cells.	  Proliferation	  of	  premalignant	  and	  malignant	  breast	  epithelial	  cells	  
can	  be	  stimulated	  by	  senescent	  fibroblasts	  (Coppe	  et	  al.	  2008;	  Krtolica	  et	  al.	  2001)	  as	  
can	  prostate	  epithelium	   (Bavik	  et	  al.	   2006).	   Increased	   cell	  migration,	   invasion,	   and	  
promotion	   of	   leucocyte	   recruitment	   (Xue	   et	   al.	   2007;	   Coppe	   et	   al.	   2008)	   are	   also	  
documented	  effects	  of	  the	  SASP.	  
The	  SASP	  may	  be	  particularly	  relevant	   in	  the	  context	  of	   ionizing	  radiation.	   It	   is	  well	  
documented	   that	   cells	   in	   contact	  with	  cells	   that	  have	  undergone	   ionizing	   radiation	  
induced	   senescence	   demonstrate	   a	   range	   of	   altered	   behaviour	   including	   cell	  
proliferation,	  adaptive	  protective	  effects	  and	  malignant	  transformation	  (Dickey	  et	  al.	  
2009;	  Mothersill	  &	  Seymour	  1997).	  This	  has	  also	  been	  demonstrated	  to	  be	  an	  effect	  
of	   senescent	   conditioned	   medium	   (Coppe	   et	   al.	   2008;	   Dickey	   et	   al.	   2009),	   and	  
candidates	   for	   this	   effect	   include	   IL-­‐8	   and	   IL-­‐6	   which	   are	   secreted	   by	   irradiated	  
senescent	  cells	  (Shelton	  et	  al.	  1999;	  Freund	  et	  al.	  2010).	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1.7.5 Senescence	  in	  Barrett’s	  oesophagus	  
The	   ability	   of	   senescent	   cells	   to	   effect	   neighbouring	   cells	   therefore	   represents	   a	  
potential	   mechanism	   for	   precancerous	   cells	   to	   affect	   neighbouring	   non-­‐senescent	  
cells,	   or	   vice	   versa	   in	   the	   context	   of	   Barrett’s	   oesophagus.	   How	   abundant	   is	  
senescence	   in	   Barrett’s	   oesophagus?	   This	   remains	   an	   understudied	   area.	   SA	   β-­‐
galactosidase	  staining	  of	   frozen	  Barrett’s	  samples	  has	  demonstrated	  that	  there	   is	  a	  
consistent	   upregulation	   in	   non-­‐dysplastic,	   low	   and	   high	   grade	   dysplastic	   Barrett’s	  
epithelium	   with	   lower	   levels	   seen	   when	   adenocarcinoma	   develops	   (Going	   et	   al.	  
2002).	   This	   is	   despite	   the	   prevailing	   view	   that	   p16	   expression	   loss	   may	   occur	   in	  
metaplasia	  (Hardie	  et	  al.	  2005)	  and	  therefore	  Barrett’s	  progression	  may	  be	  related	  to	  
an	  escape	  from	  senescence.	  A	  reconciliation	  of	  these	  views	  may	  be	  the	  upregulation	  
of	   the	   alternative	   senescence	   pathway,	   p21	   of	   which	   there	   is	   some	   evidence.	  
Immunohistochemical	   analysis	   by	   Hanas	   et	   al.	   has	   demonstrated	   that	   there	   is	   a	  
significant	   p21	   expression	   from	   low	   grade	   dysplasia	   which	   is	   maintained	   to	  
adenocarcinoma	  (Hanas	  et	  al.	  1999).	  Thus	  far	  the	  relative	  contributions	  of	  p21	  and	  
p16	  in	  Barrett’s	  progression	  have	  not	  been	  studied.	  
Barrett’s	   oesophagus	   occurs	   in	   the	   context	   of	   a	   toxic	   environment	   (Menges	   et	   al.	  
2001)	   constituents	   of	  which	   are	   able	   to	   induce	  DNA	  damage(Clemons	  et	   al.	   2007)	  
which	   is	   a	   potent	   up-­‐regulator	   of	   senescence	   (Rodier	   et	   al.	   2009).	   If	   secreted	  
senescence	  associated	  proteins	  can	  be	  protumorigenic	  then	  it	  is	  possible	  that	  clonal	  
populations	  better	  able	  to	  take	  advantage	  of	  such	  signals	  may	  progress	  through	  the	  
metaplasia	   dysplasia	   cancer	   pathway	   more	   quickly	   than	   others	   in	   a	   genetically	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heterogeneous	  population.	  As	  such,	  abrogation	  of	  a	  senescence	  response	  may	  be	  a	  
worthy	  target	  to	  prevent	  subclonal	  progression.	  
1.8 Current	  therapies	  for	  Barrett’s	  related	  cancer	  and	  dysplasia	  
As	  mentioned	   in	   section	   1.6.4,	   understanding	   field	   cancerisation	   as	   a	   spread	   of	   a	  
clonal	   epithelial	   population	   in	   the	   polyclonal	   environment	   of	   Barrett’s	   has	   several	  
clinical	   implications	   not	   least	   of	   which	   is	   an	   understanding	   of	   the	   effects	   of	  
eradicating	   clonal	   populations	   using	   endoscopic	   therapy	   on	   a	   Barrett’s	   segment.	  
Until	   relatively	   recently,	   the	  only	   therapy	  offered	   for	  BO	  was	  medical	   (largely	  with	  
proton	   pump	   inhibitors)	   with	   decreasing	   intervals	   between	   endoscopies	   for	  
everything	   up	   to	   high	   grade	   dysplasia	   (HGD)	   (British	   Society	   of	   Gastroenterology	  
2005	  guidelines	   (www.bsg.org.uk))	   ,	  or	   surgical	   therapy	   for	  cancer	   ,and	  endoscopic	  
therapy	  had	  little	  or	  no	  established	  role.	  Proton	  pump	  inhibitors	  (PPI)	  alone	  can	  be	  
effective	  in	  reducing	  the	  rate	  of	  progression	  to	  cancer	  (Hillman	  et	  al.	  2004)	  and	  can	  
cause	  regression	  of	  dysplasia	  in	  some	  but	  by	  no	  means	  all	  cases	  (Heath	  et	  al.	  2007)	  .	  
Surgery	  with	  curative	  intent	  is	  associated	  with	  high	  rates	  of	  mortality	  and	  morbidity	  
(Tan	  et	  al.	  1999;	  Müller	  et	  al.	  1990;	  Matthews	  et	  al.	  1986).	  Thus	  a	  niche	  has	  evolved	  
for	   other	   non-­‐surgical	   therapies	   particularly	   in	   the	   treatment	   of	   dysplastic	   BO.	  
Endoscopic	  therapy	  is	  of	  particular	  interest	  because	  the	  oesophagus	  is	  left	  intact	  and	  
in	   situ	  with	   obvious	   benefits	   to	   the	   patient.	   However,	   given	   the	   concept	   of	   field	  
cancerization,	   does	   endoscopic	   therapy	   remove	   macroscopically	   abnormal	   tissue	  
only,	   or	   is	   it	   successful	   at	   removing	   the	   clonal	   populations	   that	   are	   presumed	   to	  
cause	  dysplasia?	  Further,	  how	  does	  endoscopic	  therapy	  change	  the	  demographics	  of	  
clonal	   populations	   in	   this	   polyclonal	   lesion	   in	   a	   manner	   that	   has	   already	   been	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established	  in	  haematological	  malignancies	  (Landau	  et	  al.	  2013)	  and	  can	  endoscopic	  
therapies	  possibly	  negatively	  affect	  outcome?	  
1.8.1 Types	  of	  endoscopic	  therapy	  
Endoscopic	   therapy	   can	   largely	   be	   subdivided	   into	   ablation	   and	   non-­‐ablation	  
techniques.	   Ablation	   techniques	   consist	   of	   cryotherapy,	   laser	   ablation,	  
photodynamic	   therapy	   (PDT)	   and	   radiofrequency	   ablation	   (RFA).	   These	   seek	   to	  
destroy	   tissue	   and	   cannot	   retrieve	   samples	   for	   histological	   analysis.	   Non-­‐ablation	  
techniques	  include	  endoscopic	  mucosal	  resection	  (EMR)	  and	  endoscopic	  submucosal	  
dissection	  and	  seek	  to	  remove	  rather	  than	  destroy	  tissue	  so	  that	  it	  can	  be	  analysed	  
histologically.	  The	  therapies	  can	  also	  be	  divided	  according	  to	  whether	  they	  are	  focal-­‐	  
so	  that	  they	  are	  treating	  a	  specific	  area	  of	  concern,	  or	  field	  therapies	  which	  destroy	  
the	   area	   of	   concern	   and	   the	   Barrett’s	   tissue.	   Focal	   and	   field	   therapies	   can	   be	  
combined	  as	  can	  the	  different	  modes	  of	  therapy.	  Different	  types	  of	  ablation	  therapy	  
exist.	  These	  include	  argon	  plasma	  coagulation	  (APC),	   laser	  therapy	  cryotherapy	  and	  
photodynamic	  therapy.	  Although	  these	  three	  have	  been	  used	  previously,	  and	  are	  still	  
occasionally	   used	   now,	   the	  mainstay	   of	   endoscopic	   therapy	   is	   RFA	   because	   of	   the	  
lower	  complication	  and	  higher	  success	  rate	  and	  therefore	  this	  introduction	  discusses	  
this	  modality	  specifically.	  
1.8.1.1 Radiofrequency	  ablation	  
RFA	   involves	   the	   delivery	   of	   diathermy	  energy	   through	   either	   a	   balloon	  which	  will	  
deliver	   the	  energy	   in	   a	   circumferential	   fashion,	   or	  via	  a	   focal	   probe.	   The	  energy	   is	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delivered	  at	  10	  to	  12	  J/cm2	  to	  produce	  a	  depth	  of	  damage	  of	  around	  700	  µm	  which	  
corresponds	  to	  destruction	  of	  the	  mucosa	  without	  destruction	  of	  the	  submucosa	  so	  
that	  the	  complications	  of	  ablation	  such	  as	  bleeding	  fibrosis	  and	  stricturing	  are	  less	  of	  
a	  concern	  (Fleischer	  &	  Sharma	  2008).	  The	  burnt	  tissue	  (called	  the	  coagulum)	  is	  then	  
scraped	  off	  to	  ensure	  that	  RFA	  has	  been	  adequately	  and	  equally	  applied.	  
The	  first	  multicentre	  trial	  performed	  1-­‐2	  sessions	  of	  circumferential	  RFA	  in	  100	  non-­‐
randomized	  patients	  with	  CLO	  only.	   They	  were	   followed	  up	   for	   a	   period	  of	   1	   year	  
during	  which	  70%	  had	  complete	  remission	  of	  BO	  (Sharmaet	  al.	  2007).	  The	  addition	  of	  
focal	  ablation	  to	  circumferential	  seemed	  to	  improve	  this	  figure	  to	  98%	  remission	  of	  
BO	   in	   62	   patients	   who	   underwent	   surveillance	   after	   an	   initial	   session	   of	  
circumferential	  RFA	  for	  2.5	  years	  (Fleischer	  et	  al.	  2008).	  RFA	  was	  also	  studied	  in	  142	  
patients	  with	  BO	  HGD.	  At	  1	  year	  follow-­‐up,	  complete	  remission	  of	  HGD	  was	  achieved	  
in	  90.2%,	  complete	  remission	  of	  dysplasia	  in	  80.4%,	  and	  complete	  remission	  of	  CLO	  
in	  54.3%	  of	  patients	  (Ganz	  et	  al.	  2008).	  
In	  the	  largest	  randomised,	  controlled	  trial	  to	  date,	  patients	  with	  CLO,	  LGD,	  HGD	  and	  
IMC	  were	  treated	  either	  with	  up	  to	  four	  sessions	  of	  RFA	  or	  with	  a	  sham	  procedure.	  
Complete	   eradication	   of	   intestinal	   metaplasia	   rates	   were	   significantly	   higher	   in	  
patients	  undergoing	  RFA	  than	  sham	  procedures:	  73.8%	  and	  81.0%	  for	  HGD	  and	  LGD	  
respectively.	   Overall	   77.4%	   of	   patients	   had	   complete	   eradication	   of	   CLO.	  
Furthermore,	   less	   patients	   progressed	   in	   the	   RFA	   group	   (3.6%	   ablation	   vs.	   16.3%)	  
and	   there	   were	   less	   subsequent	   cancers	   in	   the	   treatment	   arm	   (1.2%	   ablation	   vs.	  
9.3%	  control)	  (Shaheen	  et	  al.	  2009).	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A	   combination	   of	   modalities	   for	   HGD	   may	   prove	   more	   effective	   yet.	   For	   visible	  
lesions,	  EMR	  followed	  by	  RFA	  of	  residual	  BO	  tissue	  has	  resulted	  in	  98%	  eradication	  of	  
dysplasia	  with	  no	  recurrence	  in	  patients	  with	  successful	  eradication	  after	  a	  21	  month	  
follow-­‐up	  (R.	  Pouw	  et	  al.	  2008).	  Interestingly	  rigorous	  biopsy	  evaluation	  of	  the	  neo-­‐
squamous	  epithelium	  in	  a	  group	  of	  22	  post-­‐RFA	  patients	  with	  baseline	  BO	  with	  IMC	  
or	  HGD	  showed	  no	  evidence	  of	  persistent	  genetic	  abnormalities	  or	  buried	  BO	  crypts	  
(Pouw	  et	  al.	  2009).	  	  
1.8.2 Methods	  of	  assessing	  success:	  ablation	  endpoints	  
1.8.2.1 The	   definition	   of	   successful	   endoscopic	   treatment	   depends	   on	   the	  
treatment	  intention.	  
The	  defined	  endpoints	  of	  ablation	   therapy	  vary	  between	  clinical	   trials	  with	  various	  
studies	   quoting	   successful	   eradication	   of	   IMC	   rates,	   or	   eradication	   of	   dysplasia,	   or	  
eradication	  to	  a	  squamous	  lining(Fleischeret	  al.	  2008;	  Shaheen	  et	  al.	  2011;	  Shaheen	  
et	  al.	  2009).	  Strong	  arguments	  exist	   for	  eradication	  to	  a	  squamous	   lining	  being	  the	  
most	  effective	  clinical	  endpoint.	  
In	  a	  study	  of	   factors	   implicated	   in	  recurrence	  of	  dysplasia	  after	  ablation,	  persistent	  
Barrett’s	  metaplasia	  was	  deemed	  to	  be	  a	  significant	  risk	  (Badreddine	  et	  al.	  2010).	  In	  
fact	  residual	  non-­‐buried	  BO	  may	  carry	  the	  same	  genetic	  abnormalities	  found	  in	  the	  
HGD	   indicating	   that	   although	   there	   is	   a	   lower	   risk	   of	   progression	   as	   defined	   by	  
histological	   grade,	   there	   is	   still	   the	   potential	   for	   progression	   (Krishnadath	   et	   al.	  
2000).	  That	  the	  intention	  of	  ablation	  has	  not	  always	  been	  defined	  as	  an	  intention	  to	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eradicate	  all	  Barrett’s	  mucosa	  has	  led	  to	  some	  confusion	  in	  defining	  poor	  responders	  
versus	   those	   in	   whom	   true	   recurrence	   is	   seen.	   As	   an	   example,	   a	   trial	   examining	  
ablation	   of	   HGD	   may	   present	   data	   as	   eradication	   of	   HGD	   with	   follow-­‐up	   data	  
showing	  its	  recurrence.	  If	  the	  HGD	  was	  only	  eradicated	  to	  LGD	  or	  even	  to	  columnar	  
lined	   oesophagus,	   then	   that	   could	   be	   interpreted	   as	   a	   poor	   response	   rather	   than	  
recurrence	   as	   in	   fact	   the	   main	   predisposing	   factor	   to	   progression	   was	   itself	  
insufficiently	  eradicated.	  
Examination	   of	   complete	   eradication	   of	   CLO	   rates	   rather	   than	   intention	   to	   treat	  
outcomes,	   reveals	   less	   impressive	   therapy	  success	   rates.	   In	  one	  study,	   cryotherapy	  
demonstrated	  a	  complete	  CLO	  eradication	  rate	  in	  6	  out	  of	  30	  patients	  only	  (J.	  Dumot	  
et	  al.	  2009).	  In	  another	  trial,	  PDT	  managed	  complete	  CLO	  eradication	  in	  only	  33%	  of	  
those	  with	   intramucosal	   carcinomas-­‐	   possibly	   a	   group	   of	   patients	  who	  most	   need	  
complete	  CLO	  ablation	  (Overholt	  et	  al.	  2003).	  RFA	  in	  various	  trials	  manages	  complete	  
CLO	  eradication	   in	  54	   to	  79%	   (Sharma	  et	  al	  2007;	  Ganz	  et	  al.	  2008;	  Shaheen	  et	  al.	  
2009;	  Herrero	  et	  al.	  2011).	  The	  most	  impressive	  CLO	  ablation	  rates	  are	  in	  fact	  with	  a	  
combination	  of	  modalities	  such	  as	  EMR	  for	  visible	  lesions	  followed	  by	  RFA	  (Pouw	  et	  
al.	  2008).	  
1.8.2.2 Treatment	  efficiency	  over	  time	  
Even	   in	  patients	  with	  complete	  eradication	  of	  non-­‐dysplastic	  Barrett’s	  oesophagus,	  
there	   is	   an	   appreciable	   recurrence	   rate	   for	   Barrett’s	   and	   dysplasia.	   The	   initial	  
regrowth	  after	  therapy	  may	  be	  squamous	  and	  although	  the	  time	  of	  re-­‐conversion	  to	  
columnar	  epithelium	  is	  unknown,	  if	  we	  assume	  it	  to	  be	  similar	  to	  the	  pathway	  that	  
untreated	   BO	   follows,	   it	   can	   take	   several	   years	   (Hamilton	   &Yardley	   1977).	   The	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progression	  of	  CLO	  to	  LGD	  may	  also	  take	  a	  number	  of	  years	  (McCallum	  et	  al.	  1990)	  
and	   assuming	   that	   LGD	   is	   always	   progressive,	  which	   itself	   is	   contentious,	   this	  may	  
also	  take	  some	  time	  (Peters	  et	  al.	  1999;	  Hameeteman	  et	  al.	  1989;	  Miros	  et	  al.	  1991).	  
Furthermore,	  longitudinal	  studies	  estimate	  of	  the	  progression	  of	  HGD	  to	  cancer	  may	  
take	   24	  months	   on	   average	   with	   a	   range	   of	   6	   to	   43	  months	   (Hameeteman	   et	   al.	  
1989)(Peters	  et	  al.	  1999).	  As	  an	  example	  ,in	  one	  PDT	  trial	  4	  patients	  whose	  original	  
histology	  had	  shown	  IMC,	  and	  who	  had	  a	  complete	  remission	  as	  defined	  by	  absence	  
of	  cancer	  or	  dysplasia,	  had	  a	  recurrence	  of	  cancer	  within	  12	  months,	  but	  a	  further	  6	  
were	  noted	  by	  48	  months	  (Pech	  et	  al.	  2005).	  Patients	  who	  have	  undergone	  RFA	  also	  
have	  an	  appreciable	  recurrence	  rate	  which	  becomes	  evident	  after	  3	  years	  even	  with	  
repeated	   RFA	   therapy	   (Shaheen	   et	   al.	   2011).	   Thus	   the	   follow-­‐up	   time	   to	   define	  
success	  is	  crucial	  to	  establish	  reliable	  recurrence	  rates.	  	  
1.8.2.3 Why	  does	  endoscopic	  treatment	  fail?	  
Although	  most	   trials	   concentrate	  on	  positive	  outcomes	   such	  as	   treatment	   success,	  
an	   interesting	  question	   is	  why	   treatment	   fails	   in	  a	  patient.	   There	  are	   four	  possible	  
causes	  of	  this:	  
1.8.2.3.1 Therapy	  has	  not	  targeted	  the	  affected	  tissue	  
Ablation	  therapy	  cannot	  always	  guarantee	  to	  ablate	  all	  Barrett’s	   tissue	  successfully	  
even	  with	   circumferential	  modalities	   as	   can	   be	   performed	  with	   RFA.	   In	   the	   AIM-­‐2	  
study	   21	   of	   69	   patients	   (30%)	   who	   had	   undergone	   an	   average	   of	   1.5	   sessions	   of	  
circumferential	   RFA	   still	   had	  evidence	  of	   intestinal	  metaplasia	   and	  had	   to	  undergo	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further	  focal	  ablation	  (Fleischer	  et	  al.	  2007).	  Residual	  tissue	  has	  also	  been	  found	  with	  
other	  ablation	  modalities	  and	  can	  be	  interpreted	  as	  the	  percentage	  who	  of	  patients	  
who	  did	  not	  achieve	  a	  complete	  eradication	  of	  intestinal	  metaplasia.The	  persistence	  
of	  non-­‐buried	  Barrett’s	  may	  relate	  to	  the	  operator’s	  application	  of	  the	  ablation	  being	  
inadequate	  or	   the	  technique	   itself	  missing	  the	  target.	  Circumferential	  RFA	  may	  not	  
adequately	  ablate	  BO	  at	  the	  gastro-­‐oesophageal	  junction	  for	  example.	  A	  third	  reason	  
may	  be	  related	   to	  mucosal	  penetration.	  Assuming	  BO	  to	  be	  a	  disease	  solely	  of	   the	  
mucosa-­‐	  and	  this	  is	  itself	  contentious-­‐	  the	  depth	  of	  ablation	  should	  be	  at	  least	  that	  of	  
the	  depth	  of	  the	  mucosa.	  This	  has	  to	  be	  balanced	  against	  the	  risk	  of	  complications	  
caused	   by	   necrosis	   and	   fibrosis	   of	   the	   submucosa.	   BO	   has	   an	   average	   depth	   of	  
0.6mm	  (Ackroyd	  et	  al.	  1999)	  .	  RFA	  typically	  penetrates	  to	  a	  depth	  of	  0.7mm.	  PDT	  can	  
produce	   tissue	   necrosis	   up	   to	   a	   depth	   of	   6mm	   which	   may	   account	   for	   its	   high	  
stricture	   rate	   (Chatlani	  et	  al.	  1991;	  Heier	  et	  al.	  1995).	  Laser	   therapy	  can	  produce	  a	  
depth	  of	  necrosis	  between	  3-­‐4	  mm	  with	  the	  Nd:YAG	   laser	  to	  1	  mm	  with	  the	  argon	  
lasers	   (van	   den	   Boogert	   et	   al.	   1999)	  and	   cryoablation	   can	   reach	   a	   depth	   of	   2mm	  
(Johnston	  et	  al.	  2005)	  .	  Clearly	  therefore	  all	  should	  be	  able	  to	  eliminate	  all	  Barrett’s	  
mucosa.	  The	  fact	  that	  this	   is	  not	  the	  case	  may	  relate	  either	  to	  the	  variability	  of	  the	  
thickness	  of	  Barrett’s	  mucosa-­‐	  the	  average	   is	  0.6mm	  but	  can	  be	  as	  deep	  as	  1.3mm	  
(Chandrasoma	   &	   Wikramasinghe	   2003)	  -­‐	   or	   to	   the	   ablation	   technique	   having	  
difficulty	  accessing	  the	  source	  of	  the	  Barrett’s	  tissue.	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1.8.2.3.2 The	  pathology	  is	  hidden	  
The	  persistence	  of	   somatic	  mutations	   thought	   to	  contribute	   to	  BO	  progression	  has	  
been	   detected	   after	   PDT	  in	   2	   out	   of	   3	   patients	  who	   had	   an	   initial	   downstaging	   of	  
their	  HGD	  after	  the	  therapy	  but	  in	  whom	  HGD	  recurred	  within	  the	  12	  month	  follow-­‐
up	  (Krishnadath	  et	  al.	  2000).	  Persistence	  has	  also	  been	  noted	  after	  RFA	  (Finkelstein	  &	  
Lyday	  2008)	  .	  In	  this	  study	  the	  persistent	  mutation	  was	  noted	  in	  only	  1	  patient	  out	  of	  
16	   who	   was	   refractory	   to	   treatment.	   This	   persistence	   of	   genetic	   phenomena	  
suggests	   the	  persistence	  of	  a	   clonogenic	   cell	   that	   can	  cause	  dysplasia	   to	   recur	  and	  
suggests	   that	   the	   treatment	   has	   not	   adequately	   ablated	   this	   clonogenic	   source.	  
Apart	   from	  the	   fact	   that	  ablation	  has	  not	  have	  been	  properly	  applied,	   this	  may	  be	  
due	  to	  the	  clonogenic	  source	  being	  effectively	  protected	  from	  diathermy.	  
Buried	   BO	   relates	   to	   the	   presence	   of	   columnar	   lined	   epithelium	   situated	   beneath	  
squamous	   tissue.	   This	   is	   thought	   to	   arise	   as	   a	   result	   of	   the	   overgrowth	   of	   neo-­‐
squamous	   islands	   (NSE).	   NSE	   is	   oesophageal	   tissue	   that	   has	   regenerated	   following	  
treatment	  for	  BO.	  It	  is	  common	  and	  seen	  in	  up	  to	  77%	  of	  BO	  patients	  after	  treatment	  
with	  PPIs	  (Ban	  et	  al.	  2004)(Sampliner	  &	  Fass	  1993)	  with	  higher	  figures	  after	  ablation	  
and	  reaching	  100%	  in	  patients	  treated	  with	  PDT	  (Ban	  et	  al.	  2004)(Biddlestone	  et	  al.	  
1998).	  
	  NSE	  may	  develop	  as	  a	  spectrum	  from	  a	  complete	  replacement	  of	  Barrett’s	  tissue	  to	  
distinct	   islands	   of	   differing	   sizes.	   The	   extent	   of	   development	   also	   depends	   on	   the	  
type	   of	   treatment.	   Patients	   treated	   with	   RFA	   for	   example	   will	   develop	   complete	  
replacement	  of	  Barrett’s	  mucosa	  with	  NSE	   in	  almost	  all	  cases(Sharma,	  Wang,	  et	  al.	  
2007;	  Sharma,	  et	  al.	  2007;	  Gondrie	  et	  al.	  2008).	  NSE	   is	  phenotypically	   the	  same	  as	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normal	  oesophageal	  squamous	  tissue	  and	  genotypically	  is	  usually	  normal	  suggesting	  
that	  the	  multipotential	  cell	  of	  origin	  for	  NSE	  and	  normal	  squamous	  tissue	  is	  likely	  to	  
be	  the	  same	  and	  different	  to	  the	  origin	  of	  BO.	  This	   is	  particularly	  so	  as	   it	  has	  been	  
shown	   that	   NSE	   surrounded	   by	   Barrett’s	   tissue	   shares	   usually	   none	   of	   the	   BO	  
associated	  mutations	   (Paulson,	   LJ	   Xu,	   et	   al.	   2006;	   Leedham	   et	   al.	   2008).	   However	  
more	  recent	  evidence	  has	  demonstrated	  a	  mitochondrial	  DNA	  mutation	  common	  to	  
both	   the	   squamous	  and	  neighbouring	  Barrett’s	  epithelium	  suggesting	   that	   the	   two	  
may	  indeed	  have	  a	  common	  stem	  cell	  origin	  (Nicholson	  et	  al.	  2011).	  
1.8.2.3.3 Buried	  Barrett’s	  
The	  presence	  of	  buried	  Barrett’s	  depends	  on	   the	   treatment	   technique	  being	  used.	  
After	  PPI	  use,	  buried	  Barrett’s	  and	  buried	  dysplasia	  can	  be	  found	  in	  as	  many	  as	  27%	  
and	  12.1%	  of	  patients	  respectively	  and	  increases	  to	  51%	  and	  27.3%	  respectively	  after	  
PDT	   (Ban	   et	   al.	   2004).	   RFA	   on	   the	   other	   hand	   does	   not	   seem	   to	   cause	   buried	  
Barrett’s	  in	  almost	  100%	  of	  patients	  (Sharmaet	  al.	  2007;	  Gondrie	  et	  al.	  2008;	  Gossner	  
et	  al.	  1988)	  although	  more	  recent	  studies	  refute	  this	  (Zhou	  et	  al.	  2012).	  
Although	   buried	   Barrett’s	   is	   pathologically	   similar	   to	   pre-­‐treatment	   BO,	   the	   main	  
concern	   is	   with	   the	   development	   of	   dysplasia	   in	   an	   area	   that	   is	   hidden	   from	   the	  
endoscopist’s	   view.	   The	   development	   of	   adenocarcinoma	   in	   such	   cases	   has	   been	  
described	   (Sampliner	   &	   Fass	   1993;	   Van	   Laethem	   et	   al.	   2000;	   Reid	   et	   al.	   2000).	  
Despite	  this,	  the	  buried	  dysplasia	  found	  after	  treatment	  may	  be	  less	  aggressive	  than	  
untreated	  dysplasia.	  Evaluation	  of	  the	  biological	  properties	  of	  buried	  dysplasia	  after	  
PDT	  for	  example	  has	  shown	  a	  lower	  crypt	  proliferation	  rate	  and	  lower	  DNA	  content	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abnormalities	   as	   measured	   by	   image	   cytometry,	   as	   compared	   with	   pre-­‐treatment	  
Barrett’s	   oesophagus	   (Hornick	   et	   al.	   2008).	   It	   has	   been	   suggested	   that	   the	   lack	   of	  
connection	  of	  the	  buried	  areas	  to	  the	  luminal	  surface	  may	  protect	  it	  from	  the	  further	  
damage	  needed	  for	  progression.	  
1.8.2.3.4 The	  dysplastic	  stem	  cell	  is	  in	  the	  submucosa	  
Another	   issue	   relates	   to	   whether	   the	   cell	   of	   origin	   of	   a	   BO	   is	   being	   adequately	  
eradicated	   by	   the	   ablation	  method;	   this	   is	   itself	   a	   question	   of	  where	   the	   origin	   of	  
Barrett’s	   tissue	   lies.	   The	   origin	   of	  metaplasia	   has	   not	   been	   firmly	   established	   and	  
there	   remain	   several	   theories.	   Initially	   BO	  was	   thought	   to	   arise	   from	   the	   stomach	  
based	  on	  the	  fact	  that	  it	  is	  commonly	  found	  in	  the	  distal	  oesophagus	  confluent	  with	  
the	   gastro-­‐oesophageal	   junction,	   it	   progresses	   upwards	   over	   time,	   and	   it	   shares	   a	  
similar	   morphology	   to	   the	   stomach	   (columnar	   epithelium).	   Using	   jejunal	  
interposition	  grafts	  between	  the	  stomach	  and	  oesophagus	   in	  canine	  models,	   it	  can	  
be	   shown,	   after	   acid	   stimulation,	   that	   columnar	   epithelialisation	   can	   still	   occur,	  
demonstrating	   that	   the	   origin	   of	   Barrett’s	   mucosa	   may	   not	   be	   from	   the	   stomach	  
(Gillen	  et	   al.	   1988);	   despite	   this	   considerable	   evidence	   exists	   that	   a	   gastric	   source	  
may	   be	   implicated	   (see	   section	   1.4.1).	   Furthermore,	   gastric	   type	   mucosa	   can	   be	  
found	   in	   the	  proximal	  oesophagus	  without	   connection	   to	   the	   stomach	  as	   found	   in	  
the	  cervical	  inlet	  patch	  (Malhi-­‐Chowla	  et	  al.	  2000).	  
A	   second	   theory	   suggests	   that	   the	   metaplastic	   change	   arises	   from	   the	   proposed	  
oesophageal	   stem	   cells	   located	   at	   the	   bottom	   of	   the	   interpapillary	   region	   of	   the	  
oesophageal	  epithelium	  (Seery	  &	  Watt	  2000)	  (see	  section	  1.4.4).	  This	  area	  was	  found	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to	  proliferate	  rarely	  and	  when	  it	  does,	  it	  results	  in	  an	  asymmetric	  mitosis	  resulting	  in	  
one	   daughter	   and	   one	   parent	   cell.	   This	   was,	   until	   recently,	   thought	   to	   be	  
characteristic	  of	  stem	  cell	  compartments	  in	  other	  tissues	  but	  more	  recent	  evidence	  
has	  demonstrated	   this	  may	  not	  be	   the	  case	   (Snippert	  et	  al.	   2010).	   If	   the	   source	  of	  
dysplasia	  was	  in	  this	  area,	  ablation	  would	  have	  direct	  access	  to	  the	  tissue	  as	  long	  as	  
the	  depth	  of	  therapy	  was	  at	  least	  equal	  to	  the	  depth	  of	  the	  epithelium	  (Jones	  et	  al.	  
2005).	  
A	  third	  theory	  suggests	  that	  the	  metaplastic	  change	  arises	  from	  cells	   located	  in	  the	  
submucosal	   layer,	   such	  as	  oesophageal	   submucosal	   gland	  ducts,	  which	  are	   located	  
throughout	   the	   oesophagus	   but	   more	   concentrated	   distally.	   The	   finding	   of	   a	  
common	  mutation	  between	  a	  duct	  cell	  and	  the	  overlying	  Barrett’s	  mucosa	  supports	  
this	   theory	   although	   most	   NSE	   is	   wild-­‐type	   (Paulson	   et	   al.	   2006)	   (Leedham	   et	   al.	  
2008).	   If	   the	   submucosal	   duct	   cell	   is	   the	   origin,	   then	   theoretically	   most	   ablation	  
methods,	  which	  produce	   injury	  only	  within	   the	  mucosa,	  would	  be	  unable	   to	   reach	  
the	  potentially	  mutated	  BO	  founder	  cell	  in	  the	  submucosal	  duct.	  In	  fact	  on	  the	  basis	  
of	   the	   clinical	   trials	   above,	   RFA	   seems	   to	   have	   the	   best	   outcome	   for	   ablation	   of	  
dysplastic	   epithelium	   with	   NSE	   regrowth	   for	   the	   follow-­‐up	   times	   measured	  
suggesting	  that	  either	  RFA	  does	  reach	  the	  submucosa	  or	  that	  the	  dysplastic	  clone	  is	  
more	  superficial.	  
1.8.2.3.5 The	  tissue	  has	  ablation	  resistant	  mutations	  
The	   progression	   of	   Barrett’s	   mucosa	   from	   metaplasia	   through	   to	   dysplasia	   and	  
cancer	   is	   associated	   with	   a	   variety	   of	   somatic	   mutations	   and	   other	   genetic	   and	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epigenetic	  events	   (Fitzgerald	  2006).	   Initial	  evidence	  pointed	  to	  a	  field	  cancerization	  
model	  of	  BO	  in	  which	  a	  genetic	  mutation	  was	  disseminated	  through	  the	  oesophagus	  
through	   as	   yet	   undescribed	   mechanisms	   but	   is	   probably	   a	   form	   of	   crypt	   fission	  
(discussed	   in	   section	   0).	   This	   field	   then	   acted	   as	   a	   permissive	   area	   for	   further	  
mutations	   to	   develop	   which	   themselves	   spread	   and	   so	   on,	   causing	   phenotypic	  
changes	  and	  eventually	   cancer.	   This	  model	  may	  have	  been	  based	  on	  experimental	  
artefact	  and	  more	  recent	  evidence	  based	  on	  exhaustive	  microdissection	  of	  Barrett’s	  
tissue	   has	   demonstrated	   that	   the	   mucosa	   is	   made	   up	   of	   cells	   with	   a	   number	   of	  
different	  mutations	  indicating	  a	  variety	  of	  clones	  (Leedhamet	  al.	  2008).	  Some	  of	  the	  
most	  common	  somatic	  mutations	  are	  associated	  with	  crucial	  cell	  cycle	  control	  events	  
(CDNK2A)(Klump	  et	  al.	  1998;	  Paulson	  et	  al.	  2008b),	  or	  regulation	  of	  apoptosis	  (TP53)	  
(Galipeau	  et	  al.	  1999).	  TP53	  in	  particular	  is	  important	  in	  a	  number	  of	  human	  cancers	  
and	   has	   been	   found	   to	   be	   mutated	   with	   increasing	   frequency	   as	   BO	   progresses	  
towards	  adenocarcinoma	   (Dolan	  et	  al.	   2003).	  Because	  of	   its	   central	   role	   in	   causing	  
apoptosis	  in	  damaged	  cells,	  lack	  of	  functional	  p53	  can	  render	  a	  cell	  more	  resistant	  to	  
apoptosis	  and	  therefore	  more	  susceptible	  to	  genomic	  damage	  and	  the	  acquisition	  of	  
further	  mutations.	  Mouse	  experiments	  have	  demonstrated	   increased	   survival	   to	   γ-­‐
irradiation	   or	   chemotherapy	   if	   the	   transgenic	  mouse	   expresses	  mutant	   trp53	   (the	  
murine	   equivalent	   to	   TP53	   in	   humans)	   (Lee	   &	   Bernstein	   1993).	   Furthermore	   in	  
humans	   patients	   with	   breast	   cancer,	   cells	   with	   TP53	   mutations	   demonstrate	  
resistance	   to	   doxirubicin	   treatment	   and	   early	   relapse	   (Aas	   &et	   al.	   1996).	   This	  
resistance,	   depending	   on	   the	  mutation,	   has	   been	   found	   to	   extend	   to	   such	   diverse	  
insults	  as	  heat	  (Ota	  et	  al.	  2000).	  It	   is	  conceivable	  therefore	  those	  certain	  genetic	  or	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epigenetic	  mutations	  confer	  a	  resistance	  to	  ablation	  type	  damage	  and	  therefore	  are	  
likely	  to	  persist.	  
1.8.2.3.6 The	  conditions	  persist	  after	  BO	  treatment	  
Some	  patients	  will	  continue	  to	  have	  evidence	  of	  reflux	  after	  ablation	  therapy	  despite	  
also	   being	   on	   a	   PPI.	   Arguably	   subsequent	   changes	   in	   the	  mucosa	   after	   squamous	  
regrowth	  may	  be	  attributable	  to	  the	  on-­‐going	  presence	  of	  gastro-­‐oesophageal	  reflux	  
disease	  (GORD).	  Certainly	  the	  risk	  factors	  for	  recurrent	  dysplasia	  after	  RFA	  are	  similar	  
to	   the	   aetiology	   of	   GORD	   (Badreddine	   et	   al.	   2010)	   and	   studies	   demonstrating	  
insufficient	   acid	   suppression	   suggest	   metaplasia	   and	   dysplasia	   is	   more	   difficult	   to	  
control	   (Overholt	  2000).	  There	   is	  evidence	   that	  PPI	   therapy	  after	   thermal	  ablation,	  
for	  example,	  significantly	  reduces	  the	  risk	  of	  recurrent	  Barrett’s	  epithelium,	  and	  that	  
this	   is	   related	   to	  normalisation	  of	  pH	   (Van	  Laethem	  et	  al.	  1998;	  Schulz	  et	  al.	  2000;	  
Kahaleh	   et	   al.	   2002).	   In	   such	   a	   scenario	   one	   would	   expect	   that	   if	   ablation	   was	  
successful,	   squamous	   regrowth	   would	   completely	   cover	   the	   previous	   Barrett’s	  
mucosa.	  If	  the	  BO	  returns	  and	  is	  due	  to	  GORD	  then	  the	  regrowth	  would	  most	  likely	  
to	   be	   due	   to	   a	   different	   clonal	   cell	   population	   to	   the	   original	   Barrett’s	  
epithelium.Studies	   analysing	   genetic	   mutations	   before	   treatment	   and	   in	   the	   rare	  
instance	  after	  a	   recurrence	  when	   the	   intervening	  mucosa	  was	  neo-­‐squamous	  have	  
not	  been	  done,	  presumably	  because	  such	  patients	  are	  difficult	  to	  find.	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1.8.2.3.7 The	  Barrett’s	  tissue	  recurs	  post	  treatment	  
As	  discussed	  in	  section	  1.8	  there	  is	  a	  recurrence	  rate	  after	  the	  endoscopic	  treatment	  
of	  BO.	  Recurrent	  dysplasia	  could	  occur	  for	  any	  of	  the	  reasons	  mentioned	  in	  section	  
1.8.2.3,	   but	   a	   further	   possibility	   remains.	   Haematological	   malignancies	   have	  
documented	   a	   change	   in	   subclonal	   structure	   after	   chemotherapy	   such	   that	  
previously	   non	   dominant	   clonal	   populations	   proliferate	   after	   the	   eradication	   of	  
dominant	  clonal	  populations	   (Obermann	  et	  al.	  2011;	  Landau	  et	  al.	  2013).	  Although	  
this	   has	   not	   been	   described	   in	   solid	   organ	   malignancies	   presumably	   because	   of	  
difficulties	  of	  longitudinal	  and	  geographic	  sampling	  of	  such	  malignancies,	  it	  remains	  a	  
possible	   explanation	   for	   recrudescence	   of	   dysplasia	   after	   eradication	   to	   a	   non-­‐
dysplastic	  BO.	  




The	  introduction	  has	  described	  BO	  as	  a	  polyclonal	  premalignant	  lesion.	  Clonal	  lesions	  
in	  BO	  expand	  through	  a	  process	  of	  field	  cancerization	  the	  underlying	  mechanism	  of	  
which	  is	  as	  yet	  undescribed.	  The	  fact	  that	  BO	  is	  polyclonal	  raises	  the	  possibility	  that	  
clonal	   interactions	   are	   responsible	   for	   field	   cancerization	   and	   adenocarcinoma	  
progression	  although	  the	  mechanism	  for	  clonal	  interactions	  has	  not	  been	  elucidated-­‐	  
one	  possible	  interaction	  is	  the	  senescence	  associated	  secretory	  pathway.	  
My	  hypotheses	  are	  therefore	  
1) That	   clonal	   interactions	   exist	   between	   clonal	   populations	   and	   may	   drive	  
carcinogenesis.	  
2) That	   a	   potential	   mechanism	   by	   which	   clonal	   interactions	   occur	   is	   through	  
senescence	  and	  its	  associated	  secretory	  phenotype.	  
3) That	   clonal	   populations	   can	   persist	   to	   cause	   cancer	   despite	   endoscopic	  
ablation	  therapy.	  
1.9 Aims	  
To	  determine	  the	  clonal	  relationships	  between	  premalignant	  Barrett’s	  and	  cancer	  by:	  
i) Comparing	   the	   mutational	   status	   of	   dysplastic	   Barrett’s	   with	   its	   related	  
adenocarcinoma.	  




To	  determine	  the	  role	  of	  senescence	  as	  a	  mechanism	  for	  clonal	  interaction	  by:	  
iii) Assessment	  of	   the	  presence	  of	  senescence	   in	  pre-­‐malignant	  and	  malignant	  
Barrett’s	  oesophagus	  by	  analysis	  of	  expression	  of	  p21	  and	  p16.	  
iv) Establishing	  an	  in	  vitro	  model	  of	  cellular	  senescence	  and	  using	  this	  model	  to	  
assess	  the	  effects	  of	  senescent	  cells	  on	  neighbouring,	  non-­‐senescent	  cells.	  
v) Assessment	   of	   whether	   senescent	   cells	   in	   malignant	   and	   premalignant	  
Barrett’s	  oesophagus	  also	   secrete	   factors	   associated	  with	   the	   senescent	  
associated	  secretory	  phenotype.	  
vi) Assessment	  of	  whether	  the	  expression	  of	  p16	  as	  a	  senescent	  marker	  is	  also	  a	  
marker	  of	  a	  clonally	  derived	  cell	  population.	  
To	  determine	  the	  clonality	  of	  pre	  and	  post	  ablation	  Barrett’s	  related	  pathology	  by:	  
vii) Examining	  a	  case	  series	  of	  patients	  who	  have	  undergone	  RFA	  and	  EMR	  and	  
understand	  the	  clonal	  correlates	  of	  persistent	  or	  recurrent	  HGD	  or	  OAC	  in	  
patients	  undergoing	  endoscopic	  therapy.	  
viii) Establishing	   the	   potential	   reasons	   why	   clonal	   cancer	   associated	   cell	  
populations	  may	  be	  persistent	  despite	  treatment	  with	  ablation	  therapy.	  




Chapter	  2 Materials	  and	  Methods	  
	   	  
2.1 Patients	  
2.1.1 Assessment	  of	  the	  clonality	  of	  premalignant	  Barrett’s	  oesophagus	  as	  
compared	  with	  its	  associated	  malignancy	  
Tissue	   was	   obtained	   retrospectively	   from	   Gloucestershire	   Royal	   Hospital	   and	  
University	  College	  London	  Hospital	  (UCLH).	  All	  tissue	  had	  been	  retrieved	  for	  clinical	  
indications	   and	   was	   formalin	   fixed	   and	   paraffin	   embedded	   (FFPE).	   The	   tissue	  
included	  biopsies,	  endoscopic	  resections	  and	  oesophagectomies	  from	  patients	  with	  
high	   grade	   dysplasia	   or	   adenocarcinoma.Access	   to	   human	   tissue	   was	   available	  
through	   the	   ethical	   procedures	   of	   the	   Multicentre	   Research	   Ethics	   Committee.	  
(MREC	  07/Q1604/17)	  and	  Multicentre	  Research	  Ethics	  Committee	  (11/LO/1613).	  
2.1.2 Clonal	  selection	  after	  endoscopic	  therapy	  of	  Barrett’s	  related	  high	  grade	  
dysplasia	  and	  adenocarcinoma	  
All	   tissue	   was	   obtained	   from	   University	   College	   London	   Hospital	   (UCLH)	   and	   was	  
formalin	  fixed	  and	  paraffin	  embedded.	  Samples	  were	  obtained	  retrospectively	  from	  
an	  archive	  kept	  at	  UCLH	  and	  had	  been	  taken	  specifically	  for	  clinical	  reasons.	  Patients	  
who	  had	  undergone	  RFA	  were	  identified	  from	  the	  RFA	  registry	  at	  UCLH	  and	  samples	  
before	   and	   after	   courses	   of	   RFA	   were	   taken.Only	   patients	   with	   recurrent	   or	  
persistent	  disease	  after	  RFA	  and/or	  endoscopic	  mucosal	  resection	  (EMR)	  of	  HGD	  or	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intramucosal	  adenocarcinoma	  (IMC)	  were	  chosen	  for	  analysis.	  Furthermore,	  patients	  
had	  to	  have	  undergone	  two	  further	  endoscopic	  samplings	  subsequent	  to	  the	   initial	  
ablation	   therapy.Access	   to	   human	   tissue	   was	   available	   through	   the	   ethical	  
procedures	  of	  the	  Multicentre	  Research	  Ethics	  Committee.	  (11/LO/1613).	  
2.1.3 Histological	  scoring	  of	  CXCL1	  (GROα)	  and	  CCL5	  (RANTES)	  
All	   tissue	  was	  obtained	   from	  a	  histopathological	  archive	  at	  UCLH	  and	  was	   formalin	  
fixed	  and	  paraffin	  embedded.	  All	  tissue	  was	  comprised	  of	  either	  endoscopic	  mucosal	  
resection	  or	  biopsies	  and	  had	  been	  taken	  for	  clinical	  reasons.	  Access	  to	  human	  tissue	  
was	   available	   through	   the	   ethical	   procedures	   of	   the	   Multicentre	   Research	   Ethics	  
Committee.	  (11/LO/1613).	  
2.2 Ex	  vivo	  tissue	  preparation	  and	  processing	  methods	  
2.2.1 Tissue	  preparation	  
All	  laser	  capture	  was	  performed	  on	  FFPE	  tissue.	  PALM	  laser	  capture	  slides	  (P.A.L.M.	  
Microlaser	  technologies,	  GmbH,	  Germany)	  were	  prepared	  by	  exposure	  to	  ultraviolet	  
light	  at	  254mm	  wavelength	   for	  30	  minutes.	   Each	  FFPE	  block	  underwent	   sectioning	  
into	  7	  sections	  at	  6	  µm	  thickness.	  The	  first	  section	  was	  cut	  onto	  a	  frosted	  glass	  slide	  
(Colorfrost,	   Thermo	   Fisher	   Scientific,Loughborough,	   UK)	   and	   was	   stained	   for	  
haematoxylin	  and	  eosin	  (see	  methods	  0).	  The	  subsequent	  6	  sections	  were	  cut	  serial	  
to	   the	   initial	   slide	   onto	   the	   ultraviolet	   treated	   PALM	   slides	   (P.A.L.M.	   Microlaser	  
technologies,	  Germany),	  and	  the	  slides	  were	  numbered	  accordingly.	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2.2.2 Methylene	  green	  staining	  
Methylene	  green	   staining	  provides	  adequate	  differentiation	  of	   the	   crypts	   from	   the	  
surrounding	   stroma	   and	   does	   not	   affect	   subsequent	   PCR.	   Sections	   on	   PALM	   laser	  
capture	  slides	  (P.A.L.M.	  Microlaser	  technologies,	  Germany)	  were	  dewaxed	  in	  xylene,	  
and	   rehydrated	   in	   decreasing	   concentrations	   of	   ethanol.Each	   PALM	   laser	   capture	  
slide	   (P.A.L.M.	   Microlaser	   technologies,	   GmbH,	   Germany)	   then	   underwent	  
immersion	  in	  methylene	  green	  stain	  for	  20	  seconds	  (Sigma-­‐Aldrich,	  UK)	  followed	  by	  
gentle	  rinsing	  in	  tap	  water.	  They	  were	  then	  left	  to	  air	  dry	  for	  thirty	  minutes.	  
2.2.3 Laser	  capture	  microdissection	  
Laser	   capture	   allows	   the	   capture	   of	   distinct	   cell	   populations	   from	   heterogeneous	  
tissue	   samples.	   The	   laser	   capture	   device	   used	   throughout	   this	   thesis	   was	   an	  
ultraviolet	   laser	   (P.A.L.M	   Microlaser	   Technologies,	   GmbH,	   Germany).	   After	  
visualisation	   of	   methylene	   green	   stained	   tissue	   under	   white	   light	   microscopy,	   the	  
laser	   capture	   device	   photo-­‐volatises	   a	   user-­‐defined	   specific	   area	   of	   tissue	   and	  
catapults	  it	  into	  a	  collecting	  tube	  using	  a	  ultraviolet	  laser	  pulse.	  
Crypts	  for	  dissection	  were	  identified	  on	  the	  H&E	  slide	  and	  followed	  through	  the	  six	  
serial,	   methylene	   green	   stained	   sections.	   Individual	   crypts	   were	   cut	   from	   the	   six	  
serial	  laser	  capture	  slides	  and	  catapulted	  into	  the	  adhesive	  caps	  of	  eppendorfs	  using	  
the	   P.A.L.M.	   Laser	   Microdissection	   system(P.A.L.M	   Microlaser	   Technologies,	  
Germany).	   This	   dissected	   sample	   was	   immersed	   in	   12	   µl	   of	   proteinase	   K	   solution	  
(Arcturus	  Bioscience,	  Mt	  View,	  California,	  USA).	  12	  µl	  proteinase	  K	  solution	  and	  no	  
laser	   capture	   material	   was	   used	   as	   a	   negative	   control	   tube.	   Tubes	   were	   then	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centrifuged	  at	  4.5	  g	  for	  1	  min	  and	  incubated	  at	  65°C	  overnight.	  A	  10	  min	  incubation	  
at	  95°C	  denatured	  the	  proteinase	  K	  and	  the	  lysate	  was	  then	  stored	  at	  -­‐20°C.	  
2.2.4 Haematoxylin	  &	  eosin	  staining	  
6µm	   FFPE	   sections	   were	   mounted	   onto	   frosted	   glass	   slides	   (Colorfrost,	   Thermo	  
Fisher	   Scientific,	   UK)	   and	  were	   immersed	   in	   Gill’s	   haematoxylin	   (Pioneer	   Research	  
Chemicals,	   UK)	   for	   4	  minutes	   and	   eosin	   (Pioneer	   Research	   Chemicals,	   UK)	   for	   3-­‐5	  
minutes.	  The	  slides	  were	  then	  washed	   in	  tap	  water	  and	  dipped	   in	  acid	  alcohol	   (1%	  
v/v	   concentrated	   hydrochloric	   acid	   in	   70%	   alcohol)	   (Sigma-­‐Aldrich,	   UK).	   They	   then	  
underwent	  a	  further	  wash	  in	  tap	  water	  before	  dehydration	  through	  graded	  alcohols	  
to	  xylene	  (BDH,	  Poole,	  UK)	  and	  mounted	  in	  DPX	  (Sigma-­‐Aldrich,	  UK).	  
2.3 Cell	  culture	  techniques.	  
2.3.1 Growth	  of	  cell	  lines	  and	  cell	  line	  assays	  
Cell	   culture	  media	   for	   individual	   cell	   lines	   are	   listed	   below.	   All	   reagents	  were	   pre-­‐
heated	   to	  37°C	  before	  use.	  The	  medium	  was	  changed	  every	  3	  days	   for	  all	   cultures	  
unless	  otherwise	  stated.	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Cell	  line	   Culture	  Media	   Tissue	  
grade	  
Provided	  by	  
BAR-­‐T	   Keratinocyte	  Growth	  Medium	  BPE	  (bovine	  
pituitary	  extract).	  	  
hEGF.	  	  
Insulin	  (recombinant	  human).	  	  
Hydrocortisone.	  
GA-­‐1000	  (gentamicin,	  amphotericin	  B).	  	  
	  (All	  constituents	  are	  from	  Lonza,	  








OE33	   RPMI-­‐1640	  (PAA,	  Yeovil,	  UK)	  	  
10%	  Heat	  inactivated	  foetal	  calf	  serum	  
(Invitrogen	  Life	  Technologies,	  UK),	  	  
1%	  penicillin-­‐streptomycin	  (PAA,	  UK)	  
Cancer	   Rebecca	  
Fitzgerald,	  MRC	  
Cancer	  Cell	  Unit,	  
Cambridge	  
GoTERT	   MCDB-­‐153(Sigma-­‐Aldrich,UK)	  
0.4	  µg/ml	  hydrocortisone	  (Sigma-­‐
Aldrich,UK)	  
20	  ng/ml	  recombinant	  human	  EGF	  
(Epidermal	  Growth	  Factor)	  (Sigma-­‐
Aldrich,UK)	  
1	  nM	  cholera	  toxin	  (Sigma-­‐Aldrich,UK)	  
20	  mg/L	  adenine	  (Sigma-­‐Aldrich,UK)	  
140	  µg/ml	  BPE	  (Bovine	  Pituitary	  Extract)	  
(Sigma-­‐Aldrich,UK)	  
0.1%	  ITS	  [Insulin-­‐Transferrin-­‐Sodium	  
Selenite	  Supplement	  (Sigma-­‐Aldrich,UK)	  
4	  mM	  glutamine	  (Sigma-­‐Aldrich,UK)	  
Foetal	  bovine	  serum	  to	  a	  final	  
concentration	  of	  5%	  (Invitrogen	  Life	  
Technologies,	  UK)	  
Dysplasia	   Rebecca	  
Fitzgerald,	  MRC	  




Dulbecco’s	  modified	  Eagle	  medium	  
(Invitrogen,	  UK)	  
10%	  Heat	  inactivated	  foetal	  calf	  serum	  
(Invitrogen	  Life	  Technologies,	  UK),	  	  
1%	  penicillin-­‐streptomycin	  (PAA,	  UK)	  










Table	  2-­‐1:	  Cell	  lines	  and	  associated	  growth	  media	  used.	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2.3.1.1 Sub	  culturing	  cells	  
Cells	   cultured	  cells	   in	  25	  cm2	   flasks	   (BD	  Falcon,	  Oxford,	  UK)	  were	  washed	   twice	  by	  
pipetting	  15ml	  of	  sterile	  PBS	  (PAA,	  UK)	  over	  the	  cells	  and	  then	  pipetting	  the	  PBS	  out.	  
4ml	  of	  1X	  trypsin	  (GE	  Healthcare,	  Buckinghamshire,	  UK)	  preheated	  at	  37°C	  was	  then	  
added	  to	  the	  flask	  and	  rocked	  so	  that	  it	  covered	  all	  the	  cells.	  This	  was	  then	  incubated	  
at	  37°C	  for	  two	  minutes.	  The	  cells	  were	  encouraged	  to	  detach	  by	  gently	  knocking	  the	  
bottom	  of	  the	  flask.	  Media	  containing	  10%	  foetal	  bovine	  serum	  (FBS;	  Invitrogen	  Life	  
Technologies,	  UK)	  was	  then	  added	  and	  then	  cells	  removed	  by	  pipetting	  into	  a	  50ml	  
Falcon.	   They	   were	   washed	   twice	   by	   centrifugation	   at	   1	   x103rpm	   for	   5	   minutes	  
followed	  by	  exchange	  of	  PBS	  and	  then	  after	  the	  final	  wash,	  the	  PBS	  was	  exchanged	  
for	  15ml	  of	  culture	  media	  and	  the	  cells	  counted	  and	  plated	  accordingly	  so	  that	  1	  x106	  
cells	   were	   placed	   in	   a	   new	   25cm2	   flask.	   Cells	   that	   were	   not	   needed	   were	   either	  
frozen	  as	  described	  (methods	  2.3.1.3)	  or	  discarded.	  
BAR-­‐T	  cells	  require	  collagen	  coating	  of	  plates	  in	  order	  to	  proliferate.	  Human	  collagen	  
IV	  (BD	  Biosciences)	  stored	  at	  -­‐20°C	  was	  thawed	  and	  diluted	  to	  10µg/ml	  using	  10mM	  
acetic	  acid	  (Sigma-­‐Aldrich,UK)	  so	  that	  the	  final	  coating	  concentration	  was	  1.0µg/cm2.	  
This	  was	  then	  incubated	  for	  1	  hour	  at	  room	  temperature	  and	  remaining	  material	  was	  
aspirated.	  Once	  the	  dishes	  had	  been	  rinsed	  carefully	  to	  remove	  remaining	  acid	  they	  
were	  ready	  for	  use.	  
2.3.1.2 Thawing	  frozen	  cells	  
Cells	  stored	   in	   liquid	  nitrogen	  were	  quickly	  thawed	  by	   immersion	  of	   the	  containing	  
cryovial	  in	  tap	  water	  at	  37°C.	  The	  cells	  were	  pipetted	  out	  and	  placed	  in	  a	  falcon	  with	  
5ml	   of	   warm	   PBS	   and	   centrifuged	   at	   1	   x103	   rpm	   for	   5	   minutes.	   The	   PBS	   was	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exchanged	   for	   5ml	   of	   warm	   RPMI-­‐1640	   (PAA,	   UK)	   and	   underwent	   further	  
centrifugation	  for	  5	  minutes	  at	  1	  x103	  rpm.	  The	  RPMI-­‐1640	  was	  exchanged	  for	  fresh	  
culture	   media	   and	   cells	   were	   counted	   as	   described	   (see	   section	   2.3.1.4)	   prior	   to	  
plating	  on	  a	  tissue	  culture	  flask	  or	  plate.	  
2.3.1.3 Freezing	  live	  cells	  for	  storage	  
Cells	   were	   trypsinised	   as	   described	   previously	   (see	   section	   2.3.1.1).	   Following	  
neutralisation	   with	   serum	   containing	   media,	   the	   cells	   were	   centrifuged	   in	   a	   50ml	  
falcon	  tube	  at	  1	  x103rpm	  for	  5	  minutes.	  The	  media	  was	  then	  replaced	  with	  PBS	  and	  
cells	   re-­‐suspended	   for	   a	   further	   5	   minutes	   centrifugation	   at	   1	   x103rpm.	   The	   cells	  
were	  then	  re-­‐suspended	  at	  a	  concentration	  of	  ~1	  x	  106cells/ml	  in	  FBS	  (Invitrogen	  Life	  
Technologies,	   UK)	   to	   which	   dimethylsulphoxide	   (DMSO;	   Sigma-­‐Aldrich,	   UK)	   was	  
added	   to	   a	   final	   concentration	   of	   10%	   (v/v)	   and	   transferred	   into	   2	   ml	   cryovials.	  
Cryovials	   were	   stored	   in	   a	   cryochamber	   containing	   isolpropanol	   (Thermo	   Fisher	  
Scientific,	  UK)	  and	  slowly	  cooled	  to	  -­‐70°C	  for	  at	  least	  4	  hours.	  The	  samples	  were	  then	  
transferred	  to	  liquid	  nitrogen.	  
2.3.1.4 Determination	  of	  cell	  concentration	  and	  viability	  
Cell	  viability	  was	  assessed	  by	  trypan	  blue	  exclusion	  assay	  after	  trypsin	  digestion	  and	  
neutralisation	   with	   the	   appropriate	   media	   for	   the	   cell	   type	   containing	   10%	   FBS	  
(Invitrogen,UK).	  50µl	  of	  the	  cell	  suspension	  was	  mixed	  with	  50µl	  of	  trypan	  blue	  (0.4%	  
w/v)	  (Sigma-­‐Aldrich,	  UK).	  Non-­‐viable	  cells	  stain	  blue,	  viable	  cells	  are	  clear.	  A	  drop	  of	  
the	   cell	   suspension	   was	   placed	   between	   a	   coverslip	   and	   a	   haemocytometer	   and	  
examined	   using	   a	   phase	   contrast	   microscope	   (Nikon	   Eclipse	   TE2000-­‐S	   inverted	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microscope,	  Nikon,	  Japan).	  The	  cells	  were	  counted	  in	  all	  four	  large	  squares	  and	  the	  
number	  of	  cells/ml	  calculated.	  Viability	  was	  determined	  by	  counting	  the	  proportion	  
of	  cells	  that	  stain	  blue	  compared	  to	  the	  total	  number	  of	  cells	  counted	  and	  expressed	  
as	  a	  percentage.	  
2.3.1.5 Irradiation	  of	  cells	  
Cells	  were	  initially	  seeded	  in	  6,12,24	  or	  96	  well	  plates	  depending	  on	  the	  experiment,	  
at	  the	  appropriate	  seeding	  density	  in	  media	  appropriate	  to	  the	  cell	  type	  (see	  	  
Table	  2-­‐1)	  and	  incubated	  at	  37°C,	  5%	  CO2	  overnight.	  24	  hours	  after	  seeding	  the	  cells	  
were	   then	  submitted	   to	  caesium	  gamma	   irradiation	   (Gamma	  Service	   Irradiator	  D1,	  
Gamma	  Service	  Medical,	  Leipzig,	  Germany)	  at	  the	  determined	  Gray.	  The	  cells	  were	  
then	   placed	   in	   an	   incubator	   at	   37°C	   5%	  CO2.	  Media	   and	   dead	   cells	  were	   removed	  
every	  2	  days	  prior	  to	  experiments	  being	  performed	  at	  the	  determined	  day.	  
2.3.1.6 Colony	  formation	  assay	  
Colorimetry	   consisted	   of	   removal	   of	   media	   from	   each	   well	   seeded	   with	   cells	   and	  
fixation	   with	   4%	   paraformaldehyde	   (Sigma-­‐Aldrich,	   UK)	   for	   20	   minutes.	   This	   was	  
washed	   off	   with	   PBS	   (PAA,UK),	   and	   0.05%	   crystal	   violet	   (Sigma-­‐Aldrich,	   UK)	   was	  
added	   for	   a	   further	   5	   minutes.	   This	   was	   washed	   off	   with	   tap	   water.	   Methanol	  
(Thermo	  Fisher	  Scientific,	  UK)	  was	  then	  added	  to	  each	  well	   to	  solubilize	  the	  crystal	  
violet	   and	   submitted	   to	  a	  plate	   reader	   (Victor,	  PerkinElmer,	  MA)	   for	  analysis	   at	   an	  
absorbance	  of	  450nm.	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2.3.1.7 MTT	  assay	  
After	  a	  specified	  number	  of	  days	  cells	  seeded	  in	  96	  well	  plates	  underwent	  MTT	  assay	  
(Vibrant	  assay,	  Sigma-­‐Aldrich,	  UK)	  to	  assess	  proliferation.	  Accordingly,	  cell	  media	  was	  
removed	  and	  washed	  with	  PBS.	  100µl	  of	  RPMI-­‐1640	  with	  no	  phenol	   red	   (PAA,	  UK)	  
was	  then	  placed	  in	  each	  well	  and	  10µl	  of	  MTT	  (Sigma-­‐Aldrich,	  UK)	  was	  added.	  Cells	  
were	   then	   incubated	   for	   4	   hours	   at	  which	   time	   75µl	   of	   the	   incubating	  media	  was	  
removed	  and	  DMSO	  (Sigma-­‐Aldrich,	  UK)	  added.	  This	  was	   incubated	   for	  10	  minutes	  
and	  then	  submitted	  to	  a	  plate	  reader	  at	  540nm	  absorbance	  for	  colorimetric	  analysis	  
(Victor,	  PerkinElmer,	  Waltham,	  MA).	  
2.3.1.8 SA	  β-­‐Galactosidase	  assay	  
SA	   β-­‐galactosidase	   is	   a	   commonly	   used	   marker	   of	   senescence	   used	   to	   detect	  
lysosomal	  β-­‐D-­‐galactosidase,	  encoded	  for	  by	  the	  gene	  galactosidase	  β-­‐1	  (GLB1)(Lee	  
et	  al.	  2006).	  The	  senescence	  response	  involves	  an	  expansion	  of	  the	  cellular	  lysosomal	  
compartment	   with	   a	   subsequent	   upregulation	   of	   lysosomal	   β-­‐D-­‐galactosidase	  
although	   the	   enzyme	   is	   not	   thought	   to	   take	   part	   in	   the	   senescence	   response	   (Lee	  
2006).	  Nonsenescent	   cells	   can	   display	   SA	   β-­‐galactosidase	   activity	   in	   the	   lysosomes	  
that	   functions	  most	  optimally	  at	  pH	  4.0	   (Lee	  et	  al.	  2006).	  Because	  of	  the	   increased	  
lysosomal	   compartment	   in	   senescent	   cells,	   SA	  β-­‐galactosidase	  becomes	  detectable	  
at	  suboptimal	  pH	  6.0(Dimri	  et	  al.	  1995).	  
	  At	   the	   specified	  day	   after	   seeding	   in	   a	   6	  or	   12	  well	   plate,	   all	  media	  was	   removed	  
from	  cells	  which	  were	  then	  fixed	  in	  4%	  paraformaldehyde	  (Sigma-­‐Aldrich,	  UK)	  for	  5	  
minutes	  at	  room	  temperature.	  This	  was	  then	  thoroughly	  washed	  off	  with	  PBS	  (PAA,	  
UK)	  and	  SA	  β-­‐Galactosidase	  staining	  solution	  (Sigma-­‐Aldrich,	  Poole,	  UK)	  addedtoeach	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well.	   The	   cells	   were	   then	   incubated	   at	   37°C	   atmospheric	   CO2.	   After	   6	   hours,	   the	  
staining	   solution	   was	   washed	   off	   three	   times	   with	   PBS	   (PAA,	   UK)	   and	   the	   cells	  
examined	   using	   a	   phase	   contrast	   inverted	   microscope	   (Nikon	   Eclipse	   TE2000-­‐S	  
inverted	  microscope,	   Nikon,	   Japan).	   SA	   β-­‐galactosidase	   positive	   and	   negative	   cells	  
were	   counted	   in	   5	   random	   fields	   of	   view	   per	   well,	   in	   triplicate.	   Randomness	   was	  
achieved	  by	  placing	  a	  transparent	  numbered	  grid	  over	  the	  well	  cover	  and	  generating	  
a	   random	   number	   (using	   http://www.random.org/)	   which	   corresponded	   to	   a	   grid	  
number.	  The	  cells	  were	  then	  counted	  in	  the	  chosen	  grid.	  
2.3.2 Transfection	  of	  cell	  lines-­‐GFP	  cell	  line	  
2.3.2.1 pBABE-­‐puro	  plasmid	  source	  and	  structure	  
Infection	  refers	  to	  the	  introduction	  of	  nucleic	  acids	   into	  a	  cell	  using	  a	  virus.	  pBABE-­‐
puro-­‐IRES-­‐EGFP	   (Addgene,	   Cambridge,	   MA)	   is	   a	   commercially	   available	   plasmid	  
based	  on	  the	  pBABE	  series	  and	  contains	  the	  long	  terminal	  repeat	  (LTR)	  allowing	  gene	  
expression,	  packaging	  sequences	  from	  the	  MoMLV-­‐LTR	   (Murine	  Moloney	  Leukemia	  
Virus).	   The	   plasmid	   contains	   the	   green	   fluorescent	   protein	   gene	   (GFP).	   Viral	  
replication	  depends	  on	   the	  presence	  of	  env	  and	   reverse	   transcriptase	  genes	  which	  
have	  been	  deleted	  in	  this	  plasmid	  rendering	  the	  plasmid	  replication	  defective.	  	  




Figure	  2-­‐1:	  PBabepuro	  Plasmid	  structure.	  
Adapted	   from	   http://www.addgene.org/browse/sequence/8086/Amplification	   of	   High	   Copy	  
Number	  pBABE-­‐puro	  plasmids	  using	  competent	  E.coli	  bacteria	  




1	  µl	  of	  the	  pBABE-­‐puro-­‐IRES-­‐EGFP	  plasmid	  (Addgene,	  MA)	  was	  mixed	  with	  0.1	  ml	  E.	  
coli	   JM109	   competent	   cells	   ,which	   had	   been	   pre-­‐treated	   by	   the	   manufacturer	   to	  
ensure	  competency	  (Promega,	  Madison,	  WI),	  in	  a	  sterile	  eppendorf	  tube	  on	  ice	  and	  
gently	  mixed	  by	  tapping.	  Competency	  refers	  to	  the	  ability	  of	  a	  cell	  to	  take	  up	  genetic	  
material.	  An	  eppendorf	  containing	  no	  DNA	  was	  also	  prepared	  as	  a	  control	  tube.	  The	  
tubes	   were	   then	   incubated	   on	   ice	   for	   20	   minutes	   and	   then	   at	   42°C	   for	   exactly	   2	  
minutes	  in	  a	  circulating	  water	  bath.	  The	  tubes	  were	  then	  further	  incubated	  on	  ice	  for	  
1-­‐2	  minutes.	  1	  ml	  of	  Luria-­‐Bertani	  Broth	  (LB)	  medium	  (Sigma-­‐Aldrich,	  UK)	  was	  then	  
added	   to	   the	   tube	   and	  mixed	   by	   gentle	   tumbling.	   This	  was	   then	   incubated	   for	   60	  
minutes	   at	   37°C.	   200µl	  was	   then	   pipetted	   onto	   an	   agar	   plate	   containing	   25mg/ml	  
ampicillin	   (Sigma-­‐Aldrich,	   UK)	   and	   the	   plate	   was	   then	   incubated	   overnight	   at	  
37°C.Individual	  colonies	  were	  selected	  with	  a	  pipette	  tip,	  incubated	  into	  LB	  medium	  
and	  put	  on	  a	  shaking	  incubator	  at	  37°C	  at	  200-­‐rpm	  for	  16	  hours.	  	  
Bacterial	  cells	  were	  harvested	  by	  centrifugation	  at	  8000rpm	  for	  3	  minutes	  at	   room	  
temperature	  after	  which	  supernatant	  was	  decanted	  off.	  Isolation	  of	  the	  plasmid	  was	  
performed	  according	  to	  manufacturer’s	  instructions	  (QIAprep	  Spin	  Miniprep,	  Qiagen,	  
UK).	  All	  chemical	  names	  and	  concentrations	  of	  constituents	  are	  confidential.	  All	  spin-­‐
columns	  and	  microcentrifuge	  tubes	  were	  provided	  by	  the	  manufacturer.	  Accordingly,	  
the	   bacterial	   pellet	   was	   resuspended	   in	   250µl	   of	   buffer	   P1	   and	   transferred	   to	   a	  
microcentrifuge	  tube	  to	  which	  250µl	  Buffer	  P2	  was	  added	  and	  mixed	  thoroughly	  by	  
inverting	  several	  times.	  350	  µl	  Buffer	  N3	  was	  then	  added	  and	  the	  tube	  again	  mixed	  
by	  inverting	  several	  times.	  The	  tube	  was	  then	  centrifuged	  for	  10	  minutes	  at	  13,000	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rpm	   to	   form	   a	   compact	   white	   pellet.	   The	   supernatant	   was	   then	   decanted	   onto	   a	  
QIAprep	   spin	   column	   and	   centrifuged	   for	   60	   seconds;	   the	   flow	   through	   was	   then	  
discarded.	  0.5ml	  of	  Buffer	  PB	  was	  then	  added	  to	  remove	  trace	  nuclease	  activity	  and	  
centrifuged	   for	   60	   seconds.	   The	   flow	   through	   was	   then	   discarded	   and	   0.75ml	   of	  
Buffer	  PE	  added	  and	  centrifuged	  for	  60	  seconds.	  Residual	  wash	  buffer	  was	  removed	  
by	  discarding	   the	   flow	  through	  once	  more	  and	  centrifuging	   the	  spin	  column	  for	  an	  
additional	   1	   minute.	   The	   spin	   column	   was	   then	   placed	   in	   a	   clean	   1.5ml	  
microcentrifuge	  tube	  and	  the	  DNA	  was	  eluted	  by	  addition	  of	  50µl	  Buffer	  EB	  (10mM	  
Tris-­‐Cl,	  pH	  8.5-­‐	  supplied	  by	  manufacturer),	  letting	  the	  column	  stand	  for	  1	  minute	  and	  
a	   subsequent	   final	   centrifugation	   for	   1	   minute.	   The	   plasmid	   concentration	   was	  
confirmed	   with	   using	   a	   calculated	   260/280nm	   absorbance	   ratio	   in	   a	   Nanodrop	  
(Thermo	  Fisher	  Scientific,	  UK	  ).	  
2.3.2.2 Growth	   and	   transfection	   of	   phoenix	   A	   packaging	   cells	   to	   produce	   vector	  
particles	  
Phoenix	  A	  cells	  are	  derived	  from	  the	  293T	  cell	  line	  (an	  embryonic	  human	  kidney	  cell	  
line)	  and	  are	  second-­‐generation	  retrovirus	  producer	  cells.	  They	  are	  highly	  effective	  in	  
lipid-­‐based	   transfection	   protocols.	   They	   contain	   a	   construct	   capable	   of	   producing	  
gag-­‐pol,	  and	  envelope	  protein	  for	  amphotropic	  viruses	  and	  therefore	  allow	  plasmid	  
to	  be	  packaged	  inside	  a	  virus	  in	  order	  to	  infect	  human	  cells.	  
1x106	  Phoenix	  A	  cells	   (Invitrogen,	  Paisley,	  UK)	  were	  seeded	   in	  a	  60mm	  dish	   in	  4ml	  
media	   containing	   RPMI-­‐1640	   (PAA,	   UK)	   supplemented	   with	   10%	   heat	   inactivated	  
foetal	   calf	   serum	   (Invitrogen	   Life	   Technologies,	  UK)	   and	  1%	  penicillin-­‐streptomycin	  
(PAA,	  UK).	  These	  were	  then	  incubated	  at	  37°C,	  5%	  CO2	  for	  24	  hours	  after	  which	  the	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media	  was	  aspirated	  off	  and	  further	  media	  added.	  100	  µl	  of	  serum	  free	  media	  was	  
added	  to	  a	  sterile	  tube	  and	  25	  µg	  Fugene	  (Promega,	  UK)	  was	  added	  drop	  wise	  to	  this.	  
This	  was	  incubated	  at	  room	  temperature	  for	  5	  minutes	  and	  8µg	  of	  the	  plasmid	  DNA	  
was	   added.	   This	   was	   incubated	   for	   15	   minutes	   at	   room	   temperature	   and	  
subsequently	  added	  to	  the	  phoenix	  A	  cells.	  Transfection	  efficiency	  was	  confirmed	  by	  
assessment	  of	  fluorescence	  using	  a	  fluorescent	  microscope	  (Nikon	  Eclipse	  TE2000-­‐S	  
inverted	  microscope,	   Nikon,	   Japan).	   48	   hours	   after	   transfection,	   once	   75%	   of	   the	  
cells	  were	  fluorescent,	  the	  cells	  were	  split	  into	  a	  culture	  dish	  with	  media	  containing	  
2µg/ml	   puromycin	   (Invitrogen	   Life	   Technologies,	   UK).	   Dead	   cells	   were	   removed	  
regularly	  and	  at	  75%	  confluence	  the	  media	  was	  removed,	  washed	  with	  PBS	  and	  10ml	  
of	  serum	  free	  media	  was	  added.	  This	  was	  then	  incubated	  at	  32°C	  overnight	  and	  the	  
following	  morning	  the	  virus	  containing	  supernatant	  was	  removed	  and	  centrifuged	  at	  
1.5x103	  rpm	  for	  5	  minutes.	  This	  was	  then	  snap	  frozen	  in	  liquid	  nitrogen	  and	  stored	  at	  
-­‐80°C.	  
2.3.2.3 Infection	  of	  OE33	  cell	  line	  with	  pBABE-­‐puro	  plasmid.	  
OE33	   cells	   were	   seeded	   in	   a	   6	   well	   plate	   at	   2x105	   cells	   per	   well	   and	   incubated	  
overnight.	   Polybrene	   (Sigma-­‐Aldrich,	   UK)	   was	   added	   to	   media	   to	   achieve	   a	   final	  
concentration	   of	   5µg/ml.	   To	   assess	   infection	   efficiency,	   different	   ratios	   of	   virus	  
supernatant	  to	  polybrene-­‐media	  mix	  (1:2,	  1:5,	  1:10,	  1:20,	  1:50,	  1:100)	  were	  added	  to	  
the	   seeded	   OE33	   cells.	   This	   was	   allowed	   to	   incubate	   for	   5	   minutes	   at	   room	  




Fluorescence	   assessment	   at	   day	   4	   demonstrated	   a	   1:2	   ratio	   to	   be	   the	   most	  
successfully	   infected	   and	   was	   therefore	   taken	   forward	   for	   further	   experiments.	  
Puromycin	  (Invitrogen	  Life	  Technologies,	  UK)	  was	  added	  to	  these	  cells	  and	  the	  dose	  
optimised	   at	   4µg/ml.	   Infection	   was	   continuously	   monitored	   until	   90%	   infection	  
efficiency	   was	   achieved	   by	   observation	   under	   a	   fluorescence	   microscope	   (Nikon	  
Eclipse	   TE2000-­‐S	   inverted	   microscope,	   Nikon,	   Japan)	   and	   confirmation	   of	   GFP	  
transfection	  efficiency	  was	  obtained	  by	  flow	  cytometry	  and	  comparison	  with	  a	  GFP	  
negative	  control	  (Figure	  2-­‐2).	  
2.3.2.4 Single	  Cell	  cloning	  of	  OE33GFP+	  cells	  
To	   ensure	   that	   cells	   used	   in	   further	   experiments	   are	   a	   clonal	   population,	   GFP	  
infected	  cells	  were	  plated	   in	  serial	  dilutions	   in	  a	  96	  well	  plate	   (BD	  Falcon,	  UK).	  The	  
wells	  were	  examined	  and	  the	  well	  that	  contained	  only	  one	  colony	  was	  selected	  for	  
further	   growth.	   Once	   at	   90%	   confluence,	   the	   cells	   in	   the	   selected	   well	   were	  
trypsinized	  and	  grown	  in	  serially	  increasing	  container	  sizes.	  
2.4 Protein	  analysis	  methods	  
2.4.1 Immunohistochemistry	  and	  Immunofluorescence	  
Throughout	   the	   thesis,	   immunohistochemistry	   was	   performed	   using	   the	   indirect	  
streptavidin-­‐biotin	  method.	  Sections	  from	  FFPE	  cassettes	  were	  prepared	  on	  frosted	  
glass	   slides	   (Colorfrost,	   Thermo	   Fisher	   Scientific,	   UK)	   at	   6	   µm	   thickness.	   Sections	  
were	   dewaxed	   in	   xylene,	   rehydrated	   in	   decreasing	   concentrations	   of	   ethanol	   and	  
incubated	  with	  0.3%	  hydrogen	  peroxide	   (H2O2;	  VWR	   International,	  Radnor,	  PA)	   for	  





Figure	  2-­‐2:	  Demonstration	  of	  proportion	  of	  OE33	  cells	  expressing	  GFP.	  
The	  cells	  have	  been	  sorted	  using	  flow	  cytometry	  based	  on	  GFP	  expression	  a)	  Negative	  control	  b)	  GFP	  
positive	  OE33	  cells.	  P2	  represents	  the	  proportion	  of	  cells	  expressing	  GFP.	  	  




Protocols	  for	  individual	  antibodies	  are	  shown	  in	  	  
Table	  2-­‐2.	   If	  antigen	  retrieval	  was	  required,	   it	  was	  performed	  by	  adding	  slides	   to	  a	  
boiling	   0.01M	   solution	   of	   sodium	   citrate	   buffer	   (Sigma-­‐Aldrich,	   UK)	   (pH	   6.0)	   and	  
microwaving	  for	  10	  minutes.	  Subsequently,	  sections	  were	  washed	  and	  cooled	  in	  tap	  
water	   and	   then	   placed	   in	   phosphate	   buffered	   saline	  with	   0.2%	   Tween	   20	   (Sigma-­‐
Aldrich,	  UK).	   The	   sections	  were	  pre-­‐incubated	   for	   15	  minutes	   in	   5%	  normal	   serum	  
from	  the	  immunised	  species	  of	  the	  secondary	  antibody	  (DAKO,	  UK)	  in	  PBS	  to	  reduce	  
the	   amount	   of	   non-­‐specific	   binding	   of	   the	   antibodies.	   Sections	   then	   underwent	  
incubation	   in	   a	   primary	   antibody	   for	   30	   minutes	   at	   room	   temperature.	   After	   3	  
washes	  in	  PBS	  for	  5	  minutes	  each,	  sections	  were	  incubated	  with	  the	  species-­‐specific	  
biotinylated	  secondary	  antibody,	  diluted	  in	  5%	  serum	  in	  PBS,	  for	  30	  minutes	  before	  
being	   further	   washed	   3	   times	   at	   5	   minutes.	   A	   tertiary	   layer	   of	   streptavidin-­‐
horseradish	   peroxidase	   (strep-­‐HRP;	   DAKO,	   UK)	   diluted	   at	   1:500	   was	   then	   applied.	  
Dilutions	   of	   all	   layers	   were	   in	   PBS.	   The	   sections	   were	   developed	   with	   3,3-­‐
diaminobenzidine-­‐tetrahydrochloride	   solution	   (DAB;	   Sigma-­‐Aldrich,	   U.K.)	   for	   2–8	  
minutes,	   guided	   by	   frequent	   observation	   under	   a	   light	   microscope,	   before	   two	   5	  
minute	   washes	   in	   PBS,	   rinsing	   in	   tap	   water	   and	   counterstaining	   with	   Gill’s	  
haematoxylin	   (Pioneer	   Research	   Chemicals,	   Colchester,	   UK).	   Sections	   were	   then	  
dehydrated	  through	   increasing	  concentrations	  of	  alcohol	  and	  finally	  rinsed	  twice	   in	  
xylene.	  DPX	   (Distyrene,	  a	  plasticizer,	  and	  xylene;	  Sigma-­‐Aldrich,	  UK)	  was	  applied	   to	  




Each	   primary	   antibody	  was	   applied	   and	  washed	   as	   per	   section	   2.4.1.	   Each	   section	  
was	   then	   incubated	   with	   the	   relevant	   secondary	   antibody	   conjugated	   to	   a	  
fluorescent	  probe	  at	  room	  temperature	  for	  35	  minutes	  in	  the	  dark	  and	  then	  washed	  
3	   times	   for	  5	  minutes	  each	   in	  PBS.	  DAPI	  hardset	   (Vector	   Laboratories,	  Burlingame,	  
CA)	   was	   then	   applied	   to	   the	   slide	   and	   left	   overnight	   at	   4°C	   for	   fluorescence	  
microscopy	   examination	   the	   following	   day.A	   separate	   isotype	   matched	   control	  
immunoglobulin	  (isotype	  matched	  immunoglobulin	  from	  unimmunised	  animals)	  was	  
used	  at	  the	  same	  concentration	  as	  all	  experimental	  primary	  antibodies	  and	  included	  
in	  each	  staining	  run.	  
2.4.2 Enzyme	  linked	  immunoabsorbent	  assay	  (ELISA)	  
Each	  ELISA	  was	  carried	  out	  using	  a	  Multi-­‐analyte	  kit	  (Qiagen,	  UK)	  and	  used	  according	  
to	   manufacturer’s	   instructions.	   This	   allows	   the	   detection	   of	   several	   chemokines	  
simultaneously	   (Interleukin	   8	   (IL-­‐8),	   Chemokine	   (C-­‐X-­‐C	   motif)	   ligand	   1,	   (CXCL1,	  
GROα),	  Chemokine	   (C-­‐C	  motif)	   ligand	  5	   (CCL5,RANTES),	  Monocyte	  chemoattractant	  
protein-­‐1(MCP-­‐1),	   Macrophage	   inflammatory	   protein	   1	   α	   (MIP-­‐1α),	   Macrophage	  
inflammatory	   protein	   1	   β	   (MIP-­‐1b),	   	   Interferon	   gamma-­‐induced	  protein	   10	   (IP-­‐10),	  
Interferon–inducible	   T	   Cell	   Alpha	   Chemoattractant	   (I-­‐TAC),	   Monokine	   Induced	   by.	  
Gamma	   Interferon	   (MIG),	   Eotaxin,	   Thymus	   and	   activation-­‐regulated	   chemokine	  	  




Antibody	   Species	   Dilution	   Antigen	  Retrieval	   Source	  
p16	   Mouse	  
monoclonal	  
(IgG2A)	  












DAKO,	  Cambridge,	  UK	  
Ki67	  (MIB-­‐1)	   Rabbit	  
polyclonal	  






1:300	   Applied	  as	  
secondary	  layer	  





1:500	   Applied	  as	  
secondary	  layer	  
DAKO,	  Cambridge,	  UK	  
Alexa-­‐Fluor	  488	   Goat	  anti	  
mouse	  
1:150	   Applied	  as	  
secondary	  layer	  
Invitrogen	  Life	  Technologies,	  
Paisley,	  UK	  
Alexa-­‐Fluor	  555	   Goat	  anti	  
rabbit	  
1:150	   Applied	  as	  
secondary	  layer	  





























1:250	   None	   Abcam,	  Cambridge,	  UK	  
	  
Table	  2-­‐2:	  Table	  of	  antibodies	  and	  conditions	  used	  for	  immunohistochemistry.	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All	  reagents	  were	  provided	  by	  the	  manufacturer.	  The	  plate	  was	  supplied	  coated	  with	  
pre-­‐optimised	   antibodies.	   Each	   cell	   line	   supernatant	   used	   was	   centrifuged	   at	  
1x103rpm	  for	  10	  minutes	  and	  decanted	  from	  the	  cell	  pellet	  prior	  to	  storage	  at	  -­‐20°C.	  
Assay	  buffer	  was	  prepared	  by	  the	  addition	  of	  0.6	  ml	  of	  10%	  bovine	  serum	  albumin	  
(BSA)	   into	   a	   final	   volume	   of	   30	   ml	   with	   Assay	   Buffer	   Stock	   (provided	   by	  
manufacturer).	   After	   addition	   of	   50µl	   of	   the	   assay	   buffer	   to	   each	   well,	   50µl	   of	  
supernatant	  was	  also	  added.	  This	  was	  performed	   in	   triplicate.	   The	  positive	   control	  
consisted	  of	  an	  antigen	  mix	  cocktail	  provided	  by	  the	  manufacturer,	  and	  the	  negative	  
control	  consisted	  of	  a	  sample	  dilution	  buffer	  also	  provided	  by	  the	  manufacturer.	  The	  
sample	   was	   gently	   tapped	   for	   10	   seconds	   to	   allow	   mixing	   and	   then	   allowed	   to	  
incubate	   at	   room	   temperature	   for	   2	   hours.	   The	   contents	   of	   the	   wells	   were	   then	  
decanted	  and	   the	  wells	  were	   then	  washed	  using	   the	  supplied	  Wash	  Buffer	   (details	  
confidential	  according	  to	  manufacturer).	  The	  plate	  was	  gently	  shaken	  to	  mix	  and	  the	  
contents	  decanted-­‐	  this	  was	  repeated	  three	  times.	  	  
100µl	   of	   detection	   antibody	  was	   then	   added	   to	   each	  well.	   After	   gentle	   tapping	   to	  
mix,	  the	  plate	  was	  incubated	  for	  1	  hour	  at	  room	  temperature.	  100	  µl	  of	  avidin-­‐HRP	  
was	  mixed	  with	  Assay	  Buffer	  at	  a	  1:1	  ratio	  by	  volume,	  was	  then	  added	  to	  each	  well	  
and	   then	   incubated	   for	   30	  minutes	   in	   the	   dark.	   The	   plate	  was	  washed	  with	  Wash	  
Buffer	  a	  further	  four	  times	  and	  100	  µl	  development	  solution	  added	  to	  each	  well	  with	  
a	  subsequent	  15	  minute	  incubation	  in	  the	  dark.	  100	  µl	  of	  the	  supplied	  stop	  solution	  
was	  then	  added.	  Absorbance	  was	  read	  at	  450nm	  and	  570nm	  to	  allow	  for	  correction	  
for	  optical	  imperfections	  in	  the	  plate	  within	  30	  minutes	  of	  stopping	  the	  reaction.	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2.4.3 Fluorescence	  activated	  cell	  sorting	  (FACS)	  
Cell	   transfected	   with	   pBabe-­‐puro-­‐IRES-­‐EGFP	   (developed	   in	   section	   2.3.2)	   were	  
harvested	  as	  described	  above.	  Cells	  were	  washed	  by	  centrifugation	  at	  400xg	  at	  4°C	  
for	   5	   minutes	   in	   ice	   cold	   FACS	   buffer	   (1X	   PBS,	   1%	   FCS,	   0.02%	   NaNH3	   and	   5	   mM	  
EDTA),	  They	  were	  then	  placed	  in	  polystyrene	  tubes	  (BD	  Falcon,	  UK),diluted	  in	  ice	  cold	  
PBS	   and	   kept	   on	   ice.	   Subsequently	   samples	   were	   processed	   on	   a	   BD	   LSRII	   Flow	  
cytometer	   (BD	   Biosciences,	   Oxford,	   UK).	   Analysis	   was	   performed	   using	   FACSDiva	  
software	  v	  6.1.3	  (BD	  Biosciences,	  UK).	  
	  
2.5 Nucleotide	  analysis	  methods	  
2.5.1 Polymerase	  chain	  reaction	  (PCR):	  
A	  nested	  PCR	  protocol	  was	  followed	  throughout	  the	  thesis.	  Reagent	  concentrations	  
and	  thermocycler	  conditions	  had	  been	  previously	  optimised	  in	  the	  lab	  (see	  Appendix	  
1).	  A	  23µl	  PCR	  reaction	  mixture	  was	  prepared	  per	  PCR	  reaction,	  containing	  0.4µmol	  
of	   first	   round	   forward	   and	   reverse	   gene-­‐specific	   primers	   (see	   Appendix	   1)	   for	  
CDKN2A	   and	  TP53,1-­‐2mM	  MgCl2	   (Qiagen,	  Crawley,	  UK),	  0.2mM	  of	  each	  dNTP	   (Life	  
Science,	  Buckinghamshire,	  U.K),	  Q	  solution	  (Qiagen,	  UK)	  and	  1unit	  of	  Taq	  polymerase	  
(Qiagen,	   UK).2µl	   of	   extracted	   DNA	   was	   added	   to	   each	   well	   of	   a	   96	   well	   plate	  
(Abgene,Epsom,UK)	  and	  the	  reaction	  mixture	  then	  added	  to	  each	  well	  so	  that	  every	  
reaction	   contained	   a	   25	   µl	   total	   volume.	   The	   plates	   were	   then	   sealed	   with	  
Thermowell	  sealers	  (Corning,	  Ewloe,	  Flintshire).	  The	  first	  round	  PCR	  was	  prepared	  in	  
an	  Omni	  PCR	  UV	  hood	  (Bioquell,	  Berkshire,	  U.K.)	  to	  reduce	  contamination	  and	  then	  
subjected	   to	   37	   cycles	   of	   denaturing,	   annealing	   and	   extension	   on	   a	   Tetrad	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thermocycler	  (MJ	  Research,	  Waltham,	  MA).	  2µl	  of	  first	  round	  PCR	  product	  was	  then	  
subjected	  to	  a	  second	  round	  of	  PCR	  using	  the	  same	  reagents	  as	  the	  first	  round	  PCR.	  
Reagent	   concentrations	   for	   MgCl2	   (Qiagen,	   Crawley,	   UK)and	   Q	   solution	   (Qiagen,	  
UK)and	  thermocycler	  conditions	  had	  also	  already	  been	  optimised	  for	  specific	  second	  
round	  primers	  (Appendix	  1).The	  other	  reagents	  used	  in	  the	  first	  round	  PCR	  reaction	  
were	  used	  at	  the	  same	  concentration	  in	  the	  second	  round	  reaction	  and	  the	  96	  well	  
plate	  was	  prepared	  without	  the	  Omni	  PCR	  UV	  hood	  (Bioquell,	  Berkshire,	  U.K.)	  on	  ice	  
prior	  to	  it	  being	  placed	  in	  the	  thermocycler.	  
	  
Number	  of	  cycles	   Step	   Temperature(°C)	   Time	  (minutes)	  
1	   Denaturation	   95	   4	  









1	   Final	  extension	   72	   10	  
	  
Table	  2-­‐3:	  PCR	  reaction	  conditions	  for	  first	  and	  second	  round	  PCR	  for	  CDKN2A	  and	  TP53	  
2.5.1.1 Gel	  electrophoresis	  of	  PCR	  product	  
1.5%	  agarose	  gels	  were	  prepared	  by	  addition	  of	  3g	  of	  agarose	  (Sigma-­‐Aldrich,	  UK)	  to	  
150ml	  of	  1	  X	  Tris/Borate/EDTA	  (TBE)solution	  (National	  Diagnostics,	  Atlanta,	  GA)	  then	  
microwaving	   for	   2	   minutes	   until	   melted.	   This	   was	   then	   cooled	   until	   starting	   to	  
become	  viscous.	  15µL	  of	  Gelred	  fluorescent	  nucleic	  acid	  dye	  (Biotum,	  California)	  was	  
then	   added	   and	   the	   gel	   allowed	   to	   set	   with	   combs	   placed	  within	   the	   gel	   to	   form	  
wells.	  Once	  set,	  the	  gel	  was	  loaded	  into	  the	  electrophoresis	  tank	  (Takara	  Bio,	  Kyoto,	  
Japan).5µl	   of	   HyperLadder	   IV	   (Bioline,	   London,	   UK)	  was	   added	   to	   the	   furthest	   left	  
well	  for	  each	  row	  of	  wells	  to	  provide	  molecular	  weight	  markers.	  For	  the	  rest	  of	  the	  
wells,	  a	  mix	  of	  2	  µl	  loading	  buffer	  (0.25%	  w/v	  bromophenol	  blue,	  0.25%	  w/v	  xylene	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cyanol,	  30%	  v/v	  glycerol)	  with	  5µl	  DNA	  was	  added	  to	  each	  well.	  The	  samples	  were	  
run	  for	  35	  minutes	  at	  135V,	  visualised	  using	  a	  UV	  transilluminator	  (wavelength	  294	  
nm)	  and	  photographed.	  
2.5.1.2 PCR	  sequencing	  
Prior	   to	   sequencing,	   PCR	   reactions	   were	   cleaned	   by	   ExoSAP-­‐IT(Affymetrix,	   Santa	  
Clara,	   CA).	   This	   consists	   of	   recombinant	   exonuclease	   I	   and	   shrimp	   alkaline	  
phosphatase	  (Pandalus	  borealis)	  in	  a	  buffered	  solution.2	  µl	  of	  ExoSAP-­‐IT	  was	  added	  
to	  5	  µl	  of	   second	   round	  PCR	  product	  on	   ice	  and	   subjected	   to	  37oC	   for	  15	  minutes	  
followed	  by	  80oCfor	  15	  minutes	  on	  a	  thermocyclerApplied	  Biosystems	  7500	  (Applied	  
Biosystems,	  UK).The	  treated	  products	  were	  then	  diluted	  with	  distilled	  water	  (10-­‐20	  
µl)	   depending	   on	   the	   intensity	   of	   DNA	   bands	   on	   the	   1.5%	   agarose	   gel	   from	   the	  
second	  round	  product.	  
PCR	  products	  were	  then	  subjected	  to	  Sanger	  sequencing	  reaction.	  Each	  sequencing	  
reaction	   contains	  4	  µl	   of	   diluted	  ExoSAP-­‐IT	   (Affymetrix,	   CA)	  product,	   1	  µlof	   primer	  
(forward	  or	  reverse),	  5	  µlof	  distilled	  water,	  and	  10	  µlof	  Big	  Dye	  Terminator	  (Applied	  
Biosystems,	  Foster	  City,	  CA).	  The	  sequencing	  reaction	  was	  run	  on	  an	  ABI	  3100	  DNA	  
sequencer	   (Life	   Science,	   CA).	   The	   sequences	   obtained	   were	   compared	   with	   the	  
Catalogue	   of	   Somatic	   Mutations	   in	   Cancer	  
(http://www.sanger.ac.uk/genetics/CGP/cosmic)	   database.	   Each	   mutated	   sample	  
was	  repeated	  from	  the	  original	  DNA	  for	  mutation	  confirmation.	  Polymorphisms	  were	  
eliminated	  by	  comparing	  their	  sequence	  against	  that	  held	   in	  the	  Ensembl	  database	  
(http://www.ensembl.org)	   and	   by	   sequencing	   non-­‐epithelial	   tissue	   (muscle)	   laser	  
captured	  from	  the	  same	  patient’s	  sample.	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2.5.2 RNA	  related	  methods	  
2.5.2.1 Total	  RNA	  extraction	  
Total	  RNA	  was	  prepared	  for	  all	  applications	  using	  the	  RNeasy	  RNA	  minikit	  as	  directed	  
by	  the	  manufacturers	  (Qiagen,	  UK).	  RNAZap	  (Invitrogen,	  Life	  Science	  Technology,	  UK)	  
was	   applied	   to	   all	   surfaces	   and	   equipment.	   Once	   cell	   culture	   medium	   had	   been	  
completely	   aspirated,	   cells	   were	   lysed	   directly	   from	   culture	   plates	   by	   addition	   of	  
buffer	  RLT	  to	  which	  10	  µl	  β-­‐mercaptoethanol/ml	  of	  RLT	  had	  been	  added.	  The	  lysate	  
was	   then	   pipetted	   into	   an	   eppendorf	   and	   vortexed	   to	   ensure	   proper	   mixing.	  
Homogenisation	  of	   the	   lysate	  was	  achieved	  by	  pipetting	  the	   lysate	  through	  a	  blunt	  
20G	  needle	  fitted	  to	  a	  RNA	  free	  syringe.	  One	  volume	  of	  70%	  ethanol	  was	  then	  added	  
to	  the	  lysate	  and	  mixed	  by	  pipetting.	  The	  sample	  was	  then	  placed	  in	  a	  spin	  column	  
within	   a	   2ml	   collection	   tip	   and	   centrifuged	   for	   15	   seconds	   at	   1x105	   rpm.	   The	   flow	  
through	  was	  discarded	  and	  700µl	  of	  RW1	  was	  added	  to	  the	  spin	  column	  and	  again	  
centrifuged	   for	   15	   seconds	   at	   1x105rpm;	   the	   flow	   through	   was	   again	   discarded.	  
Buffer	   RLT	   and	   Buffer	   RW1	   both	   contain	   guanidine	   salts	   which	   immediately	  
inactivate	  RNases.	  Having	   added	  500µl	  of	   the	  mild	  washing	  buffer	  RPE	   to	   the	   spin	  
column	  and	  again	  centrifuging	   for	  15	  seconds	  at	  1x105rpm	  and	  discarding	  the	   flow	  
through,	   a	   further	   500µl	  Buffer	  RPE	  was	   added	  and	   centrifuged	  at	   1x105rpm	   for	   2	  
minutes.	  The	  flow	  through	  was	  again	  discarded	  and	  the	  spin	  column	  was	  placed	  in	  a	  
new	   collection	   tube.	   To	   this	   30-­‐50µl	   of	   RNase-­‐free	   water	   was	   added	   to	   the	   spin	  
column	  membrane;	  the	  column	  was	  then	  centrifuged	  for	  1	  minute	  at	  10,000	  rpm	  to	  
elute	  the	  RNA.	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2.5.2.2 Determination	  of	  RNA	  quality	  and	  concentration	  
The	   RNA	   concentration	   was	   analysed	   using	   the	   Nanodrop	   ND-­‐1000	  
spectrophotometer	   (Thermo	   Fisher	   Scientific,	   UK).	   The	   degradation	   level	   was	  
assessed	  using	  the	  Agilent	  2100	  Bioanalyser	  (Agilent	  Technologies,	  Santa	  Clara,	  CA).	  
This	   is	  a	  chip-­‐based	  capillary	  electrophoresis	  machine	  which	  measures	  degradation	  
of	  RNA,	  DNA	  and	  proteins	  prior	   to	  performing	  RT-­‐PCR	  and	  derives	   a	  RNA	   Integrity	  
Number	  between	  0-­‐10	  to	  demonstrate	  how	  intact	  the	  sampled	  RNA	  is.	  RNA	  integrity	  
level	  scores	  >7	  were	  considered	  acceptable	  for	  further	  analysis.	  
2.5.2.3 Microarray	  analysis	  of	  irradiated	  OE33	  cells	  
RNA	   was	   isolated	   as	   previously	   described,	   from	   irradiated	   and	   unirradiated	   OE33	  
cells	  which	  had	  been	  cultured	  in	  triplicate	  in	  6	  well	  plates.	  Prior	  to	  analysis	  the	  cells	  
were	  stored	  at	   -­‐20°C.	  Whole	  transcript	   levels	  were	  assessed	  using	  theHumanHT-­‐12	  
v4	  Expression	  BeadChip	  (Illumina,	  San	  Diego	  ,CA)	  and	  performed	  by	  Dr	  Charles	  Mein	  
(Genome	  Centre,	  Barts	  Cancer	  Institute,	  Charterhouse	  Square,	  London).	  This	  involves	  
a	   first	   and	   second	   strand	   reverse	   transcription	   step.	   Subsequently	   an	   in	   vitro	  
transcription	   amplification	   step	   incorporates	   biotin	   labelled	   nucleotides.	   The	   final	  
step	   involves	   array	   hybridization,	   washing,	   blocking	   and	   streptavidin-­‐Cy3	   staining	  
with	  the	  results	  read	  onto	  a	  BeadArray	  Reader	  (Illumina,	  CA).	  	  
Results	  were	  analysed	  using	  Genome	  Studio	  2011	  v2011.1	  (Illumina,	  CA).	  The	  results	  
are	  expressed	  as	  an	   increase	  or	  decrease	   in	   fold	   change	  expression	   relative	   to	   the	  
control	  which	  was	   the	  unirradiated	  OE33	  cells.	  A	   fold	  change	  of	  <>2	  was	   taken	   for	  
further	   statistical	   analysis	   using	   a	   t-­‐statistic	  which	  was	   then	   corrected	   for	  multiple	  
testing	  using	  a	  Bonferroni	  correction	  with	  a	  p	  value	  of	  <0.05	  as	  significant.	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To	   ascertain	   RNA	   levels	   of	   proteins	   that	  were	   likely	   to	   be	   secreted	   extracellularly,	  
cellular	  component	  ontology	  of	  significantly	  upregulated	  RNA	  was	  undertaken	  using	  
Genego	   using	   the	   term	   ‘extracellular	   space’:	   GO:0005615	   (Thomson	   Reuters,	   NY).	  
This	   term	   is	   defined	   as	   ‘gene	   products	   from	   multicellular	   organisms	   which	   are	  
secreted	   from	   a	   cell	   but	   retained	   within	   the	   organism’	  
(http://www.ebi.ac.uk/QuickGO/GTerm?id=	   GO:0005576)	   Suggested	   genes	   were	  
then	   entered	   into	   the	   STRING	   (Search	   Tool	   for	   the	   Retrieval	   of	   Interacting	  
Genes/Proteins)	   database	   (http://string-­‐db.org/)	   which	   is	   a	   database	   of	   known	  
protein-­‐protein	   interactions.	   The	  database	  was	  queried	   to	  provide	  a	   list	   of	  protein	  
interactions	  based	  on	  the	  inputted	  data	  which	  is	  performed	  by	  scoring	  raw	  network	  
data	  for	  all	  interaction	  partners	  with	  values	  listed	  in	  descending	  order.	  	  
2.5.2.4 Quantitative	  reverse	  transcriptase	  polymerase	  chain	  reaction	  (qRT-­‐PCR)	  of	  
irradiated	  cell	  lines	  
2.5.2.4.1 Complementary	  DNA	  synthesis	  
First	   strand	   cDNA	   was	   synthesised	   using	   Superscript	   III	   reverse	   transcriptase	  
(Invitrogen	  Life	  Technologies,	  UK).	  250ng	  total	  RNA	  (per	  sample)	  was	  added	  to	  1	  µl	  of	  
random	  primers	  and	  1	  µl	  of	  10mM	  dNTP	  mix(Invitrogen	  Life	  Technologies,	  UK).	  The	  
volume	  was	  made	  up	   to	  10	  µl	  with	  diethylpyrocarbonate	   treated	  water.	  The	  cDNA	  
mix	   was	   prepared	   (pre	   reaction)	   by	   the	   addition	   of	   10X	   RT	   buffer,	   4	   µl	   of	   25mM	  
MgCl2,	   2µl	   of	   0.1M	   Dithiothreitol	   (DTT),	   1µl	   RNaseOUT	   (40	   U/µl)	   and	   1µl	   of	  
Superscript	  III	  reverse	  transcriptase	  (all	  supplied	  by	  Invitrogen	  Life	  Technologies,	  UK)	  
to	  give	  a	  final	  volume	  of	  20	  µl.	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The	   sample	  was	  mixed	   gently	   and	   briefly	   centrifuged.	  Using	   anApplied	   Biosystems	  
7500	  thermocycler	  (Applied	  Biosystems,	  UK)	  the	  sample	  was	  then	   incubated	  for	  10	  
minutes	  at	  25°C	  followed	  by	  50	  minutes	  at	  50°C;	  the	  reaction	  was	  then	  terminated	  at	  
85°C	   for	   5	  minutes	   and	   chilled	   on	   ice.	   After	   a	   further	   brief	   centrifugation,	   1	   µl	   of	  
RNase	  H	  was	  added	  to	  each	  tube	  to	  remove	  the	  RNA	  template	  from	  the	  cDNA:RNA	  
hybrid	  and	  incubated	  for	  20	  minutes	  at	  37°C.	  The	  resulting	  cDNA	  was	  stored	  at-­‐20°C	  
until	   required.	  Control	  RNA	  was	  provided	  by	   the	  manufacturer	   to	  act	  as	  a	  positive	  
control,	  and	  H2O	  acted	  as	  a	  negative	  control.	  
2.5.2.4.2 qRT-­‐PCR	  reaction	  preparation	  
Prepared	   cDNA	   and	   Taqman	   gene	   expression	   assays	   (Invitrogen	   Life	   Technologies,	  
UK)	   were	   thawed	   on	   ice,	   gently	   vortexed	   and	   centrifuged.	   The	   reactions	   were	  
prepared	   in	   triplicate,	   with	   each	   reaction	   being	   prepared	   in	   20µl	   total	   reaction	  
volume	   consisting	   of	   20x	   TaqMan®	   Gene	   Expression	   Assay	   (Invitrogen	   Life	  
Technologies,	   UK),	   2x	   TaqMan®	   Gene	   Expression	   Master	   Mix	   (Invitrogen	   Life	  
Technologies,	  UK),	   cDNA	   template	   (at	  2ng/µl)	  and	  RNase-­‐free	  water	   (Qiagen,	  UK)	   .	  
The	   reactions	   were	   run	   on	   an	   Applied	   Biosystems	   7500	   thermocycler	   (Applied	  
Biosystems,	   UK)	   with	   the	   following	   thermal	   cycling	   conditions:	   50°C	   for	   2minutes,	  




2.5.2.4.3 qRT-­‐PCR	  gene	  expression	  analysis	  
All	   reactions	   were	   performed	   in	   triplicate	   and	   the	   reactions	   repeated	   on	   two	  
occasions.	   All	   genes	   were	   normalised	   using	   the	   house	   keeping	   gene	   GAPDH	  
(glyceraldehyde	   3-­‐phosphate	   dehydrogenase;	   Hs02758991_g1	   reference	   sequence:	  
NM_001256799.1),	   UBC	   (ubiquitin	   C;	   Hs00824723_m1	   reference	   sequence:	  
NM_021009.5),	  ACTB	  (β-­‐actin	  ;	  Hs03023943_g1	  reference	  sequence:	  NM_001101.3),	  
E1f-­‐α2	   (initiation	   factor	  α2;	  Hs00426773_gH)	  between	  samples	   in	  each	  set,	   so	   that	  
the	  relative	  expression	  of	  genes	  of	  interest	  could	  be	  established.	  Unirradiated	  OE33	  
cells	  were	  used	  as	  the	  control	  in	  each	  experiment.	  The	  delta	  delta	  CT	  (ΔΔCT)	  method	  
(Livak	  &	  Schmittgen	  2001)	  was	  used	  to	  ascertain	  the	  relative	  expression	  level	  of	  each	  
gene	  as	  follows: 
1.	   ΔCT	  was	   calculated	  by	   subtracting	   the	   average	   gene	  CT	   value	   from	   the	   average	  
housekeeping	  CT	  value.	  
2.	  ΔCT	  values	  from	  each	  sample	  was	  subtracted	  from	  the	  reference	  sample	  to	  yield	  a	  
ΔΔCT	  value	   (ΔΔCT	  =	  ΔCTirradiated_Cells	  –	  ΔCTunirradiated_Cells)	  and	  relative	  gene	  
expression	  values	  2(-­‐log	  fold	  values)	  were	  calculated	  using	  the	  following	  equation	  –	  2	  –ΔΔCT.	  





GraphPad	   Prism®	   5	   programme	   was	   used	   for	   all	   statistical	   analysis.	   Error	   bars	  
represent	  standard	  error	  of	  the	  mean	  unless	  otherwise	  stated.	  All	  statistical	  analyses	  
are	  explained	  in	  further	  detail	  in	  the	  relevant	  section.	  
2.6.1.1 Statistical	   tests	   for	   assessment	  of	   immunohistochemistry	  of	   p21	  and	  p16	  
expression	  and	  for	  Ki67/p16	  and	  Ki67/p21	  co-­‐expression	  
χ-­‐squared	  test	  (section	  5.3.1&5.3.2).	  
2.6.1.2 Statistical	  test	  to	  measure	  cell	  viability	  of	  irradiated	  OE33	  cells	  
2	  way	  ANOVA	  with	  Bonferroni	  post	  hoc	  testing	  (section	  5.3.3).	  
2.6.1.3 Statistical	   test	   for	   assessment	   of	   SA	   β-­‐Galactosidase	   expression	   in	  
irradiated	  OE33	  cells	  and	  OE33	  cells	  exposed	  to	  H2O2.	  
Kruskal	  Wallis	  with	  Dunn’s	  post-­‐test	  (section	  5.3.3.1&5.3.4).	  
2.6.1.4 Statistical	  test	  for	  MTT	  assay	  to	  assess	  proliferation	  in	  OE33	  cells	  irradiated	  
at	  2Gy	  and	  10Gy	  
2	  way	  unrelated	  ANOVA	  with	  Bonferroni	  post	  hoc	  testing	  (section	  5.3.3.2).	  
2.6.1.5 Statistical	  test	  for	  colony	  formation	  assay	  of	  irradiated	  OE33	  cells	  
2	  way	  unrelated	  ANOVA	  with	  Bonferroni	  post	  hoc	  testing	  (section	  5.3.3.3).	  
2.6.1.6 Statistical	  test	  to	  assess	  proliferation	  by	  admixture	  of	  senescent	  and	  non-­‐
senescent	  OE33	  cells.	  
Kruskal-­‐Wallis	  with	  Dunn	  post	  testing	  (section	  5.3.5.1).	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2.6.1.7 Statistical	  test	  to	  assess	  response	  of	  unirradiated	  OE33	  cells	  to	  conditioned	  
media	  
Mann	  Whitney-­‐test	  (section	  5.3.5.2).	  
2.6.1.8 Statistical	  test	  for	  gene	  expression	  microarrays	  
Student’s	  t-­‐test	  with	  Bonferroni	  correction	  (section	  5.3.6).	  
2.6.1.9 Statistical	  test	  to	  assess	  qRT-­‐PCR	  results.	  
Mann	  Whitney	  test	  (section	  5.3.6).	  
2.6.1.10 Statistical	  test	  for	  ELISA	  
Mann-­‐Whitney	  test	  (section	  5.3.6).	  
2.6.1.11 Statistical	   test	   to	   assess	   the	   effect	   of	   recombinant	   protein	   on	   OE33	   cell	  
proliferation	  as	  measured	  by	  MTT	  assay	  
Goodness	  of	  fit	  and	  nonlinear	  regression	  analysis	  (section	  5.3.7).	  
2.6.1.12 Statistical	  test	  for	  assessment	  of	  CCL5	  and	  CXCL1	  immunohistochemistry	  in	  
ex-­‐vivo	  tissue	  specimens.	  
2	  way	  ANOVA	  with	  Bonferroni	  post	  hoc	  correction	  (section	  5.3.8).	  




Chapter	  3 Clonal	  selection	  after	  
endoscopic	  therapy	  of	  Barrett’s	  





BO	  represents	  a	  form	  of	  field	  cancerization.	  This	  is	  defined	  as	  a	  preconditioning	  of	  an	  
area	   or	   multiple	   areas	   of	   epithelium	   to	   tumour	   growth	   as	   a	   result	   of	   a	   clonal	  
proliferation	   of	   mutant	   cells	   through	   the	   epithelium	   without	   causing	   neoplasias	  
(Graham	   TAet	   al.2011).Longitudinal	   studies	   of	   patients	   with	   Barrett’s	   oesophagus	  
initially	   suggested	   clonal	   progression	   of	   a	   single	   clonal	   population	   from	   a	   single	  
ancestral	  crypt	  to	  adenocarcinoma	  (M	  T	  Barrett	  et	  al.	  1999).	  However,	  recent	  work	  
has	   demonstrated	   that	   a	   field	   such	   as	   BO	   may	   in	   fact	   contain	   several	   clonal	  
populations	  (Leedham	  et	  al.	  2008)and	  that	  genetic	  diversity	  per	  se	  is	  a	  risk	  factor	  for	  
progression	   to	  OAC	   (Maley	  et	  al.	   2006)	   suggesting	   that	   interaction	  between	  clonal	  
populations	  may	  drive	  OAC	  development.	  
Several	   forms	  of	  endoscopic	  ablation	   therapy	  exist	   to	   treat	  Barrett’s	  dysplasia	   (see	  
section	   1.8.1).	   The	   most	   recent	   and	   most	   successful	   is	   RFA	   which	   involves	   the	  
delivery	  of	  a	   thermal	   injury	   to	  areas	  of	  Barrett’s	  mucosa(Pouw	  et	  al.	   2008).	  1	  year	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follow	  up	  data	  of	  patients	  undergoing	  this	  therapy	  has	  demonstrated	  eradication	  to	  
squamous	   mucosa	   from	   IMC	   and	   HGD	   of	   80%	   (Ganz	   et	   al.	   2008),	   although	   it	   is	  
becoming	  apparent	  that	  with	  longer	  follow	  up,	  patients	  can	  increasingly	  suffer	  from	  
recurrent	   high	   and	   lowgrade	   dysplasia	   (Shaheen	   et	   al.	   2011).	   Endoscopic	  mucosal	  
resection,	   in	   which	   the	   tissue	   is	   removed	   endoscopically	   rather	   than	   being	  
destroyed,	   is	   often	   used	   in	   combination	   with	   RFA	   particularly	   for	   nodular	  
disease(Haidry	  et	  al.	  2013).	  
The	  cause	  of	  persistent	  and	  recurrent	  high	  grade	  dysplasia	  and	  intramucosal	  cancer	  
is	   likely	   to	   be	   related	   to	   the	   presence	   of	   a	   persistent	   cellular	   origin	   of	   Barrett’s	  
mucosa.	   Therefore	   studying	   the	   source	   of	   cells	   carrying	   persistent	   protumorigenic	  
mutations	   before	   and	   after	   ablation	   therapy	  may	   give	   insight	   as	   to	   the	   source	   of	  
regenerating	   Barrett’s	   mucosa.	   The	   theoretical	   sources	   include	   cells	   with	  
protumorigenic	   mutations	   persisting	   in	   squamous	   and	   non-­‐dysplastic	   Barrett’s	  
mucosa,	  the	  same	  cells	  being	  present	  in	  submucosal	  glands	  or	  their	  associated	  ducts	  
or	   cells	   being	   present	   in	   buried	   Barrett’s-­‐	   Barrett’s	   tissue	   located	   beneath	   normal	  
squamous	   tissue	   (discussed	   in	   section	  1.8.2.3).Understanding	   this	  may	  also	  answer	  
why	  Barrett’s	  mucosa	   is	  difficult	   to	  eradicate	  using	  RFA	   in	  a	   significant	  minority	  of	  
patients.	  Furthermore	  it	  may	  also	  give	  insight	  as	  to	  why	  patients	  develop	  recurrent	  
dysplasia	  if	  they	  are	  eradicated	  to	  Barrett’s	  mucosa.	  
Most	  work	   on	   understanding	   clonal	   progression	   in	   Barrett’s	   oesophagus	   has	   been	  
done	   in	   patients	   progressing	   to	   adenocarcinoma	   who	   have	   not	   undergone	   any	  
endoscopic	   therapy.(Wong,	  Paulson,	  L	   J	  Prevo,	  et	  al.	  2001;	  Barrett	  et	  al.	  1999).	  No	  
longitudinal	   study	   has	   assessed	   clonal	   progression	   in	   patients	   before	   and	   after	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therapy	  for	  Barrett’s	  related	  HGD	  and	  OAC	  in	  patients	  in	  which	  these	  pathologies	  are	  
persistent	   or	   recurrent.	   An	   investigation	   of	   the	   clonality	   of	   Barrett’s	   oesophagus	  
before	   and	   after	   treatment	   enables	   us	   to	   infer	   how	   therapy	  may	   alter	   the	   clonal	  
landscape	  in	  Barrett’s	  oesophagus.	  	  
3.2 Aims	  
a)	  To	  examine	  a	   longitudinal	   case	   series	  of	  patients	  who	  have	  undergone	  RFA	  and	  
EMR	  and	  understand	  the	  clonal	  correlates	  of	  persistent	  or	  recurrent	  HGD	  or	  OAC	  in	  
patients	  undergoing	  endoscopic	  therapy.	  
b)	  To	  establish	   the	  potential	   reasons	  why	  clonal	   cancer-­‐associated	  cell	  populations	  
may	  be	  persistent	  despite	  treatment	  with	  ablation	  therapy.	  
c)	   To	  establish	   the	  potential	   reasons	  why	   clonal	   cancer	  associated	   cell	   populations	  
may	  recur	  after	  treatment	  with	  ablation	  therapy.	  
3.3 Methods	  
Approval	   for	   the	   study	   was	   obtained	   from	   National	   Research	   Ethics	   Service	  
Committee	   London	   Stanmore	   (Ref:	   11/LO/1613).Patient	   records	   stored	   in	   the	   UK	  
National	   RFA	   database	   from	   2007	   to	   present	   were	   consulted.	   All	   patients	   had	  
undergone	   therapy	   according	   to	   their	   clinical	   need.	   Biopsies	   were	   largely	   taken	  
according	  to	  guidelines	  for	  Barrett’s	  surveillance	  which	  stipulates	  quadrantic	  biopsies	  
every	  two	  centimetres	   in	  the	  affected	  segment	  (British	  Society	  of	  Gastroenterology	  
2005	   guidelines	   (www.bsg.org.uk).	   All	   tissue	   was	   assessed	   by	   two	   independent	  
pathologists	  (Professor	  Sir	  Nicholas	  Wright,	  Dr	  Manuel	  Rodriguez-­‐Justo)	  for	  Barrett’s	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metaplasia,	   dysplasia	   and	   adenocarcinoma	   according	   to	   British	   Society	   of	  
Gastroenterology	  2005	  guidelines	  (www.bsg.org.uk).	  Only	  patients	  with	  recurrent	  or	  
persistent	  disease	  after	  RFA	  and/or	  endoscopic	  mucosal	  resection	  (EMR)	  of	  HGD	  or	  
intramucosal	  adenocarcinoma	  (IMC)	  were	  chosen	  for	  analysis.	  Furthermore,	  patients	  
had	   to	  haveundergone	   two	   further	   endoscopic	   samplings	   subsequent	   to	   the	   initial	  
ablation	   therapy.Persistent	  disease	  was	  defined	  as	  no	  down	  staging	  of	   the	  original	  
IMC	  or	  HGD	   to	   non-­‐dysplastic	   Barrett’s	  mucosa.	   Recurrent	   disease	  was	   defined	   as	  
HGD	  or	  IMC	  development	  after	  successful	  endoscopic	  therapy	  with	  down	  staging	  to	  
non-­‐dysplastic	  Barrett’s	  mucosa.Furthermore,	  patients	  had	   to	  have	  undergone	   two	  
further	   endoscopic	   samplings	   subsequent	   to	   the	   initial	   ablation	   therapy	   to	   be	  
included	  in	  this	  study.	  All	  paraffin	  embedded	  blocks	  available	  for	  each	  patient	  for	  the	  
entire	   therapeutic	   time	   line	   were	   obtained	   (total	   number	   of	   FFPE	   samples:	   186,	  
number	  of	  patients=	  19).	  
Sections	   containing	   the	   original	   pathology	   for	   each	   patient	   underwent	  
macrodissection	   and	   nested	   PCR	   sequencing	   for	   somatic	   mutations	   commonly	  
associated	  with	  the	  Barrett’s	  metaplasia-­‐dysplasia-­‐cancer	  sequence	  (CDKN2A	  exon	  2,	  
TP53	   (exons	  5-­‐8)).	   If	   the	  specimen	  contained	  a	  detectable	  mutation,	   further	  blocks	  
along	  the	  patient’s	  treatment	  timeline	  underwent	  further	  mutational	  analysis	  of	  all	  
of	   the	  original	   target	  genes.	   Initial	   screening	   for	  somatic	  mutations	  was	  performed	  
by	  cutting	  six	  serial	  sections	  at	  6	  µm	  thickness	  onto	  normal	  glass	  slides.	  This	   tissue	  
was	  dewaxed	  and	  needle	  scraped	  into	  30µL	  digestion	  buffer	  (Arcturus	  Bioscience,	  Mt	  
View,	  CA).	  Negative	   control	   tubes	   containing	  30	  µl	  Pico	  Pure	  proteinase	  K	   solution	  
(Invitrogen	   Life	   Technologies,	   UK)	   solution	   and	   no	   needle	   scraped	   material	   were	  
included.	   Tubes	   were	   then	   centrifuged	   at	   4.5xg	   for	   1	   minute	   and	   incubated	   at	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65°Covernight.	   A	   10	   minute	   incubation	   at	   95°C	   denatured	   the	   proteinase	   K	  
(Invitrogen	  Life	  Technologies,	  UK)and	  the	  lysate	  was	  then	  stored	  at	  -­‐20°C.	  
3.3.1 Laser	  capture	  microdissection	  
All	   cancers	   containing	   detectable	   mutations	   underwent	   laser	   capture	  
microdissection	   where	   possible.	   This	   technique	   is	   well	   described	   (Leedham	   et	   al.	  
2008).	   As	   described	   in	   section	   2.2.4,	   H&E	   slides	   of	   the	   paraffin	   embedded	   cancer	  
were	   prepared.	   These	   were	   serial	   to	   further	   sections	   prepared	   on	   laser	   capture	  
slides	   (P.A.L.M.	   Microlaser	   technologies,	   Germany).	   Once	   suitable	   areas	   for	  
dissection	   had	   been	   determined	   from	   the	   H&E,	   the	   laser	   capture	  microdissection	  
slides(P.A.L.M.	   Microlaser	   technologies,	   Germany)	   were	   stained	   with	   methylene	  
green	   (Sigma-­‐Aldrich,	   UK)	   for	   2	   minutesand	   microdissected	   on	   a	   dedicated	   laser	  
capture	   microscope	   (P.A.L.M.	   Microlaser	   technologies,	   Germany).	   The	   epithelium	  
was	   catapulted	   into	   eppendorf	   adhesive	   caps	   (P.A.L.M.Microlaser	   Technologies	  
,Germany)	   and	   digested	  with	   12	   µlPico	   Pure	   proteinase	   K	   solution	   (Invitrogen	   Life	  
Technologies,	   UK).	   A	   laser	   capture	   tube	   containing	   12	   µl	   Pico	   Pure	   proteinase	   K	  
solution	  and	  no	  laser	  capture	  material	  was	  also	  prepared	  as	  a	  negative	  control.	  The	  
tubes	  were	  centrifuged	  at	  4.5xg	  for	  1	  minute	  and	  then	  incubated	  overnight	  at	  65°	  C.	  
The	   samples	   then	   underwent	   nested	   PCR.	   Muscle	   distant	   from	   the	   pathology	   of	  
interest	   was	   taken	   for	   PCR	   sequencing	   of	   constitutional	   DNA	   to	   exclude	  
polymorphisms.	  
Once	   analysed,	   the	   sequence	   results	   from	  needle	   scraping	   and	   laser	   capture	  were	  
geographically	  plotted	  according	  to	  where	  the	  biopsies	  were	  taken	   from,	  using	   the	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gastroscopy	   reports	   as	   a	   guidewhich	   were	   anonymised	   using	   each	   specimen’s	  
pathology	  block	  number.	  
3.4 Results	  
3.4.1 Overview	  of	  results	  
Needle	   scraped	   tissue	   sections	   of	   19	   patients	   with	   recurrent	   or	   persistent	  
oesophageal	   adenocarcinoma	   or	   high	   grade	   dysplasia	   underwent	   nested	   PCR	   for	  
TP53,	   exons	   5-­‐8,	   and	   CDKN2A.	   Of	   these,	   8	   (42%)	   had	   detectable	   CDKN2A	   or	  
TP53mutations	  (3	  with	  recurrent	  disease,	  5	  with	  persistent	  disease)	  and	  all	  available	  
tissue	   specimens	   from	   the	   patient’s	   treatment	   time	   course	   were	   obtained.	   The	  
remainder	   were	   uninformative	   for	   mutations	   in	   these	   genes.	   The	   frequency	   of	  
mutations	   in	   this	   cohort	   was	   similar	   to	   those	   reported	   in	   the	   COSMIC	   database	  
(http://www.sanger.ac.uk/genetics/CGP/cosmic/).	  
Of	   the	  5	  patients	  with	  persistent	  disease,	   3	  had	  one	  mutation	  present	   throughout	  
the	  disease	  course	  (Pt	  1,	  2	  &5).	  1	  patients	  had	  several	  mutations	  in	  different	  genes	  
detected	  at	  various	  time-­‐points	  throughout	  the	  disease	  course	  (Pt	  4).	  Patient	  3	  had	  
more	  than	  one	  persistent	  mutation	  detected.	  In	  recurrent	  disease,	  one	  patient	  had	  a	  
persistent	   mutation,	   2	   patients	   did	   not.	   Overall,	   5	   patients	   had	   more	   than	   one	  
mutation	  detected	  in	  all	  the	  tissue	  analysed.The	  summarised	  results	  are	  shown	  in	  
Table	  3-­‐1.	  
	  
